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ABSTRACT 
Cerebral cavernous malformation (CCM) is a vascular disease that affects blood vessels 
in the central nervous system, which become malformed, leaky and prone to hemorrhage. The 
organ location is critical, both for neurological consequences and therapeutic intervention, 
which is exclusively surgical to date. The cause of CCM can be either sporadic or genetic. 
Mutations in three genes named CCM1/Krit1, CCM2/Malcavernin and CCM3/Pdcd10 are 
associated with hereditary CCM.  
Here we describe a novel murine model of the disease that develops after endothelial 
cell-selective ablation of the CCM3 gene in newborn mice and that we use to investigate the 
molecular mechanisms behind the development of CCM.  
We report enhanced transcription activity of β-catenin in CCM3-knockout endothelial 
cells in in vitro and in vivo models and we demonstrate that such activation is critical at early 
stage of the pathology development. In particular, we found that β-catenin is fundamental to 
trigger the process of endothelial-to-mesenchymal transition (EndMT), which has been 
previously demonstrated to be crucial for CCM development. Noteworthy, the activation of β-
catenin pathway results Wnt-independent, while it correlates with the impaired state of 
endothelial cell-to-cell junctions typical of vessels developing CCM lesions. 
We also show that a pharmacological screening of a panel of drugs targeting β-catenin 
signaling revealed the NSAIDs sulindac sulfide and sulindac sulfone as potent inhibitors of 
this signaling pathway in endothelial cells. Moreover, we found that sulindac sulfide and 
sulindac sulfone are able to attenuate β-catenin transcription activity and to significantly 
reduce the number and dimension of vascular lesions in the central nervous system of mice 
with endothelial cell-specific CCM3-knockout. These NSAIDs thus represent pharmacological 
tools for inhibition of the formation of CCM3 vascular lesions, particularly with a view to 
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patients affected by the genetic variant of CCM, who continue to develop new malformations 
over time. 
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INTRODUCTION 
 
1. VASCULAR ENDOTHELIUM 
William Harvey in 1628 was the first to describe circulating blood in vertebrates. 
Anyway, only some years later thanks to Malphigi’s experiments the existence of an intricate 
and complex grove of tubes able to transport blood and nutrients throughout the entire body, 
known as vascular network, became clear1. We had to wait until the XIX century to find a first 
detailed description, thanks to the work of Von Reckingausen first and Starlings later, of the 
cellular components of blood vessels and in 1865 Wilhem His coined the term “endothelium” 
to differentiate the inner lining of body cavities from “epithelium”.  
However, all these studies looked to the endothelium as a selective but merely static 
physical barrier. A decisive change of direction occurred immediately after the advent of the 
electron microscopy during the second half of the XX century when Palade and other 
scientists described more in details the physiological characteristic of endothelial cells and 
their interaction with other cell types such as the lymphocytes1. These studies led scientific 
world to consider the endothelium as a dynamic and active organ able to supervise to different 
biological functions. In 1973 Jaffe and Gimbrone have been able to culture endothelial cells 
derived from umbilical veins definitively laying the foundation for the modern era of vascular 
biology2, 3. 
Nowadays the concept that vascular endothelium, as a monolayer of cells forming a 
barrier between the vessel lumen, where blood stream flow, and surrounding tissue, plays a 
pivotal role in the regulation of vascular function and structure, is fully accepted. This 
regulation involve the release of various biochemical mediators and the interactions with other 
cell types including vascular smooth muscle cells, circulating cells and organ specific cellular 
constituents.  
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Altogether these elements constitute the vascular micro-environment which is crucial for 
endothelial homeostasis, signaling and differentiation as it will be discuss more in details in 
the next chapters. 
 
1.1 Endothelial differentiation 
The endothelium lines the blood-exposed surface of the entire vascular network and the 
interior heart (where it is called endocardium). However, the endothelial cells (ECs) are very 
heterogeneous at different levels. The maturation of the endothelium from an undifferentiated 
progenitor toward a mature and fully functional biological entity is a complex process, which 
involves different steps and a wide range of physiological signaling, which lead the 
differentiating ECs to acquire a repertoire of unique functional and molecular characteristics4, 
5. 
In mammals a first level of specification occurs very early during embryonic 
development when two mains processes contribute to the establishment of the vascular 
system: vasculogenesis and angiogenesis6, 7. Vasculogenesis refers to the de novo formation of 
a primitive vascular network starting from a pool of poorly-differentiated endothelial 
precursors, known as haemangioblasts, which takes place in mouse embryo between 
embryonic day (E) 6.5 and E9.5. At this stage haemangioblast progenitors start to express the 
first endothelial-specific marker, the Vascular endothelial growth factor receptor 2 (Vegfr2)8, 9. 
Starting from this primitive plexus another important process, known as angiogenesis, takes 
place starting from E8.5-E9 in mouse embryo, leading to the formation of new blood vessels 
through the extension and remodeling of pre-existing ones. Angiogenesis is supported by two 
different mechanisms:	  endothelial sprouting and intussusceptive microvascular growth (IMG). 
The sprouting process is based on endothelial cell migration, proliferation and tube formation, 
while the IMG or non-sprouting angiogenesis consists in the remodeling of existing vessels 
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that branch due to the formation of interstitial tissue into the vessel lumen10. This maturation 
process includes the acquisition by ECs of specific endothelial markers such as Platelet 
Endothelial Cell Adhesion Molecule (Pecam) and the Vascular Endothelial (VE-) cadherin7.  
During embryonic development, both vasculogenesis and angiogenesis contribute to the 
formation of blood vessels. In the adult, the formation of new blood vessels is restricted to 
certain physiological conditions (during female reproductive cycle, in the placenta during 
pregnancy and during wound healing) and occurs mainly through angiogenesis9.  
When deregulated, the formation of new blood vessels has a major impact on our health 
and contributes to the pathogenesis of many disorders such as ischemic, inflammatory, 
infectious and immune disorders and malignancies11 as it will be discuss later. 
 
1.2 Arterial-venous specification  
During embryonic angiogenesis in mammals the primitive plexus is remodeled into a 
highly organized and hierarchical structure where different vessels acquired peculiar 
characteristic differentiating into artery or veins. The specification of vascular network into 
two distinct, even if strictly inter-connected, types of blood vessel possessing unique structural 
characteristic is regulated by a variety of genetic and extrinsic factors working in concert to 
determine endothelial cell fate12, 13. A third type of vessel,	   the lymphatic vasculature, also 
starts to develop in mouse embryos at E10.5, when the cardiovascular system is already 
functioning.	   The lymphatic circulation subsequently becomes separated from the blood 
circulation thanks to poorly understood mechanisms14. 
Arteries and veins are usually described as big vessels that drive the blood flow 
respectively away or toward the heart. From both arteries and veins depart an intricate network 
of smaller vessels called arterioles and venules, which, in turn, finally branches into 
capillaries, the smallest and thinnest vessels in the body that connect arterial and venous 
	   22	  
districts. Lymphatic vessels derive from embryonic cardinal vein and their development 
requires the further specification of a subpopulation of venous ECs to a lymphatic fate via 
signals distinct from those that specify venous endothelium. 
Cardiac contractions start very early during mouse development (around E8.5)15 
generating a high-pressure blood flow through arterial vessels, which needs to be supported by 
a system of smooth muscle cells and extracellular matrix components. On the contrary, venous 
district collects blood returning to the heart under low pressure. This difference between 
hemodynamic forces in arteries and veins is crucial for ECs fate determination and different 
studies have shown a link between local environment and blood vessels specification16 in 
terms of physiology and markers expression17. 
However, several studies suggest that arteries and veins possess distinct molecular 
identity even before blood flow ensues arguing that genetic determinants may play a pivotal 
role in regulating the very initial steps of arterial-venous differentiation during development18. 
Indeed, through extensive characterization of in vitro (ECs in culture) and in vivo models 
(such as mouse, frog, and zebrafish)	   recent studies identified an array of molecules 
differentially expressed between arterial and venous ECs and many of them have been found 
to regulate signaling pathways crucial in the determination of arterial-venous fate14.  
One of the firsts molecular determinants of arterial-venous specification described were 
the Eph receptors and their ligand Ephrins. The expression of these two classes of molecules is 
very precocious during development and the binding of Ephrins to EphB receptors stimulates 
the transduction of intracellular signals essential to guide vessels remodeling. In particular, 
Ephrin B2 is specifically expressed on the surface of arterial ECs, whereas EphB4 receptor is 
peculiar of venous endothelium. The complementary expression between these two molecules 
results in the separation of the two compartments probably via mediating a repulsive signal 
that separates arterial and venous ECs. However, deletion of either EphrinB2 or EphB4 does 
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not impair initial specification of arteries and veins but EphrinB2-EphB4 signaling is required 
for maintenance of the arterial-venous interaction19, 20. This limited role leads to the 
subsequent identification of upstream factors such as Notch in the process of arterial-venous 
differentiation. 
Evolutionarily conserved across diverse species, Notch signaling occurs when a member 
of the single-pass transmembrane Notch receptors are activated by engagement of ligands, 
from Delta and JAG/Serrate family, presented by neighboring cells. The binding allows the 
cleavage by metalloprotease enzymes of the receptor extracellular domain. An enzymatic 
complex known as γ-secretase then cleaves the Notch transmembrane domain, releasing a 
Notch Intracellular Domain (NICD) able to translocate to the nucleus and to form complexes 
with other DNA-binding proteins21. 
In vivo experiment in zebrafish and mammals identified the Notch pathway as the main 
determinant of initial arterial-venous specification. Indeed, Notch signaling and the activation 
of downstream transcription factors (Hes-related proteins 1 and 2, Hey1 and Hey2) are 
required to promote arterial differentiation and to suppress venous fate choice22. Conversely, 
the transcription factor COUP-TFII is required for venous identity since it is able to inhibit the 
Notch signaling23.	  
Recently, it has been demonstrated that both Sonic Hedgehog (Shh) and VEGF signaling 
pathways act upstream of Notch pathway to determine arterial cell fate24. In particular Shh is 
able to activate VEGF, which in turn induces the expression of Notch pathway genes, 
including Notch1 and its ligand, Delta-like 4 (Dll4).  
Lymphatic ECs differentiate from venous endothelium. The transcriptional factor Sox18, 
in cooperation with COUP-TFII, progressively promotes expression of Prox1, a master gene in 
lymphatic determination and maintenance. Venous ECs start to express Prox1 at E9.75 in 
mouse embryo and by E11.5, clusters of Prox1-positive lymphatic progenitor cells emerge 
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along the anterioposterior axis of the cardinal vein. These clusters generate intermediate 
structures known as lymph sacs, from which lymphatic vessels emerge by a combination of 
sprouting and migration of lymphatic ECs from the cardinal vein25. 
In addition to the mechanisms cited above for arterial-venous differentiation, at least two 
other signaling pathways have been shown to be crucial for endothelial fate determination: 
Wnt pathway26 and Transforming Growth Factor (Tgf)β/Bone Morphogenic Proteins (Bmp) 
pathway27. Indeed, Corada et al.28 found that during vascular development in the embryo, the 
downstream effector of Wnt pathway, β-catenin, induces activation of the Notch pathway. In 
particular, β-catenin triggers the transcription of the Notch ligand Dll4, which, in turn, 
activates Notch1 and Notch4 receptors. Overexpression of β-catenin both in in vitro and in 
vivo models leads to a series of alterations of vascular morphology comparable to those 
described by overexpression of Dll4, resulting in a strong endothelial cell arterialization and 
lack of venous specification. Only recently a novel transcription factor called Sox17, a known 
regulator of endoderm differentiation and selectively expressed in arteries, has been shown to 
be a key mediator of arterial determination and the molecular link between Wnt and Notch 
pathway. Indeed, β-catenin is able to induce Sox17 expression, which, in turn, promotes Notch 
signaling upregulating Hey1, Dll4, Dll1 and Notch429.  It appears, therefore, that Wnt and 
Notch pathways act synergistically in modulating arterial differentiation. 
Another pathway important for EC fate determination is Bmp pathway. Bmps are a 
family of growth factors implicated in a multitude of biological processes including 
physiological and pathological angiogenesis27. In particular, during embryonic development in 
zebrafish Bmp2 promote endothelial specification and subsequent venous differentiation. 
Evidences showed that within the caudal vein plexus, Bmp2 expression is restricted to the 
developing caudal vein, and axial veins sprout in response to Bmp2. Downstream effectors of 
BMP signaling, Small mothers against decapentaplegic (Smads) and Extracellular signal-
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regulated kinase (Erks), mediate this effect by transcriptionally activating a program 
regulating venous sprout initiation and length30. However, the factors responsible for this 
differential responsiveness between arteries and veins are still obscure. 
Although it is now clear that specific molecular pathways guide the arterial-venous-
lymphatic determination of ECs, the contribution of other environmental cues, such as flow 
dynamics, to this process is still under investigation. Some experiments showed that 
transplanted vessels after grafting, switch their gene expression profile to match that of the 
host vessels31, 32. Moreover, overexpression or loss-of-function experiments of critical 
molecular determinants of specification can also reprogram a differentiated EC, thus 
indicating that ECs have a remarkable phenotypic plasticity33. Taken together this data suggest 
a model in which genetic predetermination coordinate initial arterial-venous specification and 
the environmental inputs regulate subsequent vascular remodeling. 
 
1.3 Endothelial heterogeneity among and within tissues 
For long time ECs have been considered as a homogeneous population of cells lining the 
blood vessels. Nowadays, it is fully accepted the idea that ECs can express specific 
phenotypes, although displaying many common features, depending on multiple factors such 
as tissues localization, vessel size and age. This heterogeneity is the primary mechanism by 
which the endothelium adapts to and sustains the specific functions of distinct tissues and 
organs. 
From a structural point of view the endothelium can be classified into three main types: 
continuous non-fenestrated, continuous fenestrated and discontinuous or sinusoidal34-36. 
Continuous non-fenestrated endothelium is distinctive of vessels in organs that need to strictly 
control the passage of substances across the vessel wall such as the brain, the skin and the 
heart. The presence of highly specialized structures such as tight junctions guarantee the 
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sealing of cell-to-cell contacts thus the extracellular molecules can cross the barrier mainly by 
the active process of transcytosis mediated by peculiar structures including caveolae, vesiculo-
vacuolar organelles and specific transporters37. Continuous fenestrated endothelium is 
characterized by the presence of transcellular pores (about 70 nm in diameter) on the surface 
of ECs called fenestrae, allowing a rapid exchange of molecules between the circulation and 
the surrounding tissue. This kind of endothelium is permeable to water and small solutes and 
typically occurs in organs characterized by increased filtration or trans-endothelial transport 
such as glands, digestive tract and kidney. Finally, the discontinuous endothelium is marked 
out by large heterogeneous fenestrae (100-200 nm in diameter) with few caveolae. This 
endothelium is found in certain sinusoidal vascular beds most notably bone marrow and liver 
which need to allow cellular trafficking37 (see Fig.1). 
 
Figure 1. Endothelial cell heterogeneity. Capillaries mediate transfer of fluids and solutes between blood and 
underlying tissue. In continuous non-fenestrated endothelium, water and small solutes (molecular radius, <3 nm) 
pass between ECs, whereas larger molecules pass through ECs either via transendothelial channels or 
transcytosis. The latter process is mediated mainly by caveolae, which are particularly prevalent in capillaries of 
heart and skeletal muscle but rare in brain. Continuous fenestrated endothelium demonstrates high permeability 
to water and small solutes but not for albumin and larger macromolecules (the diaphragms of the fenestrae act as 
molecular filters). Discontinuous endothelium is characterized by fenestrae (without diaphragms), gaps, and 
poorly organized basement membrane. These ECs contain many clathrin-coated pits, which play an important 
role in receptor-mediated endocytosis (that includes endosomal and lysosomal compartments) and transcytosis.	  
TEC indicates transendothelial channel; VVO, vesiculo-vacuolar organelles37. 
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Beside structural differences, ECs from different tissues are heterogeneous also for the 
expression of markers. For example, von Willebrand factor (vWF), used commonly as a 
marker for ECs, is not expressed uniformly by the endothelium of all types of vessels38 and the 
expression of Glucose transporter 1 (Glut1) is limited in vivo to brain vascular ECs39.	   
Indeed, microvascular ECs in the brain, liver, and other organs each expresses distinct 
patterns of cell surface markers, protein transporters, and intracellular enzymes. Some of these 
tissue-specific phenotypic differences can be only transiently maintained under tissue culture 
conditions, but they are then lost, indicating the need of specific regulators coming from 
different tissues40. Many evidences have been accumulated in last years suggesting that ECs 
heterogeneity arise as a result of exposure of ECs to tissue-specific environmental stimuli. 
Indeed, numerous exogenous factors impact on ECs phenotype including mechanical forces, 
cytokines exposure, contact with tissue specific cell types, circulating cells, extracellular 
matrix and soluble growth factors. The regulation of the endothelial phenotype through the 
microenvironment has been referred as trans-differentiation41. The expression and activity of 
general angiogenic factors such as Vegf or Angiopoietin1 (Ang1) greatly impact on ECs 
differentiation and varies in different tissues. For example Ang1 stimulates angiogenesis in the 
skin but suppresses vascular growth in the heart42, 43. 
Additional signaling molecules, such as members of the Tgfβ/Bmp superfamily, 
contribute to the resolution and maturation phases of angiogenesis, but in a pleiotropic 
manner. Tgfβ/Bmp family ligands are able to dimerize and bind to a heteromeric receptor 
complex composed by two type I and two type II receptor proteins. Endoglin is a type III 
receptor, which facilitates binding of Tgfβ/Bmp to the type II receptors. Once the ligand-
receptor complex is formed the kinetic domain of type I receptors phosphorylates and 
activates Smad proteins. Phosphorylated Smads can dimerize and translocate to the nucleus 
where they can regulate the transcription of several target genes11. Different members of the 
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Tgfβ/Bmp family can associate with different receptor complexes and trigger different 
physiological responses. Both pro- and anti-angiogenic properties have been ascribed to 
Tgfβ/Bmp factors, through effects on ECs and other cell types. For example at low doses, 
Tgfβ1 contributes to the angiogenic switch by upregulating angiogenic factors and 
proteinases, whereas at high doses, Tgfβ1 inhibits EC growth, promoting basement membrane 
deposition and stimulating smooth muscle cells differentiation and recruitment44. 
Vascular heterogeneity acquires even more prominence considering that several human 
vascular diseases such as vasculitis, atherosclerosis45 and rare diseases as Cerebral Cavernous 
Malformation (CCM)46, which will be described in details in the next chapters, show 
predilection to specific types of vessels (for schematic summary of endothelial heterogeneity 
see Fig.2).  
The basis for such vascular district-specific diseases is poorly understood, but may lie, in 
part, in the heterogeneity of ECs themselves and for this reason a detailed and deep knowledge 
of EC biology is crucial to find pharmacological solutions. 
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Figure 2. Schematic representation of different stages of vascular development. Endothelial cells 
differentiate from mesodermal progenitors called angioblasts, acquire specific markers, and form the primitive 
vascular plexus. The plexus undergo further remodeling in large and small vessels, arteries, veins, and 
lymphatics. Endothelial cells then acquire organ-specific characteristics induced by the crosstalk with cells of the 
surrounding tissues. All of these steps of endothelial differentiation are regulated by sets of transcription 
factors26. 
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2. A SPECIALIZED ENDOTHELIUM: THE BLOOD BRAIN BARRIER 
Among different type of specialized endothelia, one of the most surprising and complex 
is for sure the brain endothelium, a continuous non-fenestrated monolayer that, thanks to its 
unique barrier characteristic is able to form, together with other cellular components, a 
sophisticated structure referred as Blood Brain Barrier (BBB)47, 48. Lewandowsky was the first 
in 1900 to coin the term “Blood Brain Barrier”, when he observed that all the organs except 
the brain rapidly took up neurotoxic compounds injected into the vasculature and that only 
direct applications into the brain could lead to neuronal cell death. However, the BBB cellular 
and molecular basis remained unclear for decades. Today, we know that BBB is a peculiar 
multicellular interface that separates the central nervous system (CNS) from the peripheral 
blood circulation and carries out a fine control of both the trafficking of molecules and the 
delivering of nutrients and oxygen across the endothelium according to neuronal needs. This 
tight control allows BBB to protect the brain from toxins and pathogens, and to maintain the 
environment that allows neurons to function properly49. 
The BBB is present at all levels of the vascular tree within the CNS even if some 
regional differences are reported50, supporting a sub-specialization of the BBB functions. For 
example, there is a higher expression of nutrients transporters in the capillaries closer to 
neurons, whereas a finer regulation of leukocytes trafficking and immune modulation occurs 
in post capillary venules, which are surrounded by the perivascular space51. 
In the BBB the brain endothelium is constituted by ECs with peculiar molecular 
structure and characteristic allowing them to be the gatekeepers of the brain. These 
characteristics include continuous intercellular tight junctions, lack of fenestration, extremely 
low rate of transcytosis and consequently limited paracellular and transcellular movements of 
molecules through the EC layer. The trafficking of molecules across the endothelial layer is 
regulated by a series of specific transporters in both directions. Moreover, immune cell 
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infiltration in the CNS is very rare due to the low expression of leukocyte adhesion molecules 
on EC surface48, 49. Beside ECs, other cellular and non-cellular elements are extremely 
important for BBB development and maintenance in particular pericytes, astrocytes, neurons 
and the extracellular matrix (ECM), which enwrapped ECs to provide both structural and 
functional support. All this elements, together with the contribution of microglial cells and 
peripheral immune cells, constitute a peculiar microenvironment, which regulates BBB 
homeostasis known as neuro-vascular unit (NVU)52 (see Fig.3).  
In the last years, extensive efforts have been done in order to better characterize BBB 
unique structural and functional components. Comprehensive in vitro and in vivo analysis 
provided the elements for better understanding some of the molecular mechanism and 
signaling pathways at the basis of BBB complexity that will be discussed in the next chapter. 
 
 
 
 
 
 
 
 
 
Figure 3. The neurovascular unit at capillary level. Several cell types work in close association to maintain 
optimal brain function. Together they form the neurovascular unit. Cerebral endothelial cells are the main 
substrate of the BBB. Pericytes partially envelop the endothelial cells and share a common basal lamina with 
them. Astroglial endfeet envelope the microvessel wall. Pericytes and astrocytes are important in barrier 
induction and maintenance, and astrocytes provide links to neurons. Microglia are CNS-resident immune cells53. 
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2.1 Wnt/β-catenin signaling 
Recently different studies put a great effort trying to elucidate the molecular basis of 
BBB specialization. Extensive high-throughput genomic and proteomic approaches identified 
the Int/Wingless (Wnt)/β-catenin signaling as one of the master regulator pathways in CNS 
angiogenesis50.  
Wnt proteins belong to an incredibly evolutionary conserved family of secreted 
glycoproteins acting as ligands for receptor-mediated signaling pathways regulating different 
processes during the development and in the adults. 19 members of the Wnt family have been 
described so far, able to trigger different pathways. Wnt proteins are ∼40 kDa in size, contain 
many conserved cysteines54 and undergo several post-translational modifications55 before 
being secreted from cells. One of such post-translational modification consists in the 
attachment of a mono-unsaturated fatty acid (palmitoleic acid) to a conserved serine. This 
event takes place in the endoplasmic reticulum by the action of Porcupine enzyme. Wnt 
palmitoilation is required for efficient ligand activity and secretion56. Once secreted, Wnt 
proteins act as morphogens,	   molecules that exert their action across a distance in tissues 
forming a gradient that determines cell fate in a concentration-dependent manner. 
Wnt ligands interact with target cells recognizing a heteromeric receptor complex 
composed by both a receptor of the Frizzled (Fzd) family and a Lrp5/6 co-receptor57. 
Depending on the type of the ligand and on the molecular composition of the receptor 
complex, Wnt proteins can trigger different pathways. The best studied is the canonical 
Wnt/β-catenin pathway57, while the non-canonical pathways, including planar cell polarity 
pathway and calcium pathway, are still poorly understood58. In the canonical Wnt/β-catenin 
pathway, the association of the ligand with the receptor complex induces a conformational 
change of the receptor followed by phosphorylation of key target proteins such as Lrp5/659, 
which, in turn, activate an intracellular signaling cascade that has in β-catenin the main 
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downstream effector. In resting condition, free cytoplasmic β-catenin is maintained at very 
low levels due to the activity of the ‘destruction complex’, a multiprotein complex able to 
trigger β-catenin degradation through the proteasomal machinery. In particular the 
‘destruction complex’ harbors scaffold proteins, such as Axin and Adenomatous polyposis coli 
(APC), and kinases, such as Glycogen synthase kinase (GSK3) and casein kinase 1 (CK1), 
able to trigger sequential β-catenin phosphorylation at the level of serine 45 (by CK1) and 
then at threonine 41, serine 37 and serine 33 (by GSK3). β-catenin phosphorylation creates a 
binding site for the E3 ubiquitin ligase β-Trcp, leading to β-catenin ubiquitination and 
degradation60. The ligand-dependent activation of Wnt receptor complex initiates a series of 
events that culminate in the recruitment at cell membrane of members of the ‘destruction 
complex’ with the help of an adaptor protein called Dishevelled (Dvl)61. As a consequence, the 
‘destruction complex’ is no more active on β-catenin, which can accumulate into the 
cytoplasm and then translocate to the nucleus.	   Noteworthy, the Wnt pathway transduces 
signals differently from most of the other pathways. In many signaling cascades, the 
phosphorylation of downstream effectors amplifies the signal since individual kinases can 
target multiple substrate molecules. In contrast, Wnt stimulus titrates away negative 
regulators, the ‘destruction complex’ members, providing a stoichiometric rather than a 
catalytic mechanism of signal transduction57.  
The ultimate step of Wnt signaling cascade occurs in the nucleus where β-catenin is able 
to act as co-factor for the transcription of several target genes. The canonical partners of 
nuclear β-catenin are the transcription factors of the lymphoid-enhancer/T-cell factor (Lef/Tcf) 
family. When Wnt signaling is switched off the Lef/Tcf interact with Groucho transcriptional 
repressors, preventing gene transcription57, 62. When Wnt pathway becomes activated, the 
association with β-catenin transiently converts Lef/Tcf factors into transcriptional activators of 
target genes, with additional modulation of Lef/Tcf coming from phosphorylation63. Most of 
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the Wnt target genes are tissue or developmental stage specific and a multiplicity of molecular 
partners can modulate β-catenin transcriptionally response. However, Axin2 and Nkd1 genes 
are regarded as general transcriptional targets of β-catenin and therefore general indicators of 
Wnt pathway activity64. Among the most common transcriptional partners of β-catenin are 
CREB binding protein (Cbp) and P300, histone-modifier proteins able to induce DNA 
epigenetic activation57 (for a schematic representation of Wn/β-catenin signaling cascade see 
Fig.4). 
Other important β-catenin interactors are Smad proteins. These transcription factors are 
associated to Tgfβ/Bmp receptors and, upon receptor activation, are phosphorylated and 
translocate to the nucleus65. Smad–induced transcription is further dependent on co-activators 
that stabilize their association to DNA. Among others, Smads combined to β-catenin and this 
complex is crucial for the expression of genes involved in cell motility and endothelial to 
mesenchymal transition66-68.  
Wnt/β-catenin signaling can be modulated at many levels by physiological regulators 
including various secreted antagonists. Among these are molecules that bind Wnt proteins thus 
inhibiting ligand-receptor association such as secreted Frizzled-related proteins (sFrps) and 
Wnt inhibitory factors (Wifs). Other Wnt inhibitors include proteins of the Dickkopf (Dkk) 
family, which antagonize signaling by binding Lrp5/6 co-receptor disrupting Wnt-induced 
Fzd-Lrp complex formation57.  
The broad implications of Wnt/β-catenin signaling in different fundamental processes of 
health and disease make the pathway a prime target for pharmacological research and 
development. The complex regulation of β-catenin at its various locations provides alternative 
points for therapeutic interventions and many studies directed their attention to chemicals 
compounds screening trying to find pharmacological inhibitors of the Wnt/β-catenin pathway. 
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Figure 4. Wnt signaling cascade. (A) In the absence of Wnt, cytoplasmic β-catenin is engaged in a complex 
with Axin, APC, GSK3 and CK1 and is phosphorylated by CK1 and subsequently by GSK3. Phosphorylated β-
catenin is then uiquitinated by the E3 ubiquitin ligase β-Trcp, which targets β-catenin for proteosomal 
degradation. Wnt target genes are repressed by Tcf-TLE/Groucho and histone deacetylases (HDAC). (B) In the 
presence of Wnt ligand, Fzd and Lrp5/6 form a receptor complex and recruit Dvl, which, in turn, induces Lrp5/6 
phosphorylation and Axin recruitment. In this way degradation of β-catenin is impaired and allow β-catenin to 
accumulate in the nucleus where it serves as a co-activator for Lef/Tcf to activate Wnt target genes69. 
 
2.2 Development and maturation of Blood Brain Barrier 
The vascularization of CNS in mouse embryo starts at E9 exclusively via angiogenesis 
from a previously developed perineural vascular plexus (PNVP)70, 71. At E9.5 vascular sprouts 
start from PNVP and radially invade the neural tube toward the ventricular zone where they 
begin to remodel into capillaries70, 71. This process is not intrinsic to brain ECs but requires 
crosstalk with other cellular elements of the developing BBB. Indeed, transplantation 
experiments demonstrated that embryonic brain tissue from one species transplanted into 
ectopic sites of the embryo of a different species induced invasion of vessels from the non-
brain host tissue, which developed BBB characteristic72. These experiments provide evidences 
that ECs differentiate into BBB-forming vessels under the influence of the microenviroment. 
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More recently it became clear that the ability to induce BBB properties of neuroblasts 
implicate the activation of Wnt pathway73.  
During embryogenesis in mouse the Wnt/β-catenin pathway has been found activated in 
CNS endothelium but not in ECs of other districts, therefore pointing to a specific role of Wnt 
signaling in the CNS74. Several Wnt ligands and Fzd receptors can act at different time and in 
different regions of the CNS vasculature. In particular, the expression pattern of the most 
studied ligands such as Wnt1, 3a and 7b have been described and they were found to be 
expressed in very defined domain of CNS at early time point (E8.5 of mouse embryo 
development)74, 75. In particular Wnt1 and Wnt3a show a dorsal expression pattern while 
Wnt7b is ventrally distributed74-76. This defined distribution suggests a differential role for 
distinct Wnt factors to regulate CNS vascularization and barrier properties. 
While Wnt signaling is important at early steps of angiogenesis, it is likely down 
regulated in healthy, resting vasculature77. Evidences come from genetic experiments where 
different members of Wnt pathway have been selectively inactivated. For instance, mice 
knockout for Wnt7b but not Wnt7a die between E11.5 and E12.5 due to severe brain 
hemorrhages and abnormal vessel morphology in ventral regions. Combined inactivation of 
both ligands causes even more severe defects in CNS angiogenesis74, 78. These vascular defects 
are phenocopied by endothelial-specific inactivation of β-catenin74 in the CNS suggesting that 
Wnt7a/Wnt7b exert their function activating the canonical Wnt signaling pathway in the 
endothelium. Conversely, ablation of Fzd5 and Wnt2 leads to defects in placenta 
vascularization and, at least in the absence of Fzd5, to a defective remodeling of yolk sac 
vasculature26. Moreover, both loss-of-function (LOF) and gain-of-function (GOF) mutations 
of Fzd4 and Lrp5 recapitulate severe vascular defects resulting in early embryonic lethality26. 
Lack of the Wnt pathway effector β-catenin in ECs affects the development of the whole 
embryonic vasculature and results in early lethality due to diffuse hemorrages79. Similarly, the 
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induction of an endothelial-specific GOF for β-catenin results in even more dramatically 
vascular phenotype including lack of vascular remodeling, defects in branching and loss of 
venous identity28, 80. Consistent with these findings the endothelial-specific GOF of Fzd4 
induces a similar vascular phenotype26. Taken together these data indicate that Wnt/β-catenin 
signaling needs to be finely regulated in CNS endothelium and that either too much or too 
little can lead to major vascular aberrations. 
In addition to promote angiogenesis, Wnt/β-catenin signaling could contribute to 
vascular differentiation in the CNS by regulating the expression of the BBB genes including 
the transporter Glut1, Plasmalemmal vesicle-associated protein (Pl-Vap) and the tight junction 
protein Claudin377. Wnt/β-catenin signaling is high in ECs of CNS during embryonic life, 
while it dramatically drops soon after birth77. Nevertheless, a detectable signal subsists during 
the first post-natal days and decline slowly with the time, suggesting that BBB maturation is 
still ongoing. Therefore, the induction of EC migration into the CNS and the acquisition of 
BBB characteristics are driven by the same signaling pathway, suggesting a CNS-specific 
angiogenic program that imparts barrier-specific properties to the vasculature controlled by 
Wnt/β-catenin.  
The unique anatomical properties of CNS vessels suggest a continuous crosstalk with 
elements of the neurovascular unit. This is supported by the observation that ECs from CNS 
microvasculature lose rapidly their barrier characteristics when put in culture. This effect can 
be partially restored by co-culturing them with pericytes or astrocytes or by adding exogenous 
Wnt ligands81. As far as the maintenance of the BBB phenotype beyond the embryonic and 
neonatal phase, it has been recently shown that Norrin via Fzd4 is important to maintain 
endothelial barrier properties in the retina (another type of vasculature with BBB properties) 
and cerebellum of adult mice82. Indeed, the inactivation of either the gene or its cognate 
receptor Fzd4 leads to the loss of barrier characteristics and up regulation of the permeability-
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associated gene Pl-Vap82. This finding suggests that Wnt/β-catenin signaling can have a role in 
BBB maintenance throughout lifetime in addition to its role in BBB development and 
differentiation. Also in this case Wnt/β-catenin signaling needs to be tightly regulated during 
BBB development as suggested also by a recent work demonstrating that radial glia is 
involved in nascent vessel stabilization in cerebral cortex by inhibiting Wnt/β-catenin in 
ECs83. 
Finally, a further degree of complexity is proposed by the less-investigated possibility 
that different Wnt can determine region-specific effects potentially resulting in different 
‘subtypes’ of BBB with different functional meaning. 
 
2.3 Wnt/β-catenin signaling in pathology and pharmacological treatment 
Taking into consideration the critical role that Wnt signaling exerts during vascular 
angiogenesis and BBB maturation and maintenance, it is not surprising that many vascular 
pathologies and neurological disorders can derive from Wnt pathway deregulation and the 
resulting loss of BBB integrity. Characteristic tracts of BBB dysfunction are edema, 
recruitment of inflammatory cells and neuronal cell death, as observed for example in multiple 
sclerosis and ischemic brains in animal models for stroke. Mutations in either Fzd4 or Lrp5 
have been found in patients affected by familial exudative vitreoretinopathy characterized by 
defective retinal vascularization. The same phenotype has been observed in patients with 
Norrie disease carrying Norrin mutations. These findings leaded to the identification of Norrin 
as a ligand for Fzd4/Lrp5 receptor complex previously discussed26. Also brain tumors often 
show impaired BBB due to a continuous tumor-induced angiogenesis84. 
In addition to the CNS, mutations in different genes involved in Wnt/β-catenin signaling 
cascades have been reported in pathologies affecting different organs. For example mutations 
in Lrp5 have been found in patients with osteoporosis pseudoglioma syndrome, a recessive 
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disorder characterized by low bone mass and abnormal eye vasculature. Tcf4 is also 
implicated in type II diabetes even if the mechanisms are still unknown69. Deregulation of 
Wnt/β-catenin signaling is often associated with cancer in particular with colorectal cancer85. 
In this case different genetic alterations lead to a sustained β-catenin nuclear signaling and 
therefore to excessive stem cell renewal and proliferation. For this reason β-catenin has been 
frequently investigated as possible target for pharmacological treatment. Many lines of 
evidence attribute the beneficial effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in 
colorectal cancer therapy to their ability in inhibiting Wnt/β-catenin signaling86, 87.  
Several studies also reported β-catenin nuclear accumulation in blood vessels of 
glioblastoma multiforme characterized by abnormal vascular construction with glomeruloid 
appearance. Here the intracellular localization of β-catenin was found to be different from that 
of normal brain vessels. These data suggests an implication of endothelial Wnt/β-catenin 
signaling in tumor angiogenesis84.  
Identification of small molecules able to block Wnt/β-catenin signaling is a hot topic of 
modern research. Several compounds targeting different steps of Wnt/β-catenin pathway have 
been proposed for use in therapy, but few of them had a positive clinical outcome88. In 
preclinical models some of the most active compounds seem to be the Porcupine inhibitors, 
targeting the enzyme responsible for Wnt ligands post-translational processing and secretion. 
Other drugs, used up to now only in experimental models, include Tankyrases inhibitors88, 
which block a class of molecules responsible for Axin degradation. Increased amount of 
cytoplasmic Axin leads to enhanced β-catenin turnover. Inhibitors of the Tcf/β-catenin 
complex have also been proposed. Some examples are PKF-118 and ICG-00188. Finally, some 
natural compounds with a less defined molecular mechanism have been described to inhibit 
Wnt/β-catenin signaling such as Silibinin, Curcumin and Resveratrol89, 90. 
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Concluding, targeting Wnt/β-catenin could represent a potent tool allowing, from one 
side, to block altered pathological signaling and from the other to manipulate a complex 
system such as the BBB, critical for drug delivery into the CNS. 
 
2.4 Endothelial cell-to-cell junctions and vascular permeability 
Brain endothelium represents a very specialized vasculature with unique properties that 
ensure a tight control of permeability between blood and the nervous system. One of the 
cellular components involved in this process is the cell-to-cell junction complex. The presence 
of organized cell-to-cell junctions is a peculiar tract of all ECs. However, the molecular 
composition and physiological properties of these structures varies depending on the organ 
specific localization and vessels identity, suggesting context-specific functions34, 35. Here I will 
first focus on common features of endothelial cell-to-cell junctions, then discussing their role 
and organization in BBB. 
 
2.4.1 Common features of cell-to-cell junctions 
ECs are linked one to the other by adhesive proteins that are organized in highly 
specialized domains of the plasma membrane that control fundamental activities of the 
endothelium such as the barrier properties, growth and the response to soluble factors during 
physiological angiogenesis. At least two distinct macromolecular complexes can be 
distinguished in ECs: the tight junctions (TJs) and the adherens junctions (AJs) respectively91, 
92. These molecular structures, which occupy different positions on the cell surface, are 
associated to different functions: in particular AJs, localized more basally, initiate cell-to-cell 
contacts promoting their maturation and maintenance, while TJs, which occupy the most 
apical position of the junctional cleft, act by strictly regulating the paracellular passage of ions 
and solutes36.  
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Cell-to-cell junctions are not only mere sites of attachment between ECs but highly 
dynamic structures undergoing continuous remodelling. For this reason junctional clusters are 
subjected to multiple regulations that allow them to control crucial cell functions in vascular 
homeostasis. Likely, any change in junctional organization might either seriously impact on 
endothelial physiology or modify the normal architecture of the vessel wall.  
Although the specific molecular properties of cell-to-cell junctions in the different 
endothelia of the organism wait to be defined in details, it is clear that these structures can 
convey signals to the cell. The signals transmitted by the junctional proteins are multiple and 
regulate several fundamental aspects of endothelial physiology, generally maintaining a 
resting quiescent condition. Therefore, it is not surprising that angiogenic stimuli rapidly 
induce substantial alteration of junctional architecture and are accompanied by increased 
vessel permeability and, more in general, changes in the endothelial barrier function93. In most 
cases, changes in the endothelial permeability are reversible and intercellular junctions are 
rapidly restored with the exception of pathological conditions, such as chronic inflammation. 
Both AJs and TJs host a series of adhesive transmembrane molecules responsible for 
homophilic cell-to-cell adhesion, thus interacting with identical partners on adjoining cells 
(trans interactions) and on the same cell (cis interactions)91. In turn, the transmembrane 
proteins associate to a specific set of cytosolic partners forming multiprotein complexes, 
which have scaffold and signaling properties. The list of molecules that can localize at cellular 
contacts is constantly increasing suggesting the existence of distinct junctional complexes 
localized in discrete microdomain precisely regulating cellular response to specific conditions 
and stimuli94. What is clear is that, even if presenting several common general structural 
features, distinct molecules compose either TJs or AJs. In addition, many evidences support 
the concept that TJs and AJs are interconnected and that the state of AJs influences TJs 
organization. 
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2.4.2 Cell-to-cell junctions architecture 
Several transmembrane adhesive molecules have been identified at endothelial cell-to-
cell contacts including cell-type-specific proteins such as VE-cadherin at AJs95 and Claudin5 
at TJs96. ECs of all types of vessels express these two proteins. In particular VE-cadherin 
cannot be found in any other differentiated cell type and represents a hallmark of the 
endothelium, expressed early during development, as soon as cells become committed to the 
endothelial lineage. Although most components of endothelial junctions are not endothelial 
specific, some of them appear to play a selective role in endothelial physiology, as indicated 
by the specific vascular phenotype of KO mice and in some cases of zebrafish morphants and 
mutants97. Through their cytoplasmic tails, adhesion proteins of both types of junctions bind to 
actin microfilaments and transfer exogenous signals to the cell interior. The interaction of 
junctional adhesion proteins with the actin cytoskeleton is relevant in the maintenance of cell 
shape and polarity98. Many other actin-binding proteins and several kinases, adaptors and 
phosphatases cluster at endothelial junctions94.  
Tight junctions 
The main components of TJs are the members of Claudin family, a large family with 
more than twenty members. ECs express only few of them and in particular Claudin5 is 
predominantly expressed all along the vascular tree96. Other Claudins are found in different 
types of vessels responding to different needs in term of control of permeability such as 
Claudin16/paracellin1, which is responsible for paracellular flux of Mg2+ and Ca2+ in the 
kidney99, and Claudin3 that participates to the control of permeability in the brain 
endothelium77.	   In addiction Claudin5, but not Claudin12, critically control permeability of 
brain capillaries as indicated by the lethal leakage at brain capillaries observed early after birth 
in Claudin5 KO mice96.  
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In addition to Claudins other transmembrane proteins have been found at TJs such as 
Junctional adhesion molecules (JAMs), Occludin and Endothelial cell-selective adhesion 
molecule (ESAM)100, 101 contributing to intercellular adhesion in different ways. The 
intracellular aspect of TJs is characterized by the presence of multiple partners such as 
members of the Zona occludens (ZO) family (ZO1 and ZO2 in the endothelium), Cingulin, 
Zonula occludens associated nucleic-acid-binding protein (ZONAB), Partitioning defective 
protein (Par) 3 and Par6102-104. ZO proteins link Claudins and Occludin via Cingulin to 
intracellular actin cytoskeleton. Importantly, it has been shown that ZO1 and ZONAB are 
substrates of kinases such as Protein Kinase C (PKC), which is crucial for the formation and 
regulation of TJs105.	  Moreover different types of signaling components can bind the cytosolic 
domain of TJs such as GTP-binding proteins, kinases and phosphatases. For instance the 
signaling pathways transduced by Rho family members such as Rho have been implicated in 
the regulation of TJs106. 
Adherens junctions 
At the level of AJs the main players delegated to mediate cell-to-cell adhesion are the 
members of the cadherin family. In particular VE-cadherin is ubiquitously expressed in all 
types of vessel. N-cadherin is also expressed in the endothelium but is infrequently at inter-
endothelial contacts, except in some pathological situation such as tumors107. Several studies 
demonstrated that VE-cadherin is able to exclude N-cadherin from inter-endothelial junctions 
suggesting a differential role for these two molecules. Indeed, N-cadherin seems to promote 
endothelial communication with other cellular components of the vessels, such as pericytes 
and smooth muscle cells and to predispose ECs to a migratory phenotype107.  
Both VE- and N-cadherin bind catenins through their cytoplasmic domain: directly β-
catenin, Plakoglobin (also known as γ-catenin) and p12036 and indirectly α-catenin have a 
strong impact on the activity and stability of VE-cadherin108. Catenins, in turn, connect 
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cadherins to the cortical actin cytosckeleton and with several others molecules for the 
constitution of junctional signaling clusters. β-catenin, p120 and plakoglobin all contain 
homologous Armadillo repeats (the name of this domain come from the Drosophila 
orthologue of β-catenin, the segment polarity protein Armadillo, so-called because the mutants 
resemble armadillos) critical for their functions, which represents the binding site for most 
catenin-binding partners109. 
VE-cadherin can recruit several cytoplasmic molecules that regulate the local 
organization of the actin cytoskeleton. One of this is T-Cell lymphoma invasion and metastasis 
(Tiam)110, a guanine nucleotide exchange factor that activates Ras-related C3 botulinum toxin 
substrate (Rac) 1 for organization of peripheral actin bundles. The small GTPase, Ras-related 
protein (Rap)1, that plays a crucial role in the stabilization of endothelial junctions111, 
promotes the translocation to membrane of Tiam112. Rap1 links to VE-cadherin and can also 
mediate the association of the Rapidly accelerated fibrosarcom (Raf)1/Rho-associated protein 
kinase (Rock) complex to VE-cadherin to regulate the phosphorylation of Myosin light chain 
(MLC) 2 and actomyosin contractility at junction113.  
However, the classical cytoplasmic partner of VE-cadherin is β-catenin, which 
associates simultaneously to the carboxy-terminal cytoplasmic domain of cadherins and to α-
catenin, thereby forming a ternary complex. β-catenin is a very versatile adaptor molecule, 
which binds and recruits several regulatory and scaffold molecules to cell junctions. Therefore 
β-catenin provides a fundamental contribution to the molecular architecture and function of 
endothelial junctions. Indeed, truncated VE-cadherin, lacking the carboxy-terminal of the 
cytoplasmic domain and unable to bind β-catenin, induces in vivo and in vitro vascular defects 
superimposable to those observed after null mutation of VE-cadherin113, 114. 
It has been reported that the phosphorylation of tyrosine residues of β-catenin can 
decrease its binding affinity to VE-cadherin in response to Vegf115. Also Focal adhesion 
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kinase (FAK) could contribute to the weakening of endothelial junctions in response to Vegf, 
phosphorylating the tyrosine residue 142 of β-catenin and decreasing its association to VE-
cadherin in vivo116. However, other reports are in contrast with the model in which VE-
cadherin/β-catenin complex is modulated by tyrosine phosphorylation of β-catenin and further 
investigation would be needed to better address this issue.  
In some conditions of severely and constantly disorganized junctions, β-catenin can 
partially dissociates from VE-cadherin. For example, this has been reported in CCM1-silenced 
ECs117. A reasonable hypothesis is that in ECs even a limited decrease in the association 
between VE-cadherin and β-catenin is sufficient to create (subtle) local discontinuities in the 
molecular composition of cell-to-cell junctions that weaken the continuity of the monolayer 
and impair its barrier function.  
In addition to its adaptor role at junctions, β-catenin is a crucial regulator of 
transcription57. The relative ratio between junctional-associated β-catenin and free β-catenin is 
critical since free β-catenin is released in the cytoplasm where is either rapidly degraded by 
the ubiquitin–proteasome pathway or translocates to the nucleus to regulate several target gene 
expression in association with members of the Tcf/Lef family of transcription factors as 
previously discussed.  
Besides catenins, growth factor receptors like Vegfr2 also associate to cadherin cluster, 
as well as kinases (as Src) or phosphatases (such as vascular Endothelial protein tyrosine 
phosphatase (VE-PTP) and Density-enhanced protein tyrosine phosphatase1 (Dep1)). AJs can 
also recruit several other mediators such as Caveolin 1, CCM proteins, the polarity complex 
Par3–Par6, PKC and many others36, 118-120. For detailed lists of molecules associated to VE-
cadherin see121, while for a schematic representation of endothelial cell-to-cell junction 
organization see Fig.5. 
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Due to the central role of junction clusters in regulating the localization and the activity 
of several signaling molecules, cell junctions should not be considered only as adhesive 
complexes, but rather real signaling center conveying and processing myriads of exogenous 
and endogenous stimuli.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of tight junctions and adherens junctions in endothelial cells. In 
endothelial cells Claudins, Occludin, JAM proteins, and ESAM mediate adhesion at tight junctions. The 
cytoplasmic components of tight junctions are ZO proteins, cingulin, ZONAB, and others. At adherens junctions, 
adhesion is promoted by cadherins (VE-cadherin and N-cadherin), which directly bind to p120, β-catenin, and 
plakoglobin. Different actin binding proteins have been found to be associated to adherens junctions such as α-
catenin, vinculin and others. In addition, phosphatases (Dep1, VE-PTP, etc.) and kinases (src and others) are 
directly or indirectly associated to adherens junction components. Growth factor receptors: Vegfr2 and TgfβR 
complex could bind to VE-cadherin complex. This interaction modulates their signaling properties122.  
 
2.4.3 Endothelial cells junctions and signaling 
Besides regulation of endothelial functions, achieved through the local organization of 
specific signaling complexes to AJs as described in the previous paragraphs, the ‘degree of 
tightness’ of VE-cadherin association to junctions appears to regulate the transcriptional 
profile of ECs123. ‘Degree of tightness’ means distinct and specific molecular complexes 
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recruited by VE-cadherin to AJs as a function of the duration and stability of its engagement in 
an adhesive interaction. In general, the molecular details of the dynamic remodeling of such 
complexes are still poorly known. Some examples include the association of cell junction 
molecules with other angiogenic receptors. For example clustered VE-cadherin can modulate 
the activity of receptors that act as crucial regulators of vessel organization such as Vegfr2124 
and Tgfβr2125. Vegfr2, once activated by Vegf, becomes phosphorylated on different tyrosine 
residues (mainly Y951, Y1175 and Y1212)126. These phosphorylated tyrosines become 
docking sites for different mediators that can activate locally different signaling pathways126 
depending on the stability of the junctions. In particular, we have observed that when VE-
cadherin is engaged in stable contacts, as in confluent endothelial monolayers, activated 
Vegfr2 associates to VE-cadherin through β-catenin and activates Phosphatidylinositol3-
kinase (PI3K) (also associated to VE-cadherin through β-catenin) to phosphorylate Akt and to 
signal cell survival and resistance to apoptosis123, 124. When VE-cadherin is engaged in 
dynamic junctions, like in cells undergoing angiogenic responses, Vegf-activated Vegfr2 
preferentially stimulates PLCγ and Mitogen-activated protein kinase (Mapk) pathway, 
inducing cell proliferation127. Such signaling can take place from endocytic compartments in 
which Vegfr2 is internalized in association to VE-cadherin through a clathrin-dependent 
process127.  
VE-cadherin clustered in stable contacts can modulate the endothelial behavior forming 
a complex with another regulator of vascular physiology, the Tgfβ receptors125. The functional 
consequence of such local regulation is the activation by Tgfβ of anti-proliferative and anti-
migratory responses. Such signaling would contribute to the stability of the mature endothelial 
layer. On the contrary, in ECs with weakened junctions, as after treatment with a VE-cadherin 
blocking antibody125, or with reduced level of VE-cadherin128, Tgfβ receptors are not or less 
associated to VE-cadherin125. This dis-activates the anti-proliferative and anti-migratory 
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response elicited by Tgfβ and it can even re-direct Tgfβ signaling towards de-differentiation 
(mesenchymal transformation) of ECs.  
VE-cadherin has been recently shown also to associate to the Fibroblast growth factor 
(Fgf) receptor 1 and reduce its phosphorylation in response to Fgf2 engaging the phosphatase 
Dep1 in a multiprotein complex129. 
AJs and TJs are not completely independent units but are strictly interconnected. For 
instance AJs can transfer signals that induce TJ assembly. Indeed, VE-cadherin clustered to 
cell-to-cell junctions activates a signaling pathway that up regulates the transcription and the 
deposition at junctions of Claudin5, the major transmembrane component of the TJs123. 
Clustered VE-cadherin recruits PI3K, through β-catenin as described above. This kinase 
locally activates Akt that, in turn, phosphorylates the transcription factor Forkhead-box 
O1 (FoxO1), a major repressor of Claudin5 transcription in association to β-catenin. The 
phosphorylated FoxO1 is excluded from the nucleus (phosphorylation on Thr24 promotes its 
exclusion from the nucleus and phosphorylation on Ser256 inhibits its binding to DNA), thus 
relieving the inhibition of Claudin5 transcription123.  
Among the interactors of VE-cadherin, β-catenin plays an important role in coordinating 
the state of junction compartment to the quality and type of transcription in the nuclear 
compartment. Although, such regulation is evident from a functional point of view, the details 
of the underlying molecular mechanism are still virtually unknown.  
 
2.4.4 Cell junctions and nuclear β-catenin regulation 
β-catenin can be engaged in AJs, where exerts a scaffold role, or recognized by the 
degradation complex which triggers its phosphorylation. For this reason β-catenin can subsists 
in ECs in a phosphorylated state (Thr41 to Ser37 and Ser33) destined to proteasomal 
degradation and in a de-phosphorylated state. De-phosphorylated β-catenin, referred as active 
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β-catenin, can localize at cell-to-cell contacts or in the nucleus where acts as a crucial 
regulator of transcription in association to Lef/Tcf transcription factors57. The relationship 
between junctional and nuclear pool of β-catenin remains at the present an unsolved general 
issue in cell biology, besides ECs. It is not known whether nuclear β-catenin originates from 
junctions or whether it comes from a distinct pool. In Drosophila the existence of two distinct 
pools, junctional and nuclear, of the β-catenin homologue armadillo, is ascertained130, and 
confirmed in C. elegans131. In contrast, in mammalian epithelial cells, photo-activatable Green 
fluorescent protein (GFP)-tagged β-catenin has been observed to re-localize from E-cadherin 
to the nucleus upon dissociation of AJs132. 
While it is reasonable to hypothesize that some communication exists between these two 
pools, the molecular details of such connection are not defined. A possible mechanism through 
which cell-to-cell junctions could regulate the level of the cytoplasmic pool of β-catenin and 
indirectly the level of nuclear β-catenin has been reported in epithelial cells133. In these cells 
crucial components of the β-catenin phospho-destruction complex, such as axin, APC and 
GSK3β, are localized to cell-to-cell contacts where cadherins can promote N-terminal 
phosphorylation of β-catenin leading to its proteasomal degradation.  As a consequence, when 
junctions are tightly organized N-terminal phosphorylation of β-catenin and its turnover are 
enhanced. The reduced pool of cytoplasmic β-catenin would limit the nuclear distribution of 
β-catenin and its transcriptional activity. Whether the phospho-destruction complex acts on β-
catenin released from cadherin or on an independent pool is not yet clarified. However, such 
coordination between tightness of junctions and targeted degradation of β-catenin could 
regulate the cytoplasmic and nuclear amount of β-catenin and allow the cell to mount a 
transcriptional response, mediated by β-catenin, appropriate to the state of junctions. 
 
	   50	  
2.4.5 Nuclear β-catenin in endothelial cells 
In addition to the above general questions, ECs present a peculiarity respect to the 
classical model of a direct balance (proportion/ratio) between the cytoplasmic and nuclear 
level of β-catenin. In our experience, ECs can concentrate β-catenin in the nucleus without 
apparently requiring accumulation of (stabilized) β-catenin in the cytoplasm as generally 
observed after stimulation with Wnt in other cell types124. Constant finding in ECs is that 
when AJs are poorly organized β-catenin concentrates in the nucleus and regulates 
transcription. Examples of weak cell-to-cell contacts are ECs in non-confluent layers as during 
angiogenic responses, models of pathological conditions as after ablation of the CCM1 gene117 
and the extreme experimental situation of VE-cadherin null ECs124. Remarkably, in each of 
these circumstances, although the total level of β-catenin can decrease, even to extremely low 
level, as in VE-cadherin null ECs, residual β-catenin concentrates into the nucleus where it is 
transcriptionally active.  The mechanism of such nuclear localization of low total level of β-
catenin is not yet defined at the present. Notably, β-catenin lacks nuclear localization 
sequences117, 201. Recently, FoxM1 has been reported to be required for nuclear localization of 
β-catenin in glioblastoma134. 
When junctions are poorly organized β-catenin induces a transcriptional profile 
characterized by loss of differentiation markers and acquisition of endothelial-to-mesenchymal 
transition (EndMT) markers128 as discussed below.  
 
2.4.6 Endothelial junctions and endothelial differentiation: the case of EndMT 
Endothelial-to-mesenchymal transition (EndMT) represents a process of de-
differentiation driven by transcriptional reprogramming that targets also the composition and 
function of cell-to-cell junctions135, 136. In the course of this process, the pro-migratory N-
	   51	  
cadherin partially substitutes for VE-cadherin129. The so-called cadherin switch, with N-
cadherin substituting E-cadherin, is indeed a well-established trait of EMT (epithelial-to-
mesenchymal transition) in epithelial cells135, 137.  Transcriptional repression of E-cadherin is 
well defined in these cells and similar mechanisms involving Twist, Snai1 and Snai2 operate 
also in ECs138. Classical characteristics of mesenchymal phenotype are: increased 
proliferation, increased motility, loss of polarity, loss of contact inhibition, expression of 
mesenchymal markers such as α-SMA and S100a4. However, reorganization of cell-to-cell 
junctions might also represent a priming event of EndMT. Although the precise relationship 
between junctional and nuclear β-catenin is poorly defined, as discussed above, β-catenin 
might represent one of the molecular link(s) in the re-shaping of both junction organization 
and transcription profile that characterizes the EndMT. Indeed, β-catenin can drive the 
transcriptional up regulation of EndMT markers and properties also cooperating with the Tgfβ 
pathway135. 
A physiological example of EndMT takes place during the formation of the heart 
cushion in the embryo139. In this case, not only β-catenin is transcriptionally active in ECs 
undergoing the transformation, but also it is required for the initiation of the process, that is 
subsequently reinforced by the activation of ECs by Tgfβ2 produced in the heart tissue. At 
initial stages of transformation ECs co-express α-smooth muscle actin and the endothelial 
marker VE-cadherin139. Although the cells undergoing such transformation become highly 
motile, the organization of endothelial cell-to-cell junctions has not been examined in details, 
in particular it remains to be defined whether the expression of the pro-migratory N-cadherin 
is increased129 (Fig.6 summerize different stages of EndMT). 
EndMT has been increasingly studied for its crucial contribution to various pathologies 
characterized by fibrosis (renal and cardiac fibrosis) as well as to cancer135, 137. As far as 
vascular pathology, EndMT takes place and has a causative role128 in the Cerebral Cavernous 
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Malformation (CCM), as it will be discussed later. In this genetic vascular disease, endothelial 
AJs constitute an early target of the loss-of-function mutations of any of the three CCM genes. 
In the absence of CCM VE-cadherin and β-catenin become highly disorganized and the 
endothelium loses its barrier properties. Subsequently, N-cadherin substitutes VE-cadherin at 
junctions, which remain highly disorganized, as a consequence of delocalization of Rap1 and 
activation of Rho117, 139, 140. Reshaping of AJs is accompanied by induction of an array of 
EndMT markers, among which: CD44, S100a4, Ly6a, Klf4 and Id1 that contribute to the 
pathological vascular phenotype128.  If and how disorganization of junctions has a causative 
role in the transcriptional reshaping and in the initiation of EndMT besides being a target of 
this process remains to be defined. In addition, EndMT is reinforced by activation of the 
Tgfβ/Bmp signaling that in CCM1-knockout ECs is cell autonomous, through the production 
of Bmp6128. These observations suggest that both β-catenin and Tgfβ/Bmp pathway can be 
involved in the control of EndMT. 
 
Figure 6. Stages of endothelial-to-mesenchymal transition (EndMT). (A) Different autocrine and/or paracrine 
stimuli can initiate EndMT such as the most studied Tgfβ. Possible sources include endothelial cells themselves, 
resident fibroblasts or immune cells. The vascular basement membrane is likely to be degraded by matrix 
metalloproteinases (MMPs) derived from local immune cells. (B–C) Transitioning endothelial cells acquire a 
migratory phenotype, invade underlying basement membrane and begin to express mesenchymal markers, such 
as S100a4, while still expressing endothelial markers. (D) Cells that have undergone EndMT completely loose 
their endothelial phenotype and contribute to the local fibroblast population137. 
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2.4.7 Endothelial cell-to-cell junctions in the Blood Brain Barrier 
Since brain barrier needs to be finely controlled in terms of vessel permeability, the 
composition and the regulation of endothelial cell-to-cell junctions is crucial for BBB 
homeostasis. For this reason TJs are particularly abundant and complex in the brain where 
they explain their important role not only for barrier function but also for the maintenance of 
cell polarity and for a correct differential distribution of molecules between luminal and 
abluminal compartments.  
One of the main players involved in BBB integrity is Claudin5 as demonstrated by the 
fact that Claudin5-deficient mice exhibit a size-selective loosening of the BBB97.  
Claudin3 also participates in BBB control of permeability. Wnt3a-77 or Wnt7a- or 
Wnt7b-dependent78 activation of primary brain ECs in vitro and in vivo increases Claudin3 
expression together with other molecules important for BBB maintenance. Consistently, 
selective loss of Claudin3 was observed in altered cerebral microvessels of human 
glioblastoma multiforme where permeability control was lost141. These findings suggest that 
the BBB can be manipulated to allow selective diffusion of small molecules 
In parallel, Wnt induces stabilization of AJs, with increased localization to junctions of 
VE-cadherin and β-catenin77, 78. As far as AJs, both VE-cadherin and β-catenin appear to be 
more regularly disposed to cell-to-cell contact in Wnt3a-treated ECs from brain microvessels, 
however this is not the consequence of the transcriptional activation of these genes. The 
molecular mechanisms of strengthening of AJs in response to Wnt is not yet defined in ECs, 
although it might involve regulation of small GTPases142.   
All in all the transcriptional responses elicited by nuclear β-catenin appears to be 
coordinated to the state of endothelial cell-to-cell junctions. The molecular mechanisms that 
direct such alternative responses of ECs are still mostly unknown. 
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3. CEREBRAL CAVERNOUS MALFORMATIONS 
Vascular malformations are defined as localized defects associated with abnormal 
angiogenesis, altered vascular integrity and bleeding. In particular, BBB integrity is crucial for 
CNS homeostasis and its break down is associated to different pathological conditions47. 
Among numerous pathologies affecting the BBB one of the most relevant is the Cerebral 
Cavernous Malformation (CCM), also referred as cavernoma or cavernous angioma. CCMs 
are vascular malformations that occur predominantly in the vasculature of the CNS even if 
also retina and skin can be interested by this pathology143. CCM lesions consist in mulberry-
like enlarged clusters of sinusoids (caverns) lined by a thin layer of ECs surrounded by a thick, 
discontinuous basal membrane. Very few sub-ECs and no intervening parenchyma are features 
of the altered endothelium144. CCM lesions occur in the venous-capillary vascular bed and 
present low flow sometimes associated with thrombosis and calcifications143. The ultra 
structural analysis of ECs in the lesions revealed poorly developed TJs and AJs and the 
absence of enwrapping astrocyte end feet. The fragility of the endothelium within the lesions 
reflects a compromised BBB responsible for vessels leakiness and breaks. Indeed, clinical 
symptoms include strokes, intracranial hemorrhages, seizures and focal neurogical outcomes 
depending on the site of lesion145. No correlations between lesions development and defined 
anatomical region localization within CNS have been described. However, a CCM can also 
remain neurologically silent and it has been estimated that only approximately 60% of patients 
are symptomatic146. 
 
3.1 CCM genetics 
CCM is a relatively common disease with prevalence in the general population of 1 out 
of 200 individuals and can occurs both in a sporadic (80% of cases) and familial form (20% of 
cases), inherited in an autosomal dominant manner with variable penetrance. Sporadic CCM 
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patients usually develops a single lesion that can be detected through cerebral magnetic 
resonance imaging, while the familial form presents multiple lesions with a strong association 
between the number and size of lesions and the age of the patients146, 147.  
In contrast with the sporadic form that it is not hereditated, the familial CCM is usually 
characterized (90% of familial CCM) by germ line mutations in three different CCM genes 
known as CCM1/Krit1, CCM2/MGC4607/OSM/Malcavernin and CCM3/Pdcd10/TFAR15146, 
147. Recently a CCM2 paralog called CCM2L was found expressed selectively in ECs during 
periods of active cardiovascular growth. Anyway, although important for cardiovascular 
development, there are no evidences of CCM2L relevance in the development of the 
cavernoma148.  
The progress of CCM lesions seems to occur following a ‘second hit’ mechanism. In this 
case loss of one allele in all cells (germ line mutation) would be followed in some ECs by a 
somatic mutation in the other allele (second hit). Anyway the detection of homozygous 
mutations inside the lesion is not easy and the results, still controversial, open the possibility 
that other additionally factors potentially specific for the neurovascular environment, could be 
necessary for the development of the lesions149. Animal models, in particular genetically 
modified mice constitutively knockout for CCM1, CCM2 or CCM3, enforced the ‘second hit’ 
hypothesis since they die during embryogenesis due to cardiovascular defects, whereas 
heterozygous mice are viable and rarely develop CCM lesions143, 150, 151 as discussed better in 
the next chapter. Moreover, CCM1 heterozygous mice only when crossed with error prone 
background mice such as p53-/-152 or Msh2-/-153 develops vascular malformations.  
Mutations in CCM1 gene account for about 56% of familial CCM, whereas the CCM2 
gene occurs in 33% of the cases. Surprisingly, CCM3 locus, show mutations only in a low 
percentage of familial cases (6%), suggesting the existence of, at least, a fourth CCM gene154. 
Recently a potentially new CCM gene, named ‘zona pellucida-like domain containing 1’ 
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(ZPLD1), has been identified even if its functional role in CCM pathology remains to be 
determined155. CCM incidence can vary in certain populations, for example Hispanic 
populations of Mexican descent appear to be more susceptible to dominantly inherited CCMs 
(50% of the patients), due to a founder mutation145.  
Several causative mutations within the three CCM genes have been described mostly 
resulting in premature stop codons leading to nonsense-mediated mRNA decay or truncated 
proteins. CCM genes seem to be ubiquitously expressed in human tissues and not restricted to 
vasculature, suggesting a widespread functional significance even if endothelium is the 
election site for the disease (see above)156.  
The average age of onset is between the 2nd and 5th decades of life, but symptoms can 
start in early infancy or in old age. In particular, CCM3 mutations are associated with a more 
severe phenotype and earlier age of onset. Indeed, CCM3 mutations may confer a higher risk 
for cerebral hemorrhage, particularly during childhood. Additionally, CCM3 is the most 
evolutionary conserved among the CCM genes (from humans to insects while CCM1 and 
CCM2 are conserved from human to fish). 
 
3.2 Animal models for CCM 
Several animal models have been developed to study CCM pathology. Due to its 
transparency and genetic tractability, significant amount of work has been carried out in 
zebrafish to determine the functions of the CCM genes. Initially two orthologue of CCM genes 
have been studied: santa (san, the zebrafish orthologue of CCM1) and valentine (vtn, the 
zebrafish orthologue of CCM2). Fishes with loss-of-function mutations in san or vtn 
developed dilated, thin-walled vessels that failed to form lumens very reminiscent of human 
CCM. This phenotype seems to be due to abnormal endothelial cell spreading, a potential 
mechanistic insight into CCM pathogenesis157, 158. Most recently, it has been shown that a 
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deletion of pdcd10 (CCM3 orthologue), which is duplicated in the zebrafish genome, results in 
the same abnormal phenotype of san and vtn mutants making the zebrafish the first non-
human model organism to link all three CCM genes phenotypically159. Interesting san, vtn and 
pdcd10 mutants share a common phenotype with fish lacking heart of glass (heg). Heg is a 
single-pass transmembrane protein expressed in the endocardial cells; its mutations in 
zebrafish lead to a dilated heart phenotype. Despite multiple studies demonstrated that Heg is 
an important binding partner of CCM1 suggesting a role for it within the CCM complex, 
mutations in the human orthologue of HEG1 have not been identified in patients with CCM160, 
161. 
Different mice models have been also developed to study the etiology of the pathology, 
showing a similar widespread expression patterns for CCM1, CCM2 and CCM3 genes156. 
Although CCM proteins are not endothelial–specific, they seem to have a specific activity in 
the endothelium. The constitutive and ubiquitous ablation in the mouse of any of the three 
CCM genes determines generalized vascular disorganization and early embryonic lethality 
(around E10)140, 143, 150. Mice with a gobal deletion of CCM3 die earlier (E8.0 to E8.5) respect 
to CCM1 and CCM2 KO mice (E9.5). CNS-specificity for vascular lesions appears if gene 
ablation is induced after birth, using endothelial-restricted KO128, 143, particularly in the venous 
bed. CCM gene selective deletion in other CNS cell types failed to give a pathological 
phenotype with the exception of neural-specific deletion of CCM3, which recapitulate CCM 
lesions as described by Louvi et al.162.  Anyway, what is clear is that the vasculature of the 
CNS is particularly affected by CCM ablation with development of focal vascular 
malformations resembling human cavernomas in the brain, cerebellum and retina163. Unlike 
zebrafish, Heg1-knockout mice do not phenocopy CCM genes deletion161.  
The molecular mechanism of this typical organ specificity remains still to be explained. 
It might depend either on specific characteristics of the differentiated endothelium in the CNS 
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or on the persistence of endothelial precursors that could be particularly affected by CCM gene 
mutations128.  This hypothesis may fit with the observation in the transgenic mice that the 
number of cavernomas and the rate of their appearance is maximal when gene recombination 
is induced soon after birth and decreases sharply when recombination is postponed even by 
few days143. In addition, it is described that ECs in the CNS acquire a fully differentiated 
phenotype early after birth77. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CCM lesions from a human patient and abnormal vessel remodelling in murine CCM null 
model. (A) Cerebral MRI showing multiple CCM lesions. (B) Surgical view of a CCM lesion. (C and D) Whole 
mount PECAM staining of control (C) and CCM2 null mouse embryos (D) at E10.5 showing abnormal vascular 
remodeling in the aorta, outflow tract and head vessels122. 
 
3.3 CCM proteins function and pathological implications 
Although independent loss-of-function mutations of any of the CCM genes lead to very 
similar clinical manifestations, CCM proteins are structurally distinct and share no sequence 
homology. Anyway, it is known that CCM proteins can associate in a multiprotein complex, at 
least in in vitro overexpression experiments164, 165. For instance interaction between CCM1 and 
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CCM2 protein is necessary for correct protein localization at cell-to-cell contact in ECs166. 
Moreover, overexpression of the newly identified CCM2L protein, able to compete with 
CCM2 for CCM1 binding but unable to bind to CCM3, mimics CCM2 deletion in EC 
cultures167. By contrast, single CCM proteins can have different intracellular localization and 
can interact with different unique partners168. Actually the role of CCM protein complex in the 
cavernoma physiopathology is still controversial even if some functions of the CCM proteins 
seem to require partial complex formation. By the way, either as a part of a complex or as 
single molecular entities, CCM proteins exert a critical role in ECs processes including cell-to-
cell junctions integrity, cell polarity, cytoskeletal remodeling, lumen formation and 
angiogenesis168. 
Enhanced permeability is a peculiar characteristic of CCM lesions and now it is clear 
that CCM proteins prevent endothelial barrier dysfunction acting on endothelial junction 
formation and maintenance and actin remodeling. One of the mechanisms by witch CCM 
proteins contribute to the control of endothelial permeability is the regulation of small GTPase 
RhoA and Rho kinase140, 166. The consequence of Rho kinase activation by RhoA is the 
phosphorylation of a series of target proteins involved in stress fiber formation, motility, cell 
polarization and permeability. Alterations of these processes have been associated to CCM 
depletion in ECs. In particular endothelial ablation of CCM1 leads to an increase in number of 
stress fibers and the inhibition of Rap1-mediated stabilization of cell junctions in a RhoA-
dependent mechanism117. CCM2 mutations in ECs share the same phenotype probably due to 
the role of CCM2 in RhoA degradation169. The relationship between CCM3 and RhoA is less 
clear and many controversial reports have been presented. Anyway, CCM3 is able to associate 
with the Striatin-interacting phosphatase and kinase (STRIPAK) complex proteins including 
Protein phosphatases 2a (PP2A) and Ser/Thr kinases of the Germinal center kinase (Gck)III 
family (Mammalian STE20-like protein kinase (MST)4, Serine/threonine-protein kinase 
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(STK)25 and STK24)170, which, in turn, have been seen to activate RhoA inhibitor moesin171. 
In any case the role of STRIPAK in RhoA regulation needs to be further investigated. 
CCM proteins are also crucial for the formation and maintenance of EC junctions. As 
aforementioned, Rap1 is a partner of CCM1, which act as a scaffold protein for a membrane-
tethered complex containing VE-cadherin and β-catenin117, 201. Indeed, CCM1 deletion 
induces junction weakening and increase in permeability probably due to Rap1 mis-
localization. Lack of CCM2 or CCM3 also increase EC permeability, but while for CCM2 AJs 
and TJs disruption is a well-established hallmark, in CCM3 mutants the effect on junction 
stability has been poorly investigated140, 143.  
Due to the critical role of cell-to-cell junctions not only as structural complexes but also 
in orchestrating intracellular signaling, impaired junctional stability, in the absence of CCMs, 
leads also to a de-regulation of several signaling pathways. For instance, β-catenin associates 
with VE-cadherin in resting conditions and it has been reported that knocking down the CCM1 
protein in cultured aortic ECs promotes Wnt/β-catenin signaling117, 201. However, to date, there 
are no indications of the relevance of the β-catenin pathway in the formation of these vascular 
lesions in vivo.  
In addition to their role in supervisioning to endothelial barrier properties, CCM proteins 
are also important in angiogenesis. In vivo deletion of CCM genes has already revealed that 
CCM proteins are essential for cardiovascular development and differentiation140, 143, 150. 
Indeed, loss of CCM1 results in an excessive angiogenesis due, at least in part, to a 
deregulation of Delta-Notch pathway172. Other angiogenic signaling pathways are affected by 
the absence of CCM proteins (e.g. Mapk and Akt pathway)140, 150 but molecular functions have 
not yet been resolved and some of the data are still controversial. 
Recently our group published very important data demonstrating that CCM pathogenesis 
is driven by EndMT128. This process consists, as previously described, in the acquisition of 
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mesenchymal and stem-cell-like characteristics by the endothelium and normally plays a key 
role in the heart cushion development173. Anyway, the acquisition of EndMT markers by the 
CNS endothelium results in a loss of endothelial stability and is crucial for the development of 
CCM. The molecular mechanisms linking CCM proteins to EndMT are still unknown even if 
one of the mediators of this process is for sure the Tgfβ/Bmp pathway, acting through its 
downstream effectors Smads to a transcriptional level128. However, other important signaling 
pathway can contribute to this process and some of them are already under investigation. 
CCM3 has additional functions compared with CCM1 and CCM2 proteins174. For 
example it has been reported to associate to the Vegfr2 and to stabilize it therefore promoting 
Vegf signaling150. Anyway, most of the recent works pointed their attention on the association 
of CCM3 with the GckIII, which, in turn, can regulate proliferation, migration and apoptosis 
in ECs174. These studies suggested that the biological role of CCM3 might differ from those of 
CCM1 and CCM2, which may explain why mutations in CCM3 gene lead to high risk for 
hemorrhages, in particular at younger age in human patients. 
Despite the huge effort lavished in last years to understand CCM pathophysiology, the 
reasons behind how and why CCM lesions arise are still a mystery. Since CCM proteins seem 
to be crucial for EC homeostasis and are implicated in the regulation of several signaling 
pathways, one of the hypothesis is that loss of CCM genes could lead to a hyper-activation of 
the angiogenic program in CNS endothelium eventually resulting in irregular and unstable 
vascular structures. However, additional stimuli may be necessary to promote lesion 
development. Indeed, the endothelial-specific ablation of CCM genes in newborn mice 
(postnatal day 1) leads to the formation of severe multiple vascular malformations while, at 
least for CCM2, gene deletion in adult mice rarely results in cavernoma formation143. This 
indicates that an active angiogenesis program and environmental factors may promote 
cavernoma development. In the same direction can be interpreted the finding that CCM3 
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mutation in neuronal cells activates astrocytes and produces vascular lesions that resemble this 
pathology162. This thus reinforces the importance of cellular crosstalk within the neurovascular 
unit. 
Another critical question is why CCM lesions arise predominantly in the CNS 
endothelium despite the fact that CCM genes are widely expressed in different cell types. One 
possible explanation is that CCM proteins are required to maintain BBB integrity, which is a 
unique structure that needs fine control of many different signaling pathways essential for its 
homeostasis. 
 
3.4 Clinical intervention in CCM patients 
Nowadays the only clinical option to remove the vascular malformations for CCM 
patients is neurosurgery. Anyway, often this treatment is not possible due to lesion localization 
that does not allow operating safely. For this reason most of the hopes for the future reside in 
the possibility to find new pharmacological treatment. Recently, Whitehead and colleagues 
proposed statins as pharmacological tool to inhibit RhoA activation and consequently vascular 
permeability140. Similarly Stockton et al. used Fasudil, a direct inhibitor of Rho kinase 
activity, to reduce lesions in mice models166. Another interesting insight is our recent work 
into the link between CCM and Tgfβ/Bmps pathway and its implication for potential 
therapeutics128. In this work we found that both inhibitors of TβRI (LY-364947), TβRII (LY-
2109761) and Bmp (DMH1) are able to reduce CCM lesion extensions in murine models. 
Anyway, interventional drug treatments are still at the dawn of clinical strategies and much 
more work is still required in this direction.  
For these reasons one of the main aims of this project is to investigate deeply the 
molecular mechanisms implicated in CCM development in order to find new targets for 
pharmaceutical intervention that can be developed in clinical trials for patient treatment. 
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AIM OF THE PROJECT 
CCM is a vascular disease, which affects between 0.1 and 0.5% of the population. At the 
present the molecular mechanisms leading to CCM pathogenesis are still unknown. For this 
reason nowadays the only therapy available for CCM patients is neurosurgery that often it is 
not possible due to the CNS-specific location of CCM lesions. Recently, we have 
demonstrated that there is a physiological process known as EndMT, which is crucial for the 
development of CCM malformations even if the signaling pathways involved in this process 
are still largely unexplored.  
The main aim of this project is to investigate and to identify new signaling pathways 
involved in CCM pathogenesis and in particular in EndMT process in order to select targets 
for novel therapeutic approaches. Taking in consideration this aspect, the second main aim of 
my thesis is to test in in vivo and in vitro models molecules potentially active on new 
identified targets that could be used and developed in future for patients treatment. 
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MATERIAL AND METHODS 
Transgenic mice 
Different transgenic mice have been used in this study: 
- CCM3-flox/flox mice: these mice were generated at TaconicArtemis (Koeln, 
Germany) on a Black6/C57N background according to the knock-in procedures. In this 
case two P-lox sequences were inserted that flank exons 4 and 5 of the murine CCM3 
gene. P-lox sites can be targeted by the Cre-recombinase enzyme, which induces 
recombination and subsequent excision of the nucleotides inserted between P-lox 
sequences. These mice have been used to control in a time-dependent manner the 
deletion of CCM3 gene. 
- Cdh5(PAC)-CreERT2 mice175: these mice have been kindly donated by Dr. R.H. 
Adams, (University of Munster, Munster, Germany) and present the CreERT2 gene 
under the VE-cadherin (Cdh5) promoter. Since VE-cadherin is an endothelial specific 
gene, the expression of CreERT2 is confined to the endothelial district. CreERT2 gene 
expresses a fusion protein in which Cre-recombinase has been fused together with the 
regulatory domain of the estrogen receptor. This domain is able to retain Cre-
recombinase into the cytoplasm of ECs in resting conditions. Only after stimulation 
with estrogen or an analogue such as Tamoxifen CreERT2 fusion protein can dimerize 
and translocate to the nucleus where it can act on P-lox sites to drive homologous 
recombination. This model allows the operator to induce Cre-recombinase expression 
in an endothelial specific fashion just by Tamoxifen administration. 
- BAT-gal mice176: these transgenic mice (kindly donated by Dr. S. Piccolo, Padova, 
Italy) harbor LacZ reporter gene under β-catenin/TCF consensus sequences. In 
particular 7 TCF/LEF consensus sequences and a Siamoisis minimal promoter are able 
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to control bacterial β-galactosidase expression in all cell types. This model allows the 
operator to monitor the activation of β-catenin transcription signaling in vivo. 
- Rosa 26-Enhanced Green Fluorescent Protein (EYFP) (Rosa26EYFP) mice177: these 
mice (kindly donated by Dr. S. Casola, IFOM, Milan, Italy) express the EYFP gene in 
the Rosa26 locus. A stop codon flanked by P-lox sequences is present in the EYFP 
gene. This means that in normal condition EYFP protein is not expressed and only 
after Cre-recombinase activation the fluorescence protein can be detected in cells. This 
model is an important tool to monitor the expression of Cre-recombinase and its 
efficency in vivo through the expression of EYFP. 
 
CCM3-flox/flox mice were bred with Cdh5(PAC)-CreERT2 mice for Tamoxifen-
inducible endothelial cell-specific expression of Cre-recombinase and CCM3 gene 
recombination. The CCM3-flox/flox–Cdh5(PAC)-CreERT2 mice were further bred with 
BAT-gal mice to monitor the activation of β-catenin transcription signaling, and with Rosa 26-
EYFP mice to monitor the expression of Cre-recombinase. 
 
Endothelial cell-specific recombination in CCM3-flox/flox mice 
In order to induce Cre-recombinase activation and CCM3 recombination in vivo 
Tamoxifen (Sigma) was dissolved in corn oil and 10% ethanol (at 10 mg/ml), and then diluted 
1:5 in corn oil before single intragastric administration to dpn 1-2 pups (35 mg/kg body 
weight) (see175). The control wild-type mice included CCM3-flox/flox–Cdh5(PAC)-
CreERT2–BAT-gal mice treated with the vehicle used to dissolve the Tamoxifen (corn oil 
plus 2% ethanol), and CCM3+/+–Cdh5(PAC)-CreERT2–BAT-gal mice treated with Tamoxifen 
or treated with the vehicle used to dissolve the Tamoxifen (corn oil plus 2% ethanol). 
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Mouse genotyping 
The following probes were used for the mouse genotyping through genomic PCR: wild-
type CCM3 allele: 5’ GAT AGG AAT TAT TAC TGC CCT TCC 3’, 5’ GAC AAG AAA 
GCA CTG TTG ACC 3’; deleted CCM3 gene after recombination induced by Cre 
recombinase: 5’ GAT AGG AAT TAT TAC TGC CCT TCC 3’, 5’ GCT ACC AAT CAG 
CTT CTT AGC CC 3’, Cdh5(PAC)-CreERT2 gene: 5' CCA AAA TTT GCC TGC ATT ACC 
GGT CGA TGC 3', 5' ATC CAG GTT ACG GAT ATA GT 3'; BAT-gal gene: 5' CGG TGA 
TGG TGC TGC GTT GGA 3', 5' ACC ACC GCA CGA TAG AGA TTC 3'; Rosa 26 EYFP 
gene: 5' GCG AAG AGT TTG TCC TCA ACC 3', 5' GGA GCG GGA GAA ATG GAT ATG 
3, 5' AAA GTC GCT CTG AGT TGT TAT 3'. 
 
 
 
 
 
 
Figure 8. Mice genotyping. Representative genomic PCR using specific primer on mouse tail DNA run on a 1% 
agarose gel.  
 
Immuno-staining for fluorescence microscopy of brain sections and retinas  
Brains and eyes from mice pups were fixed in 3% paraformaldehyde immediately after 
dissection, and this fixing was continued overnight at 4 °C. The retinas were dissected from 
the eyes just before staining as the whole mount. Fixed brains were embedded in 4% low-
melting-point agarose and sectioned along the sagittal axis (150 mm) using a vibratome (1000 
Plus, The Vibratome Company, St. Louis, MO, US).  
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Brain sections and retinas (as whole-mount) were stained as floating samples in 12-well 
and 96-well plates, respectively. They were blocked overnight at 4 °C in 1% fish-skin gelatin 
with 0.5% Triton X100 and 5% donkey serum in phosphate-buffered saline (PBS) containing 
0.01% thimerosal. The samples were incubated overnight at 4 °C with the primary antibodies 
diluted in 1% fish-skin gelatin with 0.25% Triton X100 in PBS containing 0.01% thimerosal. 
Following washing with 0.1% Triton X100 in PBS, the secondary antibodies were added for 4 
h at room temperature in 1% fish-skin gelatin with 0.25% Triton X100 in PBS containing 
0.01% thimerosal. The incubation with DAPI was in PBS for 4 h, which was followed by 
several washes in PBS, post-fixating with 3% paraformaldehyde for 5 min at room 
temperature, and further washes in PBS. The brain sections were mounted in Vectashield with 
DAPI, and the coverslips fixed with nail varnish; the retinas were mounted in Prolong gold 
with DAPI. 
 
In vivo treatment with sulindac sulfide and sulindac sulfone  
Sulindac sulfide (Sigma-Aldrich) and sulindac sulfone (Sigma-Aldrich) were both 
dissolved in DMSO and further diluted 1:50 in corn oil. They were administered 
intragastrically, daily (30 mg/kg body weight), starting one day after the induction of 
recombination. The control mice were treated in parallel with vehicle only (corn oil plus 2% 
DMSO). We did not observe either increased bleeding from vascular lesions or mortality in 
drug-treated CCM3-ECKO mice in comparison to vehicle-treated ones.  
 
Assessment of lesion burden  
For the classification and counting of lesions, entire brains from 9 dpn littermate pups 
were sectioned and immunostained for Pecam as described above. Sections were then 
examined under wide-field fluorescence microscopy (10× and 20×). Lesions were classified as 
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described in178 as mulberry (multiple cavernae, group of more than two contiguous cavernae), 
single caverna (single dilated vessel with maximal diameter accommodating more than 25 red 
blood cells), or telangiectases, tortuous small vessels with abnormally dilated lumen). 
As the sections were 150-mm thick, a correction was applied to the number of mulberry 
lesions, which can span two sections. Therefore, the number of mulberry lesions was divided 
by 2.5. The lesions were counted and classified independently by two observers who were 
blinded to the treatments. 
The maximal diameter of the mulberry lesions and single cavernae was used for 
statistical comparison. 
 
Quantification of endothelial-positive nuclei after immuno-staining for specific antigens 
In order to assess the enrichment in malformed vessels of certain nuclear antigens a 
count of endothelial-positive nuclei has been performed after immune-staining with specific 
antibodies. Endothelial cell nuclei were counted in 50 random fields at 63× magnification of 
confocal acquisitions in brain sections from at least 5 CCM3-ECKO mice and 5 WT mice at 
both time points respectively. Nuclei were marked with DAPI. To better define the positive 
versus negative condition, pictures were modified using brightness and contrast Photoshop 
tool. 
 
Cell cultures 
The cell cultures used in this study were: 
- ECs derived from brain of CCM3-flox/flox adult mice (8-10 weeks old). Briefly, brains 
were removed from mice and stored in buffer A [150mM NaCl, 5.6 mM KCl, 2.3 
CaCl2, 15 mM Hepes, 5% BSA] on ice. The remainder of the isolation took place 
under aseptic conditions. Each brain was rolled on Whatman 3MM chromatography 
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blotting paper to remove the meninges. The cortices were dissected away from the 
surrounding tissue and much of the brain white matter was subsequently removed. The 
cortices were mashed with forceps and thoroughly triturated, followed by a 1h 
digestion at 37°C with 0.7 mg/mL type 2 collagenase in buffer A. Afterwards, the 
enzyme solution was diluted with buffer A and centrifuged at 1000 g for 10 min at 
4°C. The pellet was re-suspended in a 25% BSA solution and centrifuged for 20 min at 
1000 g and 4°C to obtain a microvessel enriched cell pellet. Then, the pellet was 
further digested in 1 mg/mL collagenase/dispase 15 min and 39 U/mL Dnase I for 5 
min at 37°C. The digested microvessel solution was diluted with buffer A and 
centrifuged at 700 g and 4°C for 10 min. The pellet was re-suspended and layered over 
1% rat tail collagen I (BD 354236) coated plastic plates. A concentration of 4 µg/mL 
of Puromycin have been used to remove contaminating cell types without any 
noticeable BMEC growth inhibition. Cells were than infected with an adenovirus 
encoding GFP (control) or Cre-recombinase at culture day 1 to obtain CCM3 deletion. 
These cells have been kept as primary culture for no longer than 2 weeks (see77).	   
- ECs derived from lung of CCM3-flox/flox mice. Briefly, lungs were removed from 
mice finely lungs with scalpels and disaggregate in 15-20 ml D-MEM+5% FBS N.A.+ 
Collagenase A (1.5 mg/ml, Roche)+ DNase (25 µg/ml, Roche). Suspension was 
incubate in agitation at 37°C for 2-3 hours and then filtered in 70 µm filters and then 
centrifuged at 1200 rpm for 5 min. Pellets were re-suspended in complete medium and 
cells seeded in gelatin 0.1% coated wells (24 wells plate) 30000 cells/wells. After two 
days endothelial cells were immortalized through retroviral expression of polyoma 
middle T gene179 and than infected with an adenovirus encoding GFP (control) or Cre-
recombinase to obtain CCM3 deletion. In this case a continuous cell line has been 
established and kept in culture for more than 20 passages. 
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Brain ECs has been cultured in DMEM medium supplemented with 10% North 
American (NA) fetal bovine serum (FBS) (Hyclone), glutamine (2 mM), 
penicillin/streptomycin (100 units/l; Sigma) and sodium pyruvate (1 mM). Lung ECs have 
been cultured in MCDB 131 (GIBCO) medium with 20% FBS (HyClone), glutamine (2 mM; 
Sigma), penicillin/streptomycin (100 units/l; Sigma), sodium pyruvate (1 mM; Sigma), 
heparin (100 µg/ml, from porcine intestinal mucosa; Sigma), and EC growth supplement 
(ECGS) (5 µg/ml, made in our lab from calf brain) (complete culture medium). Starving 
medium was MCDB 131 (GIBCO) with 1% bovine serum albumin (BSA) (EuroClone), 
glutamine (2 mM), penicillin/streptomycin (100 units/l) and sodium pyruvate (1mM). All ECs 
were seeded on flask coated with 0.1% DifcoTM gelatin (BD). 
293T-Phoenix-Ecotropic packaging cells were provided by IFOM Cell Culture facility 
and cultured in DMEM medium supplemented with 10 % South American (SA) FBS 
(Hyclone), glutamine (2 mM) and sodium pyruvate (1 mM). Low passage AD-HEK293 cell 
line (human embryonic kidney, American Type Culture Collection, Manassas, VA), used for 
adenoviral production, were provided by IFOM Cell Culture facility and grown in DMEM 
medium supplemented with 10% FBS NA, glutamine (4 mM), penicillin/streptomycin (100 
units/l), and sodium pyruvate (1 mM). 
All cells were cultured at 37°C in a humidified atmosphere with 5% CO2. 
 
Drug treatment of cells in culture 
Drugs were added to confluent cells for 48 h before the indicated assays. The final 
concentrations used were: 135 mM sulindac sulfide (Sigma-Aldrich, Calbiochem), 125 mM 
sulindac sulfone (Sigma-Aldrich), 200 mM silibinin (Sigma-Aldrich), 40 mM curcumin 
(Sigma-Aldrich), 40 mM resveratrol (Sigma-Aldrich), 0.5 µg/ml Dkk1 (R&D system), 0.5, 2.5 
and 5 µM IWP2 and IWP12 (Sigma-Aldrich). As all of these were dissolved in DMSO, 
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control treatment (vehicle) was 0.1% DMSO final concentration, as for drug treatment. 
Preliminary experiments to assess the right dose have been carried out before choosing the 
experimental conditions. 
 
Lentiviral and adenoviral preparations 
The following lentiviral constructs were used: 
- Lef-ΔβCTA (in HIV3 vector): encoding a stabilized mutant of β-catenin was obtained 
from C. Brancolini, University of Udine, Udine, Italy180. 
- GFP control (in HIV3 vector) 
Packaging plasmids were kindly donated by L. Naldini (HSR-TIGET, San Raffaele 
Telethon Institute for Gene Therapy, Milan, Italy). Lentiviral vectors were produced according 
to the following protocol: 4x106 293T-Phoenix-Ecotropic packaging cells were seeded in 
158cm2 flasks and on day 1 were transfected with the viral vectors using calcium chloride 
(6mM) and HBS and incubated overnight with the transfection mix. On day 2 the medium 
containing the transfection mix was removed and 293T-Phoenix-Ecotropic cells were grown 
in as little medium as possible to concentrate the virus. On day 3 the medium containing the 
virus was removed, passed through a 0.45 µm diameter filter, supplemented with Polybrene (8 
µg/ml, from IFOM Cell Culture facility) and placed on cells to be infected. The same 
procedure was repeated on day 4. Infected cells were selected with Puromycin 3 µg/ml. Cells 
were kept under selection until control non-infected cells died. 
  
The dnTCF4 adenoviral construct was kindly donated by S. J. George (Bristol Heart 
Institute, Bristol, UK). Infectious viruses were purified and titered using standard techniques. 
Briefly, for adenovirus production AD-293T cells were infected with 2 pfu/cell in DMEM 
without serum for 1 h at 37°C. Then, the infection medium was removed and cells were grown 
	   72	  
in an appropriate volume of DMEM + 5% horse serum until complete cell lysis is obtained 
(usually 72h later). The medium containing the viruses was then subjected to 3 freeze-and-
thaw cycles in order to destroy all the cells and to set as many virions as possible free. The 
resulting supernatant was then centrifuged at 3000 rpm for 30 min at +4°C to eliminate the 
cellular debris, aliquoted and stored at -80°C. For the infection of ECs two consecutive cycles 
of infection [5h and overnight (O/N)] were performed with MOI of 300 in 1 ml of complete 
culture medium. 
 
Western blot 
Cells in culture have been solubilized to obtain total proteins lysates using Sample 
Buffer (SB) containing 2% SDS, 5% glycerol 0.05 M Tris-HCl (pH 6.8), 0.004% 
Bromophenol blue and 5% β-mercaptoethanol. Lysates were incubated for 5 minutes at 100°C 
to allow protein denaturation and then spinned for 5 min at 13000 rpm to discard cell debris. 
The supernatants were collected and the concentration of protein was determined using a 
BCATM Protein Assay Kit (Pierce) according to manufacturer’s instructions. Equal amounts of 
proteins were loaded on gel and separated by SDS-PAGE, transferred to a Protran 
Nitrocellulose Hybridization Transfer Membrane 0.2 µm pore size (Whatman) and blocked for 
1 h at RT in 1X Tris Buffered Saline Tween (TBST) [150 mM NaCl, 10 mM Tris-HCl (pH 
7.4), and 0.05% Tween] containing 5% (w/v) powdered milk. For phospho-protein analysis 
5% BSA have been used instead of milk. The membranes were incubated overnight at 4°C 
with primary antibodies diluted in 1X TBST-5% BSA. Next, membranes were washed 3 times 
with 1X TBST for 5-10 minutes each and incubated for 45 minutes at RT with HRP-linked 
secondary antibodies (diluted in 1X TBST-5% BSA). Membranes were rinsed 3 times with 
TBST for 5-10 minutes each and specific binding was detected by the enhanced 
chemiluminescence (ECL) system (Amersham Biosciences) using HyperfilmTM (Amersham 
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Biosciences) or the ChemiDoc gel imaging system (BIORAD). The molecular masses of 
proteins were estimated relatively to the electrophoretic mobility of co-transferred prestained 
protein markers, Broad Range (Cell Signalling Technology). 
Quantification of western blot bands optic densitometry was performed using ImageJ. 
 
Cell fractionation 
Experiments were carried out starting from 2 flasks with 75 cm2 area of confluent cells 
for each cell types and all procedures were done in cold room at 4°C and on ice. Cells were 
washed 2 times with ice-cold PBS and finally collected in 5 ml volume. Lysates were 
transferred in 15 ml tubes and centrifuged at 5000 RPM for 5 minutes at 4°C. Supernatant 
were discard and pellet re-suspended in hypotonic buffer [10 mM Hepes, 100 mM KCl, 1.5 
mM MgCl2, 0.5 mM DTT] in a volume 3 times the pellet size. Suspensions were homogenized 
using Dounge homogenizer to induce cell breaks. Cells were transferred in a 15 ml tube and 
centrifuged at 1000 x g 4°C for 5 minutes. Supernatants representing the cytoplasmic fraction 
were collected. The pellet containing cells nuclei were washed 3 times with hypotonic buffer 
and then incubated with nuclear extract buffer [20 mM Hepes, 20 mM NaCl, 420 mM MgCl2, 
0.2 mM EDTA, 25% glycerol] 30 minutes 4°C under gently shacking. Nuclei were 
centrifugated 30 minutes at 15000 x g and supernatants, containing the nuclear fraction, 
collected. Nuclear extracts were diluted in order to reduce the high concentration of NaCl 
1:2.8 (NaCl final concentration=150 mM). Hot SB 4x were added to cell fractions and boiled 
for 5 minutes. Also the pellet containing cell membranes were lysated with SB to obtain a 
third fraction. All the buffers contained freshly added protease inhibitor cocktail (IFOM 
Kitchen Facility). Protein concentration was determined with BCATM Protein Assay Kit and an 
equal amount of protein was incubated with either immune antibodies overnight at +4°C as 
previously described for western blot. 
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Co-Immunoprecipitation 
Cells were grown until confluent and starved overnight. Cells were then washed once 
with DMEM without serum and incubated with 0.4 mg/ml of 
dithiobis(succinimidyl)propionate (DSP) (Pierce) for 30 min at 37°C to induce molecules 
crosslinks. After several washes with ice-cold PBS, cells were lysed in ice-cold modified 
RadioImmunoPrecipitation Assay (RIPA) buffer (Tris HCl pH 7.5 100 mM, NaCl 150 mM, 
Deoxycholic acid 1%, SDS 0,1%, CaCl2 2 mM). The protein lysate was precleared with an 
appropriate volume of Protein G Sepharose 4B (Zymed) for 3 h at +4°C. Then, protein 
concentration was determined with BCATM Protein Assay Kit and an equal amount of protein 
was incubated with either immune antibodies or species- matched control antibodies overnight 
at +4°C. On the following day immunocomplexes were collected using Protein G Sepharose 
4B for 3 h at +4°C. Beads were then washed several times with modified RIPA buffer and 
boiled in an appropriate volume of SB. Samples were analyzed by standard Western blot 
analysis as described above.  
All the buffers contained freshly added protease inhibitor cocktail (IFOM Kitchen 
Facility). 
Co-Immunoprecipitation for VE-cadherin shown in this work has been performed with 
two different antibodies against VE-cadherin. 
 
RNA interference 
Stealth RNAi Duplexes (Life Technologies) and the correspondent Medium GC Stealth 
RNAi Control Duplexes (Life Technologies) were used to knockdown VE-cadherin and 
CCM3. The sequences of the oligonucleotides used were the following: 5'-
AGACAGACCCCAAACGUAA-3', 5'-GAAAAUGGCUUGUCGAAUU-3', 5'-
AGGGAAACAUCUAUAACGA-3', 5'-CCGCCAACAUCACGGUCAA-3' for VE-cadherin 
	   75	  
and 5'-ACUUCACCGAGUCCCUCCUUCGUAU-3', 5'-
GGGCACUUAAGAUUCUCAGUAA-3', 5'-GACAAUCAAGGAUAUAGCUAGUGCA-3'  
for CCM3. Transfection was performed using LipofectAMINE 2000 (Invitrogen) according to 
the manufacturer's instructions. 
 
Immuno-staining microscopy on cell culture 
Immunofluorescence microscopy staining was performed using standard technique. 
Briefly, cells were fixed and permeabilized for 25 minutes with 1% paraformaldehyde, 
0.875%	  tri-ethanol-ammine with 0.1% triton-100 and 0.1% NP40. Fixed cells were incubated 
for 1h in a blocking solution (5% BSA in PBS). Cells were then incubated overnight at 4 °C 
with primary antibodies diluted in blocking buffer. Appropriate secondary antibodies were 
applied on cells for 45 min at RT and mounted with VECTASHIELD with DAPI (Vector 
Biolabs). 
Samples were observed under an epifluorescence microscope (DMR; Leica) or confocal 
microscope (Leica) using a 20X, 40X and 63X objectives. Images were processed with Adobe 
Photoshop using adjustments of brightness and contrast in the preparation of the figures. For 
comparison purposes, different sample images of the same antigen were acquired under 
constant acquisition settings. 
 
rt-PCR  
RNA extraction was performed with RNeasy kits (74106; Promega) according to the 
manufacturer's protocol. The RNA (1 µg) was reverse transcribed with random hexamers 
(High Capacity cDNA Archive kits; Applied Biosystems). The cDNA was amplified with 
TaqMan gene expression assays (Applied Biosystems) by the IFOM rq-PCR facility. For each 
sample, the expression levels were determined with the comparative threshold cycle (Ct) 
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method, and normalized to the housekeeping genes encoding 18S and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The probes to identify the CCM3 mRNA transcript were 
custom designed, as: forward, CGAGTCCCTCCTTCGTATGG; reverse, 
GCTCTGGCCGCTCAATCA; reporter sequence, CTGATGACGTAGAAGAGTACA. 
Probes (Applied Biosystems) that have been validated to recognize the following mouse 
transcripts in rt-PCR were used: Axin2, Lef1, Myc, Ccnd1, Klf4, Ly6a, S100a4, Cd44, Id1, 
Nkd1, Cdh5, Bmp2, Bmp6, Tuba1a, Tubb1. 
 
Top/Fop-Flash assay  
For the detection of β-catenin-dependent transcription of a reporter target, the Top-Flash 
plasmid was used (0.3 mg/cm2 cell culture area), which contains seven Tcf/Lef binding sites 
that control the transcription of firefly luciferase181 (kindly donated by Dr. M.P. Cosma, 
previously at Telethon Institute for Genetics and Medicine, Naples, Italy, now at Centre for 
Genomic Research, Barcelona, Spain). This was transfected into the ECs from lung using 
Lipofectamine 2000, according to the manufacturer’s instructions (Invitrogen). The pCMV 
plasmid for constitutive expression of β-galactosidase was co-transfected (0.1 mg/cm2), for 
normalization of luciferase expression over transfection efficiency. As the negative control, a 
Fop-Flash plasmid was used that contained six mutated (i.e., inactive) Tcf/Lef sites upstream 
of a minimal promoter and the firefly luciferase gene (0.3 mg/cm2). This was co-transfected 
with the β-galactosidase plasmid, for normalization, as above. The Dual-Light Reporter Gene 
assay system (Applied Biosystems) for the combined detection of firefly luciferase and β-
galactosidase was used. The cell extraction and detection of chemiluminescence (Glomax 96 
microplate luminometer; Promega) was carried out according to the manufacture’s 
instructions.  
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Affymetrix 
Primary ECs have been derived from the brain of CCM3-flox/flox mice ten weeks old, 
put in culture (see cell cultures paragraph) and treated with recombinant Wnt3a (100 ng/ml, 
Peprotech, 315-20) or Ctr vehicle every 24h and infected with adeno Cre or adeno GFP virus. 
RNA was extracted and analyzed using Affymetrix GeneChip arrays Gene ST 1.0 covering 
29.000 murine genes. For each condition, total RNA from three distinct extractions was used 
to measure biological variability. In order to identify the modulated genes, an initial filter was 
applied to select transcripts regulated at least 2 fold and with a statistical p-value below 
0.05182.  
 
Active Rap1 pull-down assay  
Active Rap1 pull-down assay was performed using the GST-fused Rap1-binding domain 
of Ral GDS obtained by transforming E. coli strain BL21 with a pGEX-2T-RalGDS-RBD 
expression vector (kindly donated by Ruggero Pardi, San Raffaele Scientific Institute, Milan, 
Italy)183. The fusion protein was affinity purified on Glutathione-Sepharose 4B beads (GE 
Healthcare) by standard methods.  
Briefly, ECs were lysed by addition of 1 volume of cold 2x RIPA lysis buffer to cell 
suspension. Lysis was performed at 4°C for 10–30 min. Lysates were clarified by 
centrifugation at maximal speed in an Eppendorf centrifuge for 10 min at 4°C. Five µg of 
RalGDS-RBD coupled Glutathione-Sepharose 4B beads (GE Healthcare) were added to the 
supernatant and incubated at 4°C for 30–90 min with slight agitation. Beads were washed four 
times in 1x RIPA. After the final wash, Laemmli sample buffer was added to the samples. 
Next, proteins were fractionated by SDS–PAGE and transferred to Protran Nitrocellulose 
Hybridization Transfer Membrane 0.2 µm pore size (Whatman).  
Densitometric analysis was performed using ImageJ imaging software.  
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Antibodies and reagents 
The following antibodies were used: anti-Pecam (hamster; MAB1398Z, Millipore); anti-
β-galactosidase (chicken; ab9361, Abcam); anti-VE-cadherin (rat monoclonal; 550548, BD 
Biosciences); anti-VE-cadherin (goat; sc-6458, Santa Cruz); anti-active-β-catenin 
(dephosphorylated on Ser37 or Thr41, mouse monoclonal; clone 8E7 05665, Millipore); anti-
total-β-catenin (mouse monoclonal; 610154, BD Bioscience); anti-S100a4 (rabbit; 07-2274, 
Millipore); anti-Klf4 (goat; AF3158, R&D); anti-CD44 (rat; 553131, BD Biosciences); anti-
Id1 (rabbit; sc-488, Santa Cruz); anti-Ly6a (rat; ab51317, Abcam); anti-GFP (rabbit; A-6455, 
Invitrogen); anti-Podocalyxin (goat; AF1556, R&D); anti-KI67 (rabbit; Ab1667, Abcam); 
anti-CCM3 (rabbit; 10294-1-AP, Proteintech); anti-α-tubulin (mouse monoclonal; T9026, 
Sigma); anti-p-Smad1 (Ser463/465) (rabbit; BA3848, Millipore), anti-p-Smad1 (rabbit; 9516, 
Cell Signaling); anti-Smad1 (rabbit; 6944, Cell Signaling); anti-p-Smad3 (rabbit; 18801, 
Epitomics); anti-Smad3 (rabbit; 9523, Cell Signaling); anti-p-Lrp6 (Ser1490) (rabbit; 2568, 
Cell Signaling); anti-Total Lrp6 (rabbit; 3395, Cell Signaling); anti-Vinculin (mouse; V9131, 
Sigma); anti-Rap1 (rabbit; Sc-65, Santa Cruz);  anti-histone H3 (rabbit; ab1791, Abcam); anti-
VE-cadherin (rat, Produced in our laboratories, clone BV13), Biotin-conjugated isolectin B4 
(Vector Lab), revealed with Alexa555-conjugated streptavidin (Molecular Probes), was also 
used to identify ECs in retina and brain sections. 
The secondary antibodies for immunofluorescence were anti-Alexa448 and anti-
Alexa555, and Cy3-conjugated antibodies raised in the donkey against immunoglobulin of the 
appropriate animal species (Molecular Probes or Jackson Laboratories).  
The secondary antibodies for Western blotting were HRP-linked anti-mouse, anti-rat and 
anti-rabbit antibodies (Cell Signaling), and HRP-linked anti-goat antibodies (Promega). 
Recombinant Wnt3a (Peprotech, 315-20) was used to stimulate cells in culture. 
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Statistical analysis  
Non-parametric Wilcoxon signed-rank tests were used to determine the statistical 
significance of the lesion burdens after the pharmacological treatments in vivo. Student’s two-
tailed non-paired t-tests were used to determine the statistical significance in the other in vitro 
and in vivo analyses. The significance level was set at p <0.05. Pearson test was also used for 
Affymetrix analysis. 
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RESULTS 
 
Establishment of a mouse model for CCM3 cavernomas 
In order to study the role of CCM3 gene in cerebral cavernous malformations we 
developed a mouse model that recapitulates the hereditary form of the human pathology. To 
this aim CCM3-flox/flox mice were crossed with Cdh5(PAC)-CreERT2 mice77, for 
Tamoxifen-inducible endothelial-cell-specific expression of Cre-recombinase and CCM3 gene 
recombination. CCM3-flox/flox–Cdh5(PAC)-CreERT2 mice were then bred with Rosa 26-
Enhanced Green Fluorescent Protein (EYFP) mice177 to monitor the expression of Cre-
recombinase through the expression of EYFP.  
CCM3-ECKO mice (with endothelial-specific-inactivation of CCM3 gene induced at 
early postnatal stage) presented evident malformations and hemorrhages (see Fig.9a and 
Materials and methods) in the cerebellum and retina vasculature comparable to CCM vascular 
lesions in patients. These lesions began to appear three to four days after treatment with 
Tamoxifen, and they progressively increased in size. Starting from 10 days after Tamoxifen 
treatment, CCM3-ECKO mice die with evident hemorrhagic cerebellum. In the brain, some 
superficial vascular malformations can also be observed, but most of the lesions can only be 
detected after sectioning and immunostaining (Fig.9b, 9c and 9d). No vascular malformations 
have been detected in other organs of CCM3-ECKO mice. While constitutive endothelial-
selective inactivation of CCM3 is embryonically lethal with general angiogenic defects150, this 
is the first report of endothelial-cell-selective inactivation of CCM3 after birth. 
These malformations exclusively develop on the venous side of the vascular network, 
which can be distinguished morphologically in the retina (Fig.9b) and by Endomucin-positive 
staining (Fig.9c), even though Cre recombinase is also active in the arteries as attested by  
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Figure 9. Establishment of in vivo model for endothelial-specific and inducible deletion of CCM3 gene.      
(a) The CCM3-flox/flox–Cdh5(PAC)-CreERT2 mice were treated with Tamoxifen (10 mg/kg body weight, as 
described in Materials and Methods) at 1 dpn to induce endothelial-cell-selective expression of Cre recombinase 
and recombination of the flox/flox CCM3 gene (CCM3-ECKO mice). The macroscopic appearance following 
dissection showed evident lesions in the cerebellum and retina (arrowheads). In the brain, some superficial 
vascular malformations can also be observed (small arrowheads), but most lesions can only be detected after 
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sectioning and immunostaining, as shown in the main text. Tamoxifen did not induce any phenotype both in 
CCM3-flox/flox–Cdh5(PAC) mice negative for CreERT2, that did not express Cre recombinase, and in the 
heterozygous CCM3-flox/+–Cdh5(PAC)-CreERT2 mice. The WT mice were CCM3+/+–Cdh5(PAC)-CreERT2 
mice treated with Tamoxifen. CCM3-flox/flox–Cdh5(PAC)-CreERT2 mice treated with the vehicle used to 
dissolve Tamoxifen also showed a WT phenotype. Scale bar, 1cm. (b) CCM3-flox/flox–Cdh5(PAC)-CreERT2 
mice were bred with Rosa 26-Enhanced Green Fluorescent Protein (EYFP) mice (see Materials and Methods), to 
monitor the expression of Cre-recombinase through the expression of EYFP. In vessels of the retina from 
CCM3+/+–Cdh5(PAC)-CreERT2–R26-EYFP mice and CCM3-flox/flox–Cdh5(PAC)-CreERT2–R26-EYFP 
(CCM3-ECKO) mice, Cre-induced recombination (with Tamoxifen treatment, as above) is indicated by the 
expression of the reporter gene EYFP. This was frequent in arteries (arrowheads), veins (arrows) and 
microvessels of both of these mouse models, and was seen as extensive co-localization (yellow) of EYFP (red) 
and Pecam (green, marker of endothelial cells) labeling. The CCM3 transcript was reduced by more than 80%, as 
assessed by rt-PCR in freshly isolated brain microvessels of CCM3-ECKO pups, in comparison to the vehicle-
treated WT mice. Scale bar, 200 µm. c. In the retina of the CCM3-flox/flox–Cdh5(PAC)-CreERT2 (CCM3-
ECKO) mice, malformations only developed on the venous side of the vascular network, which can be 
distinguished morphologically in the retina (as in b) and by Endomucin-positive staining (red, arrows). 
Arrowheads indicate arterial vessels, which are Endomucin negative and Isolectin B4 positive (endothelial 
marker, green). Scale bar, 700 µm. d) Higher magnification of brain vessels (red) in WT and CCM3-ECKO mice. 
ECs in the lesions present high number of KI67 positive nuclei (green) indicating an active proliferative state of 
these cells compared to WT. Scale bar 30 µM. In (b, c and d) retinas from 9 dpn littermate mouse pups are 
shown. 
 
EYFP expression (Fig.9b). The efficiency of Cre recombinase activation was also assessed by 
rt-PCR in freshly isolated brain microvessels of CCM3-ECKO pups where CCM3 transcript 
was reduced by more than 80%, in comparison to the vehicle-treated WT mice. A similar 
venous-specific defect has been observed after endothelial-specific ablation of CCM1128.  
The malformations in CCM3-ECKO mice appear both as abnormally enlarged vessels 
growing on multiple layers and clusters of vascular sacs characterized by a huge lumen. ECs 
lining the malformations are highly proliferative (Fig.9d). Tamoxifen did not induce any 
phenotype both in CCM3-flox/flox–Cdh5(PAC) mice negative for CreERT2, that did not 
express Cre recombinase, and in the heterozygous CCM3-flox/+–Cdh5(PAC)-CreERT2 mice. 
The WT mice were CCM3+/+–Cdh5(PAC)-CreERT2 mice treated with Tamoxifen. CCM3-
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flox/flox–Cdh5(PAC)-CreERT2 mice treated with the vehicle used to dissolve Tamoxifen also 
showed a WT phenotype. 
As CCM3-ECKO mice develop vascular malformations in the central nervous system 
this model provides a tool for testing pharmacological treatments as described below. 
 
Tgfβ/Bmp pathway is hyper-activated in vivo in endothelial cells of endothelial-cell-specific 
CCM3-knockout mice only in late stage vascular malformations 
In a previous work128 we demonstrated that CCM lesions develop through an 
endothelial-to-mesenchymal transition (EndMT) mechanism and that Tgfβ/Bmp pathway 
significantly contributes to this process. In order to confirm this data also in CCM3-ECKO 
mice we analyzed the phosphorylation state of the Tgfβ/Bmp downstream effector Smad1. 
Therefore, we performed immunostaining for phospho-Smad1 on CCM3-ECKO brains at day 
post natal nine (9 dpn) when vascular malformations are fully established. In addition, we also 
investigated CCM lesions at a very early stage that is 3 dpn, in order to assess if the 
phosphorylation of Smad1 is an early event in CCM progression. Interestingly, we found that, 
at variance with the late stage (9 dpn) where p-Smad1 staining is significantly increased in the 
nuclei of ECs lining the vascular malformations, very few endothelial nuclei are positive for p-
Smad1 at 3 dpn in comparison to WT vessels (Fig.10a upper panel, 10b and 10c). Moreover, 
we observed that in 9 dpn CCM3-ECKO mice only lesions larger than 50 µm (main diameter), 
which likely developed earlier, express p-Smad1 and that this expression is even more 
pronounced in the largest lesions (Fig.11a upper panel and 11b). Very similar data were 
obtained using antibody against p-Smad3 (data not shown).  
Noteworthy, we also confirmed that EndMT markers expression is up regulated in ECs 
lining CCM3 lesions starting from 3 dpn in comparison with WT vessels (Fig.22) as better 
described later.  
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These findings led us to hypothesize that other signaling pathways could be involved in 
the initiation of vascular lesions. In particular, due to the crucial contribute of the Wnt/β-
catenin pathway in the physiology of the BBB, in angiogenesis and in EndMT74, 76, 139, we 
investigated the role of this signaling cascade in CCM.  
 
β-catenin-mediated transcription is enhanced in vivo in endothelial cells of endothelial cell-
specific CCM3-knockout mice in very early stage vascular malformations 
We crossed CCM3-flox/flox–Cdh5(PAC)-CreERT2-R26(EYFP) mice with BAT-gal 
mice176, which show β-catenin-activated expression of the nuclear β-galactosidase (β-gal) 
reporter gene (see Materials and Methods). In this case β-galactosidase is expressed only in 
cells in which Wnt/β-catenin pathway is active and could be detected through 
immunofluorescence using specific antibodies. When we analyzed mice at 3 and 9 dpn we 
found that β-catenin-dependent transcription of the nuclear β-gal reporter gene is highly 
increased in ECs of brain vessels of the newborn CCM3-ECKO, in comparison to matched 
control animals at both ages (Fig.10a lower panel, 10b and 10c). The percentage of β-gal-
positive nuclei is even higher at 3 dpn in comparison to control and this indicates that it is 
likely to be a very precocious event in the development of the lesions. In contrast with p-
Smad1 staining, β-gal staining is present in lesions of any size in 9 dpn CCM3-ECKO pups as 
illustrated in Fig.11a (lower panel) and 11b. The quantification by random-field counting 
using Podocalyxin labeling of ECs showed that small lesions in CCM3-ECKO brains have 
almost 50% β-gal-positive nuclei and that this proportion tends to decrease in larger lesions 
even if it remains significantly higher in comparison to WT control vessels. 
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Figure 10. Endothelial cells in brain vessels of CCM3-ECKO mice show hyper-activation of Tgfβ /Bmp 
signaling and enhanced β-catenin transcription activity respectively at distinct stages of vascular 
malformation development. Representative immunostaining of brain sections (a, b) from WT and CCM3-
ECKO mice at 3 dpn and 9 dpn. (a) Upper panel shows p-Smad1 (Ser463/465) expression (red) as a marker of 
Tgfβ/Bmp active signaling in Podocalyxin-positive (endothelial) cells (green), while lower panel shows β-gal 
expression (red), as a gene reporter of β-catenin transcription activity in Podocalyxin-positive cells (green). In (a) 
nuclei were stained with DAPI (blue). Arrows, p-Smad1 or β-gal-positive nuclei; empty arrows, p-Smad1 
negative nuclei. (b) Co-staining of β-gal (red) and p-Smad1 (green) in 3 dpn and 9 dpn brain sections of CCM3-
ECKO mice. (c) Endothelial cell nuclei were counted in 50 random fields at 63× magnification in brain sections 
from 5 CCM3-ECKO mice and 5 WT mice at both time points respectively (see Materials and Methods). β-gal-
positive nuclei in brain endothelial cells were more abundant both at 3 dpn and 9 dpn in CCM3-ECKO mice than 
WT mice. p-Smad1 expression is significantly enhanced in endothelial cells in CCM3-ECKO mice at 9 dpn in 
comparison to WT mice but not at 3 dpn. (a) and (b) Scale bars, 50 µm. (c) *, p<0.05, t-test. 
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Figure 11. Tgfβ /Bmp signaling is hyper-activated only in endothelial cells of large lesions while β-catenin-
mediated transcription is enhanced in endothelial cells of any size of lesions and in pseudonormal vessels in 
the brain of CCM3-ECKO mice. Representative immune-staining of brain sections (a) from WT and CCM3-
ECKO mice at 9 dpn. Upper panel shows p-Smad1 (Ser463/465) (red) expression in Podocalyxin-positive 
(endothelial) cells (green) while lower panel shows β-gal expression (red) in Podocalyxin-positive cells (green). 
Nuclei were stained with DAPI (blue). Pseudo-normal vessels of CCM3-ECKO mice are shown as well as 
vascular lesions of increasing size (from left to right). Arrows, p-Smad1 or β-gal-positive nuclei; empty arrows, 
p-Smad1 negative nuclei. Scale bars, 50 µm. (b) and (c) p-Smad1 and β-gal-positive endothelial cell nuclei were 
counted in 50 random fields at 63× magnification from 5 CCM3-ECKO mice and 5 WT mice (see Materials and 
Methods). *, p<0.05, t-test. 
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Interestingly, also pseudo-normal vessels in CCM3-ECKO mice showed a higher 
percentage of β-gal-positive nuclei in comparison to WT. 
Altogether these data led us to hypothesize that Tgfβ/Bmp pathway could be important 
for the progression of the lesions and the development of the pathology, but likely Wnt/β-
catenin pathway could play an important role in the very initial steps of the lesion 
establishment. 
 
CCM3 gene ablation induces β-catenin nuclear localization in endothelial cells in culture 
In order to better study the role of Wnt/β-catenin signaling in CCM we used different in 
vitro models. In particular we isolated ECs from the brain of the CCM3-flox/flox mice 
(Fig.12a, WT, primary culture) and we induced CCM3 gene recombination in vitro (CCM3-
knockout brain endothelial cells) (Fig. 12a, KO, primary culture) using an adenoviral vector 
expressing Cre recombinase (see Materials and Methods). After recombination CCM3-
knockout cells showed high level of active β-catenin in the nucleus (i.e., dephosphorylated on 
Ser37 and Thr41184) (Fig.12a). This effect paralleled strong alterations to the AJ organization 
that was seen as delocalization from the junctions of active β-catenin and VE-cadherin 
(Fig.12a). 
Due to limitations in both the supply of freshly isolated ECs from the brain and their 
extremely limited mitotic index after the first in vitro passage, detailed analyses of their β-
catenin nuclear distribution and signaling were not possible. We therefore established cultured 
endothelial cell lines where CCM3 was recombined in vitro as above (CCM3-knockout 
endothelial cell line) (see Materials and Methods). In these CCM3-knockout endothelial cell 
line, we confirmed enhanced nuclear localization of β-catenin both by immunofluorescence 
(Fig.12b, KO endothelial cell line) and cell fractionation (Fig.13).  
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Figure 12. CCM3 KO endothelial cells in culture show delocalization of active β-catenin from cell-cell 
junctions and its concentration into the nucleus. Representative immunostaining of WT and CCM3-knockout 
(KO) endothelial cells for active β-catenin (dephosphorylated on Ser37 and Thr41) (red) and VE-cadherin (green) 
in primary culture (a) and cell line (b). Nuclei were stained with DAPI (blue). Arrowheads, β-catenin-positive 
nuclei. Arrows indicates dismantled cell-to-cell junctions. In these CCM3-knockout endothelial cells, the CCM3 
transcript was reduced by 70% to 90% (primary culture) and not detectable (line) by rtPCR. Scale bar, 20 µm. 
 
 
 
 
 
 
 
 
Figure 13. β-catenin is concentrated in the nuclear fraction of CCM3 null endothelial cells. Representative 
cell fractionation and Western blotting of membrane (M), cytoplasm (C) and nucleus (N) compartments of WT 
and CCM3-knockout (KO) endothelial cell line. Total, membrane and nucleus active β-catenin were decreased by 
34% to 42%, decreased by 58% to 75%, and increased by 51% to 66%, respectively (ImageJ bands 
quantification); active β-catenin was almost undetectable in the cytoplasm of CCM3-knockout versus WT 
endothelial cells. In WT, CCM3 was enriched in the cytoplasm; in the CCM3-knockout, no CCM3 was detected 
by Western blotting. Tubulin and Histone H3 accumulation respectively in the cytoplasm and nuclei confirm a 
good level of separation of cell fractions. 8 µg proteins per lane were loaded. 
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CCM3 gene ablation activates β-catenin-driven transcription in endothelial cells in culture 
Since nuclear β-catenin is able to interact with Tcf/Lef transcription factors and to drive 
target gene transcription we investigated whether CCM3-knockout cells presented an 
increased β-catenin-mediated transcription activity. To do this Tcf/Lef-dependent transcription 
of the exogenous luciferase gene was measured in Top/Fop Flash reporter assays. We found 
that in CCM3-knockout endothelial cell line, the transcription activity of β-catenin was 
significantly increased by 2.7-fold, compared to control WT cells (±0.6 SD; p <0.01) (Fig.14).  
 
 
 
 
 
 
 
Figure 14. β-catenin-Tcf/Lef signaling is up regulated in CCM3-knockout endothelial cells in culture. 
Activation of β-catenin-Tcf4/Lef-dependent transcription in CCM3-knockout (KO) and WT cells was assessed 
using a luciferase reporter gene in the Top/Fop Flash assay (see Materials and Methods for details). The ratio 
between Top-flash and Fop-flash values normalized over transfection efficiency (β-galactosidase activity) is 
shown as fold change in comparison to the ratio in WT (Luciferase fold induction). *, p<0.05, t-test. Data are 
means of three independent experiments. 
 
Furthermore, the expression of some typical endogenous targets of β-catenin 
transcription activity was increased in CCM3-knockout endothelial cell line (i.e., Axin2, Nkd1, 
Lef1, Ccnd157) and, importantly, it was inhibited by in vitro infection with the adeno viral 
vector coding for a dominant-negative Tcf4 (dnTCF4)	   123 (Fig.15a). In parallel we validated 
this data also in primary ECs where we found that transcription of β-catenin target genes is 
also enhanced (Fig.15b). In these experiments we used as markers for β-catenin transcription 
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activity Naked1 gene (Nkd1) instead of Axin2 since it was more sensible to β-catenin 
activation in this system. These data demonstrated that CCM3 ablation in vitro in ECs lead to 
β-catenin accumulation into the nucleus where it can directly mediate, in association to Tcf4 
transcription factor, the transcriptions of canonical target genes. 
 
Figure 15. β-catenin canonical target genes are up regulated in CCM3 null endothelial cells in culture. 
Quantification of typical β-catenin transcription targets without (-) and with (+) expression of dominant-negative 
Tcf4 (dnTCF4), in WT and CCM3-knockout (KO) primary endothelial culture (a) and endothelial cell line (b). 
Data are means (±SD) of triplicate rt-PCR assays from three independent experiments. Tubulin transcripts (α, β), 
which are not targets of β-catenin, were not modified by dominant-negative Tcf4 (data not shown). *, p<0.05 for 
CCM3-knockout versus control (WT). ^, p<0.05 for CCM3-knockout plus dominant-negative Tcf4 versus 
CCM3-knockout plus GFP (t-test). 
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β-catenin regulates EndMT in endothelial cells culture 
Since we previously demonstrated that endothelial-to-mesenchymal transition 
(EndMT) is a crucial process for CCM pathophysiology that occurs upon the loss of CCM1 
gene128, we analyzed the expression of genes related both to acquisition/maintenance of 
endothelial progenitor phenotype185 and EndMT135 in our models taking in consideration that 
β-catenin transcription signaling has been shown to regulate the processes of differentiation 
and epithelial-to-mesenchymal transition (EMT) in other cell types186, 187as well as EndMT in 
heart cushion formation139. Transcription of Klf4188, Ly6a189, S100a4190 and Id1191 (referred as 
EndMT markers) were found to be significantly enhanced in CCM3-knockout ECs as 
compared to control cells (Fig.16a and 16b). In addition, these increases were dependent on 
β-catenin transcription activity, as they were inhibited by dominant-negative Tcf4 (Fig.16a 
and 16b). The enhanced transcription of these genes also corresponded to their increased 
protein expression (Fig.32). 
  
Figure 16. Nuclear β-catenin activates the transcription of EndMT target genes in CCM3 null endothelial 
cells in culture. Quantification of dominant-negative Tcf4 (dnTCF4) inhibition of transcription of β-catenin 
target genes Klf4, Ly6a, S100a4 and Id1 in WT and CCM3-knockout (KO) brain endothelial cells in primary 
culture (a) and endothelial cell line (b) by rt-PCR 48h after adenovirus infection. *, p<0.05; **, p<0.01(t-test) for 
the comparison CCM3-knockout versus WT under basal conditions. ^, p<0.05; ^^, p<0.01  (t-test) for the 
comparison CCM3-knockout plus dominant-negative Tcf4 versus CCM3-knockout plus GFP (-). Data are means 
of three independent experiments. 
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In addition, WT ECs expressing a constitutive active form of β-catenin, Lef-ΔβCTA180, 
after lentiviral infection show higher levels of β-catenin target genes such as Axin2 and Nkd1 
and of EndMT markers Id1, S100a4 and Ly6a in comparison to control cells infected with the 
vehicle bearing GFP (Ctr) (Fig.17). Although far from being conclusive, these data suggest 
that β-catenin could be directly implicated in the regulation of EndMT genes in ECs. Thus, 
abrogation of CCM3 expression in ECs leads to an increase in β-catenin transcription activity 
and target gene expression and to an increas in EndMT markers gene expression in vitro. 
 
 
 
 
 
 
 
Figure 17. Constitutive active nuclear β-catenin transcriptionally activates EndMT target genes in 
endothelial cells in culture. Quantification of Klf4, Ly6a, S100a4 and Id1 transcripts by rt-PCR, in WT 
endothelial cell line 2 weeks after infection with a lentivirus vector expressing a constitutive active nuclear β-
catenin (Lef-ΔβCTA). *, p <0.05 (t-test). Data are means of three independent experiments. 
 
Down regulation of CCM3 transcript after siRNA enhances β-catenin-mediated 
transcription and the expression of EndMT genes 
We also transiently down regulated CCM3 expression using siRNA and analyzed the 
time course of activation of β-catenin signaling. We found that at early time point (24h after 
siRNA transfection with CCM3 transcript already decreased by more than 80%), (Fig.18) β-
catenin signaling is up regulated, as indicated by increased Axin2 transcript (Fig.18) and by 
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nuclear β-catenin accumulation (Fig.19) in comparison to control (not-targeting siRNA 
transfected cells). In addition, CCM3 down regulation is accompanied by a significant increase 
of EndMT marker expression (which is delayed at 48h in comparison to Axin2) (Fig.18) and 
by a progressive disorganization of cell-to-cell junctions (already detectable after 24h) 
(Fig.19). 
 
 
Figure 18. Acute down regulation of CCM3 transcript induces transcription activation of β-catenin target 
genes and Bmp2 with distinct kinetics in endothelial cells in culture. Acute down regulation of CCM3 
transcript through siRNA (>80%) in WT endothelial cells correlates with transcription activation of β-catenin 
target genes (Axin2, Myc, Ccnd1), EndMT markers (Id1, Ly6a, S100a4, Klf4, CD44) and Bmp2 although with 
different kinetics as discussed in the text. Transcripts were analyzed by rt-PCR 24h, 48h, 72h after siRNA 
transfection while cells at 144h time point had a second round of siRNA transfection 72h after the first one. 
Every time point has been compared with time-matched control. Controls were treated with negative (not-
targeting) siRNA. *, p<0.05, t-test. Data are means of three independent experiments. 
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Figure 19. Acute down regulation of CCM3 transcript induces junction dismantling together with β-
catenin nuclear accumulation in endothelial cells in culture. Representative immunostaining of active-β-
catenin (red), VE-cadherin (green) and p-Smad1 (ser463/465)  (purple) at different time points after CCM3 acute 
down regulation through siRNA. Junction dismantling is a very precocious event after CCM3 down regulation 
(already visible after 24h) (arrows) and correlates with nuclear accumulation of active-β-catenin (DAPI 
indicating nuclei is in blue). Conversely p-Smad1 accumulation in the nuclei is not significantly increased (empty 
arrowheads). Controls were treated with negative (not-targeting) siRNA. Scale bar, 30 µm. 
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We also measured at different time points after CCM3 silencing the expression of Bmp2 and 
Bmp6, two important activators of the Tgfβ/Bmp pathways27. While Bmp6 transcript is not 
modulated, Bmp2 is significantly increased in CCM3 silenced cells in comparison to controls 
(not-targeting siRNA transfected cells). Interestingly, while Bmp2 expression progressively 
increased at late time points after CCM3 silencing, β-catenin signaling tended to decrease in 
parallel. Although Bmp2 is reported to be able to trigger Smad1 phosphorylation, we couldn’t 
detect any increase of p-Smad1 both in immune-staining and western blot analysis (Fig.19 
and Fig.20).  
Taken together these results confirm, as previously observed in vivo, that β-catenin 
signaling is a very early event upon CCM3 deletion and is able to trigger EndMT in ECs 
before the activation of Tgfβ/Bmp signaling.  
 
Figure 20. Acute down regulation of CCM3 transcript is not associated with increased phosphorylation of 
Smad1. (a) Representative western blot of phosphorylated Smad1 (Ser463/465) protein at different time points 
after CCM3 siRNA. (b) Western blot bands have been quantified using ImageJ and normalized on respective 
Vinculin (housekeeper). 20 µg of proteins per lane were loaded. Ratio between p-Smad1 and total Smad1 in (b) 
shows that activation of Tgfβ/Bmp signaling is not an early response to CCM3 silencing (t-test). Controls were 
treated with negative (not-targeting) siRNA. Data are means of three independent experiments. 
 
 
 
 
	   96	  
Bmp2 expression is directly regulated by β-catenin in CCM3-knockout endothelial cells  
In a previous work we identified Bmp6 as an important mediator of EndMT in CCM1 
null ECs. However, another important member of Bmp family, Bmp2 is up regulated upon 
CCM3 ablation in our model as discussed above. Bmp2 expression is increased at early time 
point in vitro although delayed in respect to β-catenin transcription signaling. For this reason, 
we investigated if Bmp2 could be a target of β-catenin. Experiments using both dominant-
negative Tcf4 and Lef-ΔβCTA indicate that Bmp2 is, indeed, a direct target of β-catenin-
mediated transcription (Fig.21). However, Bmp2 transcription activation induced by CCM3 
siRNA fails to trigger Smad1 phosphorylation at tested time points (as discussed before and 
reported in Fig.20). It could be that either longer exposure to Bmp2 or higher level ligand are 
needed to induce such response (cell autonomous). Interestingly, chronic expression of a 
constitutive active form of β-catenin (Lef-ΔβCTA) induces both Bmp2 transcript and 
phosphorylation of Smad1 (Fig.2c). 
Although suggestive, the role of Bmp2 in CCM pathology remains to be analyzed.  
 
Figure 21. Bmp2 transcription is directly regulated by β-catenin in CCM3-knockout endothelial cells.      
(a) Bmp2 transcript is strongly up regulated in CCM3-knockout endothelial cells line (KO) (*, p< 0.05 WT ctr vs. 
KO ctr, t-test), and is significantly reduced by dominant-negative TCF4 (dnTCF4) (^, p <0.05 KO dnTCF4 vs. 
KO ctr, t-test) indicating a direct regulation of Bmp2 expression by β−catenin/Tcf signaling. (b) The expression 
of β−catenin canonical target Axin2 and Bmp2 are up regulated by a constitutive nuclear active form of β−catenin 
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(Lef-ΔβCTA) 2 weeks after infection. *, p<0.05, t-test. Data are means of three independent experiments. (c) The 
same construct Lef-ΔβCTA is able to induce p-Smad1 phosphorylation. 20 µg proteins per lane were loaded.  
 
Activation of β-catenin-mediated transcription correlates with the expression of EndMT 
markers in endothelial cells of CCM3 vascular lesions 
In order to assess if the expression of EndMT markers in vivo was associated to β-
catenin-dependent transcription we performed co-staining analysis of β-catenin reporter gene 
(β-gal) together with EndMT markers in CCM3-flox/flox–Cdh5(PAC)-CreERT2-R26(EYFP)-
BAT-gal. We found that Ly6a (Fig.22a), Id1 (Fig.22a), S100A4 (Fig.22a) and Klf4 (Fig.22a) 
expression is significantly increased in ECs lining CCM lesions in comparison to WT vessels 
both at 3 and 9 dpn. The percentage of nuclei positive either for β-gal and EndMT markers in 
ECs was also calculated (Fig.22e). Here we show that the percentage of endothelial nuclei 
expressing both β-gal and EndMT markers over the total number of endothelial nuclei 
analyzed (merge) is significantly higher than in WT vessels and that it tends to decrease at 9 
dpn. This is probably due to the fact that the number of β-gal expressing ECs decreases while 
the number of cells expressing EndMT markers increases. These data are referred to all 
endothelial nuclei inside CCM lesions. However, considering only EndMT markers-positive 
nuclei (EndMT markers/β-gal) we found that most (about 80%) of this ECs co-express also β-
gal. This is suggestive of a direct association between β-catenin signaling and EndMT marker 
expression that is particularly high at 3 dpn and decreases (at least for Id1 and Klf4) at the late 
stage. This finding supports the idea that after an initial phase in which β-catenin is essential 
to trigger the EndMT, other factors, such as Tgfβ/Bmp, can contribute to the progression of 
the pathology in vivo.  
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Figure 22. Increased β-catenin-dependent transcription correlates with overexpression of EndMT markers 
in endothelial cells of CCM3-ECKO vessels. Representative co-immunostaining of β-gal (red), as a gene 
reporter of β-catenin transcription activity, in Podocalyxin-positive (endothelial) cells (blue) and EndMT markers 
(green) in CCM3-ECKO and WT brains of 3 and 9 dpn mice. Ly6a (a), Id1 (b), S100a4 (c) and Klf4 (d) 
concentrated in the nuclei of these CCM3-ECKO blood-vessel endothelial cells both at 3 and 9 dpn together with 
β-gal. Scale bar, 40 µm. (e) Quantification of β-gal, Id1, Klf4 and S100a4 positive endothelial nuclei and their 
co-localization in CCM3-ECKO lesions in comparison to WT vessels at 3 and 9 dpn. Endothelial cell nuclei were 
counted in 50 random fields at 63× magnification in brain sections from 5 CCM3-ECKO mice and 5 WT mice at 
both time points respectively (see Materials and Methods). The percentage of positive nuclei over total nuclei 
inside lesions is reported. Merge indicates the percentage of endothelial nuclei expressing both β-gal and EndMT 
markers over the total number of counted endothelial nuclei. EndMT marker/β-gal indicates the percentage of 
EndMT marker expressing endothelial nuclei, which express also β-gal. *, p<0.05 CCM3-ECKO 3 dpn versus 
WT 3 dpn; ^, p<0.05 CCM3-ECKO 9 dpn versus CCM3-ECKO 3 dpn, t-test. 
 
The induction of β-catenin transcription activity in CCM3 null endothelial cells is 
independent from Wnt stimulation 
Since β-catenin signaling is usually regulated by Wnt stimuli we investigated whether 
increased β-catenin-mediated transcription in CCM3 null ECs could be caused by the 
activation of Wnt receptors through Wnt ligands.  
Wnt ligands are responsible for the activation of a receptor cluster composed by Frizzled 
receptors and Lrp5/6 co-receptors. In particular phosphorylation of Lrp5/6 is a crucial event in 
the activation of the canonical Wnt signaling cascade. For this reason we checked for 
phospho-Lrp6 protein levels in CCM3-knockout endothelial cell line in comparison to WT 
cells and for their response to recombinant Wnt3a stimulation in a time course experiment. 
We found that Lrp6 in CCM3 null cells was less phosphorylated in comparison to WT 
cells in normal culture conditions and that recombinant Wnt3a stimulates in a similar way the 
phosphorylation of Lrp6 both in WT and CCM3-knockout cells (Fig.23a and 23b). 
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Figure 23. The Wnt co-receptor Lrp6 is neither constitutively hyper-activated in CCM3 null endothelial 
cells in culture, nor more sensible to Wnt stimulation in comparison to WT cells. CCM3-knockout (KO) and 
WT endothelial cells were treated with recombinant Wnt3a (100 ng/ml) for different time (5 min, 30 min, 1h, 5h). 
Wnt receptor activation was evaluated as phosphorylation of Wnt co-receptor Lrp6. (a) Representative western 
blots of p-Lrp6 (Ser 1490), total Lrp6 and their respective Vinculin as housekeeper are shown. 20 µg of proteins 
per lane were loaded. (b) Western blot bands were quantified (O.D. assessment by Image J) and the ratio between 
phosphorylated and total Lrp6, each normalized on respective Vinculin, is reported in the graph (mean of three 
independent experiments) as index of Lrp6 activation. No differences between WT and CCM3-knockout cells are 
observed at any time points. *, p<0.05, t-test. CCM3-knockout cells showed lower level of Lrp6 activation both 
in resting condition (Ctr 0’) and at all time points after Wnt3a stimulation. 
 
In addition, CCM3-knockout cells were treated with recombinant Dkk1 protein, a 
physiological inhibitor of Lrp5/6192 and we checked for the level of Axin2 and S100a4 
transcripts as readout respectively of β-catenin signaling and EndMT (Fig.24a). Despite the 
ability of Dkk1 to inhibit a Wnt3a-induced stimulation (Fig.24b), it failed to reduce the 
expression of Axin2 and S100a4 in CCM3-knockout ECs (Fig.24a).  
Other two inhibitors of Wnt pathway, IWP2 and IWP12193, targeting Porcupine, an 
essential enzyme for Wnt processing and secretion, have been used. Also in this case the 
treatments at 3 different doses showed no effect on Axin2 and S100a4 transcripts (Fig.24c and 
24d) in CCM3-knockout ECs.  
In order to further confirm that Wnt exogenous stimulus is not responsible for the 
abnormal β-catenin signaling in CCM3-knockout ECs, we treated these cells with Wnt3a. We 
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found that the stimulation by the ligand is sufficient to trigger the expression of canonical 
targets of Wnt pathway such as Axin2 but it is not able to induce the expression of EndMT 
markers (Fig.25). 
 
Figure 24. Inhibitors of Wnt receptor and of Wnt ligand secretion fail to down regulate enhanced β-
catenin-mediated transcription in CCM3 null endothelial cells in culture. Quantification of the effects of 
drugs inhibiting the initial steps of Wnt/β-catenin pathway on the overexpression of a β-catenin target gene 
(Axin2) and an EndMT marker (S100a4) through rt-PCR. (a) Recombinant Dkk1, able to inhibit Wnt receptor 
activation, (0.5 µg/ml) failed to inhibit the constitutive over expression of Axin2 and S100a4 in CCM3 null 
endothelial cells while (b) it inhibited exogenous Wnt3a activation. *, p<0.05. Two different porcupine 
inhibitors, IWP2 (c) and IWP12 (d) were used in a range of concentrations reported active in the literature and 
analyzed at different time point. 48h treatment has been shown as representative of results obtained. No effect on 
the expression of Axin2 and S100a4 was observed. Data are means of three independent experiments. 
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Figure 25. Exogenous Wnt3a fails to up regulate EndMT markers in endothelial cells in culture. 
Quantification of the effects of Wnt3a (100 ng/ml) in WT endothelial cell on the expression of EndMT markers. 
Despite its ability to trigger a transcriptional response (see Axin2 up regulation), Wnt3a failed to induce 
transcription of EndMT markers. Cells were treated with Wnt3a for different time. 72h treatment is shown in 
figure. *, p<0.05, t-test. Data are means of three independent experiments. 
 
High throughput analysis of the transcriptome of CCM3 null endothelial cells 
To further analyze the role of Wnt/β-catenin pathway in CCM, we performed high 
throughput Affymetrix analysis of the transcriptome of CCM3-knockout brain ECs in primary 
culture treated or not with Wnt3a. WT control ECs were analyzed in parallel.  
We performed both a qualitative and quantitative analysis of Affymetrix data. In a 
quantitative analysis, in which we measured the fold change of Wnt target genes expression 
independently from their starting level, we observed that the gene expression profile is very 
similar between WT and CCM3-knockout cells when treated with Wnt3a (p>0.05, paired t-
test. R2=0.89, Pearson test), suggesting a similar sensitivity of the two cell type to stimulation 
by Wnt3a ligand (Fig.26a). In addition, in a quantitative analysis, we compared the expression 
levels of Wnt target genes in WT cells treated with Wnt3a versus CCM3-knockout cells 
(Fig.26b). In agreement with previous ratius we found that Wnt stimulation doesn’t mimic the  
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Figure 26. High throughput analysis reveals no difference in the transcription responses to Wnt3a between 
CCM3 null and WT endothelial cells. In addition, the transcriptional profile of un-stimulated CCM3 null 
endothelial cells is different from that induced by Wnt3a in WT endothelial cells. The transcriptome of 
CCM3-knockout (KO) and WT primary cells treated or not with Wnt3a (100 ng/ml, 72h treatment) has been 
analyzed using Affymetrix technique. (a) Qualitative analysis of the transcriptional response to Wnt3a in CCM3-
knockout and WT cells on Wnt3a target genes (40 genes have been found selectively regulated by Wnt3a in vitro 
in endothelial cells) shows no significant differences between CCM3-knockout and WT endothelial cells (paired 
t-test=0.0801, Pearson test: R2=0.8965). In this case fold change induced by Wnt3a in comparison to control 
vehicle is plotted for each condition. (b) Quantitative analysis. Genes transcriptionally modulated by the deletion 
of CCM3 in comparison to WT cells were selected and analyzed using a color code in a heat map. The same 
genes in WT cells treated with Wnt3a show a different profile indicating a different regulation. A p-value<0.01 
have been calculated using t-test. Data are means of three independent experiments. 
 
ablation of CCM3 in terms of gene expression levels (Fig.26b), confirming that β-catenin 
transcriptional signaling activation in these cells is independent from regular Wnt/β-catenin 
signaling pathway. For the list of genes see appendix table 1. 
 
Endothelial cell-to-cell junctions regulate β-catenin transcription activity 
Since β-catenin, besides its transcription role into the nucleus, is also a key constituent 
of AJs we investigated whether junctions dismantling that we observe in CCM3-knockout 
cells could be related to β-catenin nuclear localization and signaling. To do this we induced 
junctions dismantling through different techniques in WT ECs. In particular we found that 
upon down regulation of VE-cadherin through siRNA or after treatment with an anti-VE-
cadherin antibody (BV13) or with EGTA (a calcium sequestering agent) β-catenin 
accumulates in the cytoplasm and into the nucleus of treated cells where it can mediate 
transcription of target genes (Fig.27 and Fig.28). Very interestingly down regulation of VE-
cadherin through siRNA correlates also with a significant up regulation of some EndMT 
marker expression (e.g. Id1 and S100a4 but not Ly6a) (Fig.27). These findings suggest that 
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also in CCM3-knockout cells, where cell-to-cell junctions are impaired, a similar mechanism 
could occur. 
 
 
Figure 27. Junctions dismantling induces up regulation of β-catenin signaling in endothelial cells in 
culture. Quantification of the effect of (a) VE-cadherin (Cdh5) down regulation using siRNA at different time 
points and (b) monoclonal antibody directed against VE-cadherin (BV13 for 72h) as well as calcium-sequestering 
agent (EGTA for 30 min.) in WT endothelial cells at different time points by rt-PCR. Acute down regulation of 
VE-cadherin transcript (~60%) (a) and protein (see Fig.19) correlates with transcription up regulation of β-
catenin target genes (Axin2, Nkd1, Myc) at 24h. The response of Nkd1 and Myc is lost in long term treatment, 
while that of Axin2 declines, but is maintained. EndMT markers like Id1 and S100a4 are also increased in these 
cells even if delayed in comparison to canonical β-catenin target genes. Junction dismantling using BV13 induces 
only Axin2 transcript, while EGTA stimulates the three transcripts. Controls were treated with negative (not-
targeting) siRNA. * p<0.05, t-test. Data are means of three independent experiments. 
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Figure 28. Junctions dismantling induces β-catenin nuclear accumulation in endothelial cells in culture. 
Representative immunostaining of active-β-catenin (red) and VE-cadherin (green) at different time points after 
VE-cadherin acute down regulation through siRNA. Junction dismantling and VE-cadherin down regulation 
(arrows) is accompanied by nuclear accumulation of active-β-catenin (DAPI indicating nuclei is in blue) 
(arrowheads). Controls were treated with negative (not-targeting) siRNA. Scale bar 30 µm. 
 
Sulindac sulfide reduces β-catenin transcription activity and expression of endothelial 
progenitor and EndMT markers in endothelial cells in culture  
Due to the crucial role of β-catenin in mesenchymal transition in CCM3-knockout ECs, 
we investigated whether pharmacological inhibitors of β-catenin signaling could be a real 
therapeutic opportunity for CCM treatment.   
We then initially tested a range of agents in our experimental model in vitro that have 
been described as affecting β-catenin signaling194 and, most importantly, are already in clinical 
use: sulindac sulfide, sulindac sulfone194, 195, silibinin, curcumin and resveratrol90 (Fig.29). 
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Figure 29. In vitro screening of pharmacological antagonists of β-catenin signaling in CCM3 null 
endothelial cells in culture. Quantification of the effect of drugs that have been reported to target different steps 
of the β-catenin signaling pathway (135 µM sulindac sulfide, 125 µM sulindac sulfone, 200 µM silibinin, 40 µM 
curcumin, 40 µM resveratrol), on the overexpression of a β-catenin target gene (Axin2) and EndMT markers 
(Klf4, S100a4) in WT and CCM3-knockout (KO) endothelial cells line 48h after treatment. Sulindac sulfide and 
sulindac sulfone show the greatest inhibition of the strong induction of transcription of Axin2, Klf4 and S100a4 
seen in these CCM3-knockout endothelial cells. Among the other drugs tested here, silibinin was effective against 
these three transcripts. Data are mean rt-PCR values from at least three independent experiments, each carried out 
in triplicate. *, p<0.05, **, p<0.01 versus the respective transcripts in the vehicle-treated CCM3-knockout 
endothelial cells (t-test). See Materials and Methods for further details. Comparable results were obtained with 
cells from between five and 25 passages after knockout of CCM3.  
 
 
Sulindac sulfide and sulindac sulfone were the most effective of these for inhibition of 
expression of Axin2, Klf4 and S100a4 as representative endogenous targets of β-catenin 
transcription activity in the CCM3-knockout endothelial cell line (Fig.29). In addition, 
sulindac sulfide reduced β-catenin transcription activity as measured by the Top/Fop Flash 
reporter assays (Fig.30).  
We therefore further analyzed the effects of sulindac sulfide on the CCM3 null 
phenotype. In primary cultures of CCM3-knockout brain ECs, we found that sulindac sulfide 
effectively inhibited the expression of endogenous β-catenin target genes with efficiency 
similar to the dominant-negative Tcf4  (Fig.31). In parallel, sulindac sulfide  
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Figure 30. Sulindac sulfide inhibits β-catenin-mediated transcription in CCM3 null endothelial cells in 
culture. Sulindac sulfide inhibited (^, p<0.05, sulindac sulfide KO versus vehicle KO, t-test) the significant 
increase (*, p<0.05, vehicle-KO versus vehicle-WT, t-test) of β-catenin/Tcf4-dependent transcription of the 
luciferase reporter gene in the Top/Fop Flash assay (see Materials and Methods for details) in CCM3-knockout 
(KO) endothelial cells. The ratio between Top-flash and Fop-flash values normalized over transfection efficiency 
(β-galactosidase activity) is shown as fold change in comparison to the ratio in vehicle WT (Luciferase fold 
induction). Data are means of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
Figure 31. Sulindac sulfide inhibits the transcription of β-catenin target genes in CCM3 null endothelial 
cells in culture. Quantification of sulindac sulfide inhibition of transcription of β-catenin target genes Klf4, Ly6a, 
S100a4 and Id1 by rt-PCR, in WT and CCM3-knockout (KO) brain endothelial cells in primary culture. *, 
p<0.05; **, p<0.01 (t-test) for the comparison CCM3-knockout versus WT under basal conditions. ^^, p<0.01 (t-
test) for the comparison CCM3-knockout plus sulindac sulfide versus vehicle treated CCM3-knockout. Data are 
means of three independent experiments. 
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inhibited the nuclear localization of active β-catenin while increasing its concentration at cell-
cell junctions (Fig.32). We got the same findings using CCM3-knockout endothelial cell line 
where we observed that VE-cadherin was more localized at cell-to-cell contacts in sulindac 
sulfide treated cells (Fig.33). Sulindac sulfide also restored regular apical polarization of 
Podocalyxin, which was impaired in CCM3 null ECs (Fig.33).  
Consistently, by co-immunoprecipitation and Western blotting analysis sulindac sulfide 
restored the reduced association between β-catenin and VE-cadherin (minus 35% ±0.32 SD, p 
<0.05) in CCM3-knockout endothelial line (Fig.34a and 34b).  
The better organization of cell-to-cell junctions after sulindac sulfide treatment is 
confirmed also by increased activity of Rap1, which is conversely down regulated in CCM3-
knockout cells in comparison to WT cells (Fig.35). 
In parallel with inhibition of transcription of β-catenin target genes, sulindac sulfide also 
inhibited the overexpression of respective proteins in CCM3-knockout ECs (Fig.32 and 
Fig.36). 
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Figure 32. Sulindac sulfide induces re-localization of active β-catenin from the nucleus to adherens 
junctions in CCM3 null endothelial cells in primary culture. Representative immunostaining of brain 
endothelial cells in primary culture under sulindac sulfide treatment. Nuclei were stained with DAPI (blue). Top 
three rows: sulindac sulfide-mediated redistribution of active β-catenin (red) and VE-cadherin (green) from the 
nucleus (arrowheads) to cell-cell junctions in these CCM3-knockout (KO) endothelial cells. Co-localization of 
active β-catenin and VE-cadherin is shown in the merge (yellow). Scale bar, 15 µm. Bottom two rows: Sulindac 
sulfide inhibition of overexpression of Klf4 (green) and S100a4 (green) in these CCM3-knockout endothelial 
cells (turquoise shows co-localization with DAPI; arrowheads). Klf4 is exclusively nuclear and S100a4 is both 
nuclear and cytoplasmic in these CCM3-knockout endothelial cells. Scale bar, 30 µm. 
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Figure 33. Sulindac sulfide induces re-localization of active β-catenin from the nucleus to adherens 
junctions in CCM3 null endothelial cell line in culture. Representative immunostaining for effects of sulindac 
sulfide on re-localization of active β-catenin from the adherens junctions into the nucleus in WT and CCM3-
knockout (KO) endothelial cell line. Active β-catenin (red) and VE-cadherin (green) were lost from cell-to-cell 
contacts (adherens junctions) in these CCM3-knockout endothelial cells (top main panels, XY axis; small lower 
panels, Z projection along X axis). The active β-catenin is concentrated into the nucleus, as also seen in the 
merge with nuclei stained with DAPI (blue) (right panels, vehicle, arrowheads). Co-localization of active β-
catenin and VE-cadherin is shown in the merge (yellow). Treatment with sulindac sulfide restored the distribution 
of active β-catenin (red) and VE-cadherin (green) to the adherens junctions (right panels, sulindac sulfide, 
arrowheads, and small lower right panels, sulindac sulfide, small arrowheads, for distribution along Z axis). 
Bottom panels of Z projection along X axis: a marker of apical polarity in endothelial cells, podocalyxin (red), 
shows loss of apical polarity in CCM3-knockout endothelial cells. Podocalyxin is re-localized from the apical 
surface (left panels, WT, arrows) to be ectopically distributed on the basal side with CCM3-knockout (right 
panel, vehicle, arrowheads), as it has been reported for CCM1-knockout121. Sulindac sulfide re-establishes the 
correct apical distribution of Podocalyxin (right panel, sulindac sulfide, arrows). Scale bar, 30 µm. 
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Figure 34. Sulindac sulfide counteracts β-catenin dissociation from VE-cadherin in CCM3 null endothelial 
cells in culture. Representative Western blotting (a) and quantification (b) of the effects of sulindac sulfide on 
the co-immunoprecipitation complex of β-catenin and VE-cadherin. (a) Western blotting with the WT and 
CCM3-knockout (KO) endothelial cells of total extracts and immunoprecipitates with VE-cadherin antibodies 
(IP: VE) are shown. With sulindac sulfide treatment, the reduction in the level of VE-cadherin in the CCM3-
knockout was restored (compare in total sulindac sulfide KO and vehicle WT). (b) With the co-
immunoprecipitation complex measured as the β-catenin/VE-cadherin ratio, with sulindac sulfide treatment, the 
significantly reduced association between β-catenin and VE-cadherin in the CCM3-knockout (35% ±0.32 SD, *, 
p<0.05, vehicle-KO versus vehicle-WT) was restored to the level observed in the WT cells (^, p<0.05, sulindac 
sulfide KO versus vehicle KO, t-test). The quantification of the bands from the Western blotting was assessed as 
the means of three independent experiments, using ImageJ. 
 
Figure 35. Rap1 activity is reduced in CCM3 null endothelial cells in culture and sulindac sulfide induces 
activation of Rap1 in these cells. (a) Although the total amount of Rap1 protein is slightly increased in CCM3 
null endothelial cells (KO), the amount of active form of Rap1 (GTP-bound) is down regulated in these cells (b) 
as assessed also by quantification of WB bands using ImageJ (data are means of three independent experiments). 
For controls (Ctr) WT and KO extract were incubated with purified GST. Activity of Rap1 in CCM3-knockout 
and WT cell line treated or not with sulindac sulfide was analyzed using Rap1 activation assay (see Materials and 
Methods). M=markers. *, p<0.05, sulindac sulfide versus vehicle, t-test and ^, p<0.05, WT versus CCM3-
knockout, t-test. 
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Figure 36. Sulindac sulfide inhibits the overexpression of progenitor and EndMT markers in CCM3 null 
endothelial cells in culture. CCM3-knockout (KO) endothelial cell line shows sulindac sulfide inhibition of 
overexpression of EndMT markers. Representative immunostaining showing that compared to the WT, there was 
increased expression of Klf4, S100a4, Id1 and CD44 in CCM3-knockout endothelial cells. Nuclei were stained 
with DAPI (blue). The overexpression of Klf4 (top row, red) and Id1 (third row, green) in CCM3-knockout was 
confined to the nucleus, as shown by double staining with DAPI (blue) (KO, vehicle, arrowheads). Similarly, 
S100a4 (second row, green) was both nuclear (KO, vehicle, arrowheads) and cytoplasmic (KO, vehicle), while 
CD44 (bottom row, green) was mostly cytoplasmic (KO, vehicle), Treatment with sulindac sulfide (right-hand 
panels) strongly reduced the overexpression of these proteins in CCM3-knockout endothelial cells. Scale bar, 30 
µm. 
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Sulindac sulfide reduces β-catenin transcription activity and expression of EndMT markers 
in endothelial cells from the CCM3-ECKO mice  
Sulindac sulfide was then investigated in vivo in newborn mice after induction of 
CCM3-ECKO in a time course experiment (brain analyzed at 3, 5, 7 and 9 dpn). Macroscopic 
analysis following dissection showed that lesions present in the brain and cerebellum of 
CCM3-ECKO mice are clearly reduced at different stages in animals treated with sulindac 
sulfide in comparison to matched control animal (Fig.37a) as discussed in the following 
paragraph. In parallel, sulindac sulfide is also able to strongly inhibit the expression of nuclear 
β-catenin transcription activity reporter gene β-gal in these brain’s vessels (Fig.37b and 
Fig.37c). Noteworthy, some β-gal positive endothelial nuclei are still present in lesions of 
treated animals. VE-cadherin also appeared to be better localized at endothelial cell-to-cell 
junctions in vivo in the brain vessels of newborn CCM3-ECKO mice treated with sulindac 
sulfide (Fig.37d).  
In addition, sulindac sulfide is able to inhibit the expression of EndMT markers (Fig.38, 
Fig.39, Fig.40 and Fig.41) in the endothelial cell of the brain vasculature. Interestingly, the 
lesions still present in the brains of treated animals, even if reduced in number and size (see 
following paragraph), express EndMT markers at higher levels in comparison to 
pseudonormal vessels.  
Finally, sulindac sulfide is able to reduce cell proliferation as assessed by KI67 
immunostaining in vivo (Fig.42).  
Even if there is a tendency of animals treated with sulindac sulfide to live longer in 
comparison to vehicle treated animals, this increase failed to be significant in a statistical 
analysis due to the high standard deviation (Fig.43). 
Taking together this data showed that sulindac sulfide is able to inhibit, in part, β-
catenin signaling and that this correlates with a reduction of EndMT markers.  
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Figure 37. Sulindac sulfide inhibits β-catenin transcription activity and induces re-localization of VE-
cadherin to adherens junctions from diffused distribution in endothelial cells in brain vessels of CCM3-
ECKO mice. (a) Representative macroscopic appearance of CCM3-ECKO mice brains following dissection 
without (vehicle) and with sulindac sulfide treatment in pups at different time points. Scale bar, 0.3 cm. (b) 
Representative immunostaining for β-gal (red) as reporter of β-catenin transcription activity in Podocalyxin-
positive (endothelial) cells (green) in brain sections without (vehicle) and with sulindac sulfide treatment of the 
CCM3-ECKO mice at different time point. Arrowheads, β-gal positive nuclei. Scale bar, 50 µm. (c) Sulindac 
sulfide mediated inhibition of nuclear β-gal reactivity at different pup ages was quantified, * p, <0.05. (d) 
Sulindac sulfide-mediated re-localization of VE-cadherin (green) from diffused distribution to cell-to-cell 
junctions (arrowheads) in these blood-vessel CCM3-ECKO endothelial cells, for a distribution similar to matched 
WT mice (right panel, arrowheads). Sections in (d) are from 9 dpn littermate pups. Scale bar, 25 µm. 
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Figure 38. Sulindac sulfide inhibits overexpression of Klf4 in endothelial cells of brain vessels of CCM3-
ECKO mice. Representative immunostaining for effects of sulindac sulfide on Klf4 (red) expression in 
endothelial cells (Pecam positive) of CCM3-ECKO mice brain vessels (green) at different ages after CCM3 
ablation. Dashed lines delineate CCM lesions. Scale bar, 700 µm. 
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Figure 39. Sulindac sulfide inhibits overexpression of Id1 in endothelial cells of brain vessels of CCM3-
ECKO mice. Representative immunostaining for effects of sulindac sulfide on Id1 (green) expression in 
endothelial cells (Pecam positive) of CCM3-ECKO mice brain vessels (red) at different ages after CCM3 
ablation. Dashed lines delineate CCM lesions. Scale bar, 700 µm. 
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Figure 40. Sulindac sulfide inhibits overexpression of Ly6a in endothelial cells of brain vessels of CCM3-
ECKO mice. Representative immunostaining for effects of sulindac sulfide on Ly6a (green) expression in 
endothelial cells (Pecam positive) of CCM3-ECKO mice brain vessels (red) at different ages after CCM3 
ablation. Dashed lines delineate CCM lesions. Scale bar, 700 µm. 
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Figure 41. Sulindac sulfide inhibits overexpression of S100a4 in endothelial cells of brain vessels of CCM3-
ECKO mice. Representative immunostaining for effects of sulindac sulfide on S100a4 (green) expression in 
endothelial cells (Pecam positive) of CCM3-ECKO mice brain vessels (red) at different ages after CCM3 
ablation. Dashed lines delineate CCM lesions. Scale bar, 700 µm. 
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Figure 42. Sulindac sulfide inhibits proliferation in endothelial cells of brain vessels of CCM3-ECKO mice. 
Representative immunostaining of the effects of sulindac sulfide on proliferation (a) quantified (b) as percentage 
of KI67 endothelial positive nuclei (green) inside lesions in CCM3-ECKO mice brain at 3 and 9 dpn. Endothelial 
cell nuclei were counted in 50 random fields at 63× magnification in brain sections from 5 CCM3-ECKO mice 
and 5 WT mice at both time points respectively (see Materials and Methods). Vessels are in red. Scale bar, 700 
µm. *, p<0.05 sulindac sulfide treatment versus vehicle treated mice. 
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Figure 43. Sulindac sulfide fails to prolong the survival CCM3-ECKO mice. Survival of CCM3-ECKO mice 
treated or not with sulindac sulfide is reported (as days of survivor after CCM3 deletion). a) Kaplan-Meier curves 
for mice survival after Sulindac sulfide treatment. b) Mean and SD is shown. Although there was a trend for 
sulindac sulfide treated mice to live longer, no statistical significance was achieved (t-test). 
 
Sulindac sulfide reduces development of vascular lesions in the brain and retina of the 
CCM3-ECKO mice 
A crucial aspect of our study is whether inhibition of β-catenin signaling by sulindac 
sulfide may also reduce the vascular lesions in CCM3-ECKO pups. We found that, indeed, the 
mean number and size of vascular lesions were reduced by sulindac sulfide treatment. As 
illustrated in the immunostaining in Fig.44a and quantified in Fig.44b, the mean number 
(±SD) of vascular lesions per brain in the vehicle-treated CCM3-ECKO pups was 166.8 ±22, 
with 72.6 ±9 vascular lesions with sulindac sulfide treatment (p<0.005; non-parametric 
Wilcoxon signed-rank test) and the mean maximal diameter of mulberry lesions (±SD) in the 
vehicle-treated CCM3-ECKO pups was 386 ±56 µm and 244 ±38 µm with sulindac sulfide 
treatment (p<0.05, t-test). Sulindac sulfide treatment did not significantly reduce the maximal 
diameter of single cavernae. 
Sulindac sulfide treatment also inhibited the vascular malformations in the retina of 
CCM3-ECKO mice. In these mice the retinas show multiple-lumen vascular lesions that are  
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Figure 44. Sulindac sulfide reduces the vascular malformations of CCM3-ECKO mice. (a) Representative 
immunostaining of vascular lesions of brain sections without (vehicle) and with sulindac sulfide treatment of 
CCM3-ECKO mice, as mulberry (multiple cavernae), single caverna and telangiectases (Telang.). Lesions 
classified as in179. (b) Top panels: quantification of brain lesions as illustrated in (a) (see Materials and methods 
for details). Littermates (9 dpn pups) from five independent litters: vehicle treated (n=8) or sulindac sulfide 
treated (n=7). *, p<0.005, Wilcoxon signed-rank test. Bottom panel: quantification of brain lesion sizes (mm, see 
Materials and Methods). *, p<0.05, t-test. (c) Representative immunostaining for Pecam (red; endothelial cells) of 
vessels in the retina of WT and CCM3-ECKO mice (9 dpn littermate pups) treated without (vehicle) and with 
sulindac sulfide. Multiple-lumen vascular lesions (arrowheads) develop from veins (arrow). Sulindac sulfide 
(bottom right) reduces the malformations (arrowheads) and vein diameter (arrow), (see also e). (d) Quantification 
of the retina vascular lesions illustrated in (c) as percentages of retinal perimeter affected by vascular lesions 
(n=14 for both vehicle and sulindac sulfide, see Materials and methods). *, p<0.05, t-test. (e) Representative 
immunostaining of the retina vascular lesions illustrated in (c). As well as the peripheral vascular malformations, 
sulindac sulfide induced reductions in vein diameters (see text for details). Arteries of these CCM3-ECKO mice 
do not show this aberrant phenotype (endothelial cells isolectin B4-labelling: green) Scale bars, 100 µm (a); 700 
µm (c); 60 µm (e). 
 
particularly concentrated at the periphery of the vascular network. Such lesions develop from 
veins, which are enlarged, although straight. Sulindac sulfide partially normalized this aberrant 
vascular network in CCM3-ECKO mice (Fig.44c and 44d). In addition, the enlargement of the 
most internal tract of the veins that characterizes the retinas of these CCM3-ECKO mice was 
inhibited after sulindac sulfide (89.5 ±7.1 µm in vehicle-ECKO versus 35 ±7.8 µm in sulindac 
sulfide-ECKO, mean ±SD of 30 measurements in 14 retinas each for WT and KO) (Fig.44e 
and Fig.45). At variance, arteries	  do	  not	  show	  this	  aberrant	  phenotype	  (Fig.44c	  and	  44e). 
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Figure 45. Sulindac sulfide reduces the diameter of abnormally enlarged vessels in CCM3-ECKO mice 
show. CCM3-ECKO pups (at 9 dpn) treated (from 2 dpn) with vehicle or sulindac sulfide, as described in the 
Materials and Methods, show sulindac sulfide reduction of the malformations in cerebral vessels. Representative 
immunostaining of brain sections with Pecam (red, endothelial cells). Vessels of the superior sagittal sinus that 
enters the brain from the dorsal surface. With the CCM3-ECKO (Vehicle), the straight vessels with large 
diameters are seen to terminate in budding branches that form cavernae. In a comparable vessel, sulindac sulfide 
treatment in this CCM3-ECKO mice greatly reduces the diameters of these vessels and promotes apparently 
normal terminal branching. The panels show maximal projections of confocal optical sections of samples 
acquired at 20× magnification. Scale bar, 100 µm.  
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Sulindac sulfone reduces both β-catenin transcription activity and the expression of 
EndMT markers in endothelial cells of CCM3-ECKO mice  
The data reported above strongly suggest that sulindac sulfide may have a therapeutic 
activity in CCM patients. However, it has been reported that this drug inhibits cycloxygenease 
in platelets possibly increasing the risk of hemorrhage. We therefore tested sulindac sulfone, 
which is devoid of anti-cyclooxygenase activity196 and does not have an impact on coagulation 
response. As observed after sulindac sulfide treatment, sulindac sulfone also reduced the 
nuclear accumulation of active β-catenin and restored cell-to-cell junctions in cultured CCM3-
knockout endothelial cell line  (Fig.46). In addition, sulindac sulfone inhibited the expression 
of β-catenin target genes, (see for instance Klf4 and S100a4 in Fig.46), as did sulindac sulfide 
(see above). When tested in vivo, sulindac sulfone reduced the number of lesions in the brain 
of the CCM3-ECKO mice to a level comparable to sulindac sulfide (the mean number of 
lesions per mouse brain (±SD) in the untreated control was 153.5 ±28 and was reduced to 68.6 
±10 with sulindac sulfone treatment, p<0.01; non-parametric Wilcoxon signed-rank test) 
(Fig.47a and 47b). In addition, in vivo, in the endothelium of brain vessels of the CCM3-
ECKO mice, sulindac sulfone inhibited the expression of Klf4 and S100a4 (Fig.47c). 
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Figure 46. Sulindac sulfone inhibits the transcription of β-catenin target genes and induces the re-
localization of active β-catenin from the nucleus to adherens junctions in CCM3 null endothelial cells in 
culture. Similar to the effects of sulindac sulfide, CCM3-knockout (KO) endothelial cell line show sulindac 
sulfone inhibition of loss of active β-catenin and VE-cadherin from cell-to-cell contacts (adherens junctions), of 
accumulation of active β-catenin in the nucleus, and of overexpression of EndMT markers. Representative 
immunostaining showing that the loss of active β-catenin (red) from cell-to-cell contacts (top row) and its 
relocalization to the nucleus (second row) in these CCM3-knockout endothelial cells (Vehicle, arrowheads) was 
inhibited by sulindac sulfone treatment. Nuclei were stained with DAPI (blue). Similarly, VE-cadherin (green) 
loss from cell-cell contacts was inhibited by sulindac sulfone treatment (third row). Overexpression of Klf4 (red; 
nuclear, Vehicle, arrowheads) and S100a4 (green; cytoplasmic and nuclear) in CCM3-knockout endothelial cells 
was also strongly reduced by sulindac sulfone treatment (bottom rows). Scale bar, 30 µm. 
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Figure 47. Sulindac sulfone reduces the vascular lesions in the brain and retina vessels of CCM3-ECKO 
mice. Similar to the effects of sulindac sulfide CCM3-flox/flox–Cdh5(PAC)-CreERT2–BAT-gal (CCM3-ECKO) 
mice show sulindac sulfone reduction of the malformations in cerebral vessels. These mice were treated with 
Tamoxifen (10 mg/kg body weight, as described in Materials and Methods) at 1 dpn to induce endothelial-cell-
selective expression of Cre recombinase and recombination of the flox/flox CCM3 gene (CCM3-ECKO mice). 
They were also treated with vehicle or with sulindac sulfone (30 mg/kg) daily, starting from 2 dpn. (a) The 
macroscopic appearance of the 9 dpn mouse pup brains following dissection showed evident lesions in the 
cerebellum of the CCM3-ECKO mice (arrowheads). Scale bar, 0.65 cm. Lower panels: Further magnification of 
the cerebellum. Scale bar, 0.3 cm. (b) Quantification of mean brain lesions as the mulberry (multiple lumens), 
single caverna, or telangiectases lesions in the entire brains (as described in179, see Materials and Methods) from 
	   129	  
five vehicle-treated and five sulindac sulfone-treated CCM3-ECKO mice. The brains were sectioned along the 
sagittal axis (150 mm sections, vibratome), immunostained for Pecam (endothelial cells) and examined by wide-
field fluorescence microscopy (10× and 20× magnification). *, p = 0.0053, 0.006, 0.004 for mulberry, single 
caverna and telangiectase lesions, respectively (Wilcoxon test). (c) Representative immunostaining of 
localization of VE-cadherin, Klf4 and S100a4. Left: from the diffuse state of VE-cadherin (green) in vehicle-
treated CCM3-ECKO mice, sulindac sulfone restored its localization to cell-to-cell junctions (arrowheads). 
Middle, right: from the nuclear staining for the expression of Klf4 (middle, red) S100a4 (right, green) in vehicle-
treated CCM3-ECKO mice, sulindac sulfone reduced this nuclear reactivity for both Klf4 and S100a4. Scale bar, 
15 µm. 	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DISCUSSION 
 
In the present study we investigated the molecular mechanisms behind the development 
of the vascular disease known as Cerebral Cavernous Malformation (CCM) and we found that 
endothelial-cell-selective deletion of the CCM3 gene activates β-catenin transcription 
signaling in vivo in brain ECs. Activation of such signaling pathway appears to play a crucial 
role in the establishment of vascular malformations in CCM3 null mice. Indeed, 
pharmacological inhibition of β-catenin transcriptional activity with the NSAIDs sulindac 
sulfide and sulindac sulfone reduces the number and dimension of cerebral and retinal 
vascular malformations in this murine model suggesting that β-catenin transcription signaling 
in ECs contributes to the pathogenesis of CCM3-mediated vascular lesions. 
 
Definition of murine model of CCM3 pathology 
Here, we report that endothelial cell-selective deletion of the CCM3 gene in mice is able 
to recapitulate the human pathology as it produces hemorrhagic vascular malformations in the 
brain, cerebellum and retina. Previous work demonstrated that constitutive endothelial-
selective inactivation of CCM3 gene is embryonically lethal with general angiogenic 
defects150. For this reason we established a model in which CCM3 gene is deleted postnatally 
taking advantage of a Cre-lox Tamoxifen inducible system (CCM3-ECKO mice). This is also 
the first report of endothelial cell-selective inactivation of CCM3 after birth.  With this model 
we have been able to confirm the pathological phenotype observed for CCM1 and CCM2 
endothelial-specific inducible KO obtained with a very similar protocol linking also in mice 
the absence of any of the three CCM genes with the same pathological phenotype. Using this 
tool we have been able to confirm the implication of EndMT in CCM pathogenesis previously 
observed in CCM1 KO mice demonstrating the relevance of such process in the familial CCM. 
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To a microscopic analysis CCM lesions in CCM3-ECKO mice are characterized by 
clusters of enlarged sinusoids (caverns) lined by a thin layer of hyper-proliferative ECs. The 
fragility of the endothelium within the lesions reflects a compromised BBB responsible for 
vessels leakiness and breaks, which can lead to intracranial hemorrhages. Since CCM genes 
are widely expressed in different type of tissues, these findings highlight the importance of 
CCM genes in endothelial physiology and in particular in brain vasculature. 
An important aspect of this work is that since CCM3-ECKO mice develop vascular 
malformations in the central nervous system in short time, this model provides a tool for 
testing pharmacological treatments. 
 
β-catenin transcription signaling contributes to the pathogenesis of CCM3-mediated 
vascular lesions 
In a recent work we have shown that CCM lesions in a CCM1-ECKO mice model 
develop through the process of endothelial-to-mesenchymal transition (EndMT) and that 
Tgfβ/Bmp pathway significantly contributes to this process128. Here we demonstrated that 
Tgfβ/Bmp pathway is enhanced also in CCM3-ECKO mice but only at late stages of lesion 
development (9 dpn). In parallel, we found that the activation of β-catenin-mediated 
transcription is a very early event in lesion formation and it is already high in CCM3-ECKO 
mice brain vessel ECs at 3 dpn when lesions start to appear. However, the expression of 
EndMT markers, checked as readout of EndMT process, is already increased at very early 
time point (3 dpn) in ECs of the lesions in comparison to WT vessels.  
These findings led us to hypothesize that the activation of β-catenin signaling could 
represent the first driving event that initiates CCM lesions and activates the mesenchymal 
transcriptional program. In contrast, Tgfβ/Bmp signaling become hyper-activated only 
relatively late (increase of nuclear p-Smad1 in ECs of 9 dpn pups) and contributes to the 
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progression of the pathology. Interestingly, also pseudo-normal vessels of the brain in CCM3-
ECKO mice show higher levels of β-catenin mediated transcription in comparison to WT 
vessels even if no regional preference has been observed. Anyway, this is suggestive of the 
fact that β-catenin signaling is activated in vessels before the onset of phenotype. Moreover, at 
early stages the over expression of EndMT markers in ECs lining CCM lesions correlates with 
expression of β-gal. This positive correlation is very high at 3 dpn while it decreases at late 
stages. To such reduction contributes also the fact that the percentage of β-gal positive nuclei 
in a lesion decreases at later stages, while EndMT markers positive nuclei increase.  
Using in vitro model of CCM3 null ECs we demonstrated that β-catenin signaling is 
directly implicated in the regulation of EndMT marker genes in these models. Indeed, some β-
catenin targets and EndMT markers are activated through β-catenin transcription signaling 
under basal conditions in the CCM3-knockout ECs, as their expression is inhibited by a 
dominant-negative Tcf4. Consistently, in another model the constitutive activation of nuclear 
β-catenin shows increased expression of some EndMT markers linking β-catenin 
transcriptional activity with EndMT regulation. 
CCM malformations develop largely, although not exclusively, in the central nervous 
systems in patients and in mouse models143, 146. Wnt/β-catenin canonical pathway exerts a 
critical role in angiogenesis and in particular in the determination and specification of the 
phenotype of ECs at the BBB74, 77, 78. However, Wnt signaling must be abrogated postnatally 
to avoid abnormal vascular proliferation and morphogenesis in the CNS74, 77, 78. In a model of 
endothelial specific β-catenin-gain-of-function we observed vascular lesions in the retina 
comparable to those observed here in CCM3-ECKO28. In tumor cells, the sustained induction 
of canonic Wnt signaling is associated to increased growth and invasion57, 197. In particular, 
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upon activation of β-catenin-mediated transcription, carcinoma cells switch from an epithelial-
to-mesenchymal phenotype (EMT) 57, 197. 
These findings support the hypothesis that β-catenin signaling is important for initiation 
of the EndMT, while other signaling pathways, such as Tgfβ/Bmp, can sustain further steps of 
lesion progression. 
 
How is β-catenin signaling up regulated in CCM3 null endothelial cells? 
Deregulated β-catenin signaling in CCM could be supported by either endothelial-
autonomous activation of the Wnt/β-catenin pathway or by abnormal responses of mutated 
ECs to environmental Wnt, or by a combination of the two. Our data indicate that at least the 
first of these mechanisms appears to operate in ECs in culture after ablation of the CCM3 
gene.  
Evidences in cultured cells point to cell-autonomus activation of β-catenin signaling. 
Indeed, we didn’t find abnormal activation of upstream mediators of canonical Wnt/β-catenin 
pathway (ligand and receptors) nor increased sensibility to Wnt stimuli in CCM3 null cells in 
culture. In addition, a high throughput analysis using Affymetrix technique revealed that the 
transcriptome of CCM3 null ECs is different from the one of WT cells treated with Wnt3a in 
the sense that the set of genes altered upon CCM3 ablation (in particular EndMT markers) is 
different from the one modified in response to Wnt3a stimulus (see appendix table1). 
Moreover, both WT and CCM3 null cells respond with the same relative fold change to Wnt3a 
stimulus. These data reinforce the hypothesis that the abnormal β-catenin signaling that we 
observed in CCM3 null ECs is different from the canonical Wnt/β-catenin signaling induced 
by Wnt in WT ECs. 
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Nuclear accumulation of active β-catenin appears to be a significant characteristic of the 
mutated genotype, although we do not have direct indications of the processes that drive the β-
catenin concentration into the nucleus of the CCM3-knockout ECs. In general, the issue of the 
molecular mechanisms that regulate nuclear accumulation of β-catenin remain virtually 
unknown (for review, see57).  
Concomitant with the accumulation into the nucleus, we observed that β-catenin 
dissociates from cell-to-cell junctions in both our in vitro and in vivo models of endothelial-
cell-specific deletion of CCM3. Junctional β-catenin is mostly associated with VE-cadherin, 
the transmembrane constituent of the AJs121, as well as with the β-catenin destruction 
complex133. In the CCM3-knockout ECs, the AJs are disorganized, as also observed after 
ablation of both CCM1117, 120 and CCM2143. In addition, the β-catenin amount associated with 
VE-cadherin is reduced here, as it has also been observed after ablation of CCM1117, 201. We 
speculate that this decreased association of β-catenin with VE-cadherin is accompanied by 
accumulation of active β-catenin in the nucleus. This concentration of active β-catenin into the 
nucleus characterizes conditions of decreased junction stability in ECs, as previously observed 
in sparse and in VE-cadherin-knockout ECs123 and as we reproduced using VE-cadherin 
siRNA. In all of these cases, the total amount of β-catenin is reduced, even to very low levels, 
although the residual active β-catenin accumulates in the nucleus where it mediates activation 
of target genes. In particular after VE-cadherin down regulation through siRNA we found that 
also some EndMT genes start to be up regulated. Inhibition of proteasomal degradation with 
‘passive’ redistribution of active β-catenin into the nucleus appears not to be likely, as the total 
amount of active β-catenin actually decreases.  
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Pharmacological approach to inhibit β-catenin signaling and development of CCM3 
vascular lesions 
The understanding of the molecular mechanisms implicated in CCM pathogenesis is 
only the first step in the fight against CCM. One of our aims is to lay the foundations for 
future pharmacological intervention. To this purpose we identified two inhibitors of β-catenin 
transcription signaling, sulindac sulfide and sulindac sulfone195, 196, that also inhibit the 
development of vascular lesions in CCM3-ECKO mice.  
Sulindac sulfide and sulfone are both able to inhibit β-catenin nuclear translocations 
upon CCM3 deletion and subsequent transcription of target genes (canonical targets and non 
canonical targets such as EndMT markers). Moreover, sulindac sulfide and sulindac sulfone 
are able, in part, to restore junctions organization, β-catenin association with VE-cadherin and 
to activate Rap1. Active Rap1 (GTP-bound), which is down regulated in CCM3-knockout 
ECs, has been shown to play a crucial role in junction dismantling after CCM1 ablation117 
(Fig.48).  
Sulindac sulfide and sulindac sulfone are both NSAIDs that have significant 
chemopreventive efficacies against colon cancer in human patients (where β-catenin signaling 
is hyper-activated), and inhibit tumor progression in experimental models of several types of 
cancer198. The relative efficacy of sulindac sulfide versus sulindac sulfone varies depending on 
the type of cancer195, 199. Sulindac sulfone is potentially more interesting than the Sulindac 
sulfide for therapy of CCM since it lacks anti-platelet activity, which could be detrimental in 
patients prone to hemorrages. Structural research is very active on sulindac metabolites, to 
identify chemical modifications (e.g., phosphorylation200) that might enhance their activity 
while reducing their toxicity. 
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Figure 48. Schematic representation of key events following CCM deletion and critical points of 
intervention of sulindac. (a) CCM3 gene deletion in endothelial cells is associated with adherens junctions 
dismantling possibly via Rap1 and subsequent β-catenin dissociation from VE-cadherin. Free β-catenin 
translocates into the nucleus where, in association with Tcf4 and potentially with other transcription factors, 
regulates canonical and non-canonical (EndMT markers) target genes expression. (b) Sulindac treatment (sulfide 
and sulfone) is able to counteract junction dismantling and to activate Rap1, thus limiting β-catenin nuclear 
accumulation and subsequently inhibiting β-catenin-mediated transcription. 
 
Which is the relationship between Wnt/β-catenin and Tgfβ/Bmp pathways? 
In this work we demonstrated that β-catenin signaling is crucial for the development of 
CCM3 vascular malformations since early stages of lesion formation. We previously 
demonstrated that Tgfβ/Bmp pathway is implicated in CCM progression and EndMT128 and in 
the present study we observed that this signaling is likely to intervene in later stages of lesion 
progression. Various studies report a crosstalk between β-catenin and Tgfβ/Bmp signaling in 
promoting de-differentiation and EMT. However, it remains still to be investigated whether 
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cooperation between these two pathways could play a role in the pathogenesis of CCM. β-
catenin and Tgfβ/Bmp could cooperate at different levels, in particular at transcriptional level, 
since Smads and β-catenin can bind to the same promoters66-68. In addition, one pathway could 
activate the other one. For instance we demonstrated that at least Bmp2 is a target gene of β-
catenin transcription activity in ECs. Whether Bmp2 can contribute to CCM development and 
whether this regulation could be important for EndMT still needs to be investigated. However, 
considering that enhanced β-catenin signaling precedes Tgfβ/Bmp activation during the 
progression of CCM lesion, we can speculate that β-catenin signaling could, at least in part, 
activate the Tgfβ/Bmp pathway (see Fig.49).  
The critical role that both β-catenin and Tgfβ/Bmp pathway play in CCM development 
is underlined by the fact that inhibitors of both signaling pathways lead to a significant 
reduction of lesions in murine models of CCM pathology. For this reason it would be 
interesting to test potential synergistic effect of the two types of treatment on CCM3-ECKO 
mice. 
 
Why CCM arise specifically in CNS? Some speculative hypothesis 
Endothelium, such as many others tissues, undergoes a process of maturation and fate 
specification during development which leads to the acquisition of specific markers and 
properties fundamental to explain its role in the physiology of the body4, 5. However, a great 
heterogeneity among ECs is necessary in order to fulfill the specific different functions and 
needs of different organs. The process of differentiation is mediated by different exogenous 
stimuli coming from the local environment and allowing ECs to enter into a specific 
specialization program. 
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Fig. 49. Functional model of molecular pathways implicated in CCM3 pathogenesis. CCM3 gene deletion in 
endothelial cells induces enhanced β-catenin signaling through still undefined mechanism, although junctions 
dismantling via Rap1 is likely involved. In parallel, CCM3 ablation induces up regulation of Tgfβ/Bmp signaling 
via unknown mechanism. β-catenin signaling can induce Bmp2 expression, but other points of crosstalk between 
the two pathways are possible. Both β-catenin and Tgfβ/Bmp signaling contribute to EndMT and CCM 
development thus pharmacological tools to inhibit these pathways could be employed for CCM treatment also in 
human patients. 
 
For this reason it is not surprisingly that some pathologies such as CCM arise in certain 
specific regions, probably reflecting impairment of local molecular and physiological 
properties34, 35. In particular CCM seems to arise specifically in the vasculature of the CNS, 
the BBB, which is an extremely peculiar vascular entity49, 143. Indeed, BBB is unique under 
different point of view and many factors are responsible for its determination47. One of the 
most relevant is Wnt/β-catenin pathway77. It is known that this signaling pathway needs to be 
finely regulated both in time and levels and any alterations of these parameters can lead to 
major vascular malformations. In the present work we demonstrated that β-catenin signaling is 
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up regulated in ECs lacking CCM3 both in vitro and in vivo. Thus, a reasonable hypothesis is 
that CCM lesions originate from de-regulated expression (kinetics and location) of β-catenin 
signaling in ECs of brain vessels.  
Besides its crucial role in BBB angiogenesis, β-catenin signaling is important in other 
cell types for stem cell maintenance and differentiation181, 197. One of the process that we 
found to be critical for CCM is EndMT, a process of de-differentiation in which ECs lose their 
mature phenotype to acquire a mesenchymal one128, 135, 137. Here we demonstrated that β-
catenin is able to mediate this process in ECs upon CCM3 deletion. We can therefore 
speculate that up regulation of β-catenin signaling in CCM3 null ECs in brain induces from 
one side abnormal angiogenesis and from the other a mesenchymal transition with subsequent 
loss of peculiar barrier functions. All together this events can contribute to the manifestation 
of CCM phenotype predominantly in the CNS. 
Anyway, not all the vessels in CCM3-ECKO brain develop vascular lesions. It has 
recently been reported in retina and brain ECs that activation of the canonical Wnt pathway by 
Norrin/Frizzled4 induces development and maintenance programs through both cell-
autonomous and cell-non-autonomous signaling82. This can explain local vascular phenotypes 
in different regions of the central nervous system82. It is true that different areas in the brain 
are subjected to different factors and different regulation, but is also true that no preferential 
association of lesions development with defined anatomical regions has been observed145, 146.  
Glading and Ginsberg117, 201 reported similar activation of β-catenin transcription activity 
in bovine aorta ECs and primary human arterial ECs in culture after depletion of CCM1 using 
RNA interference. They also reported inhibition of β-catenin signaling by CCM1 in epithelial 
cells, both in vitro and in vivo. In addition, they reported that the phenotype of β-catenin-
driven intestinal adenomas in ApcMin/+ mice is exacerbated in a CCM1+/- background. This 
implies a more general regulatory role for CCM1 and, possibly, CCM3 in β-catenin signaling 
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in other cells as well as in ECs. As the occurrence of intestinal and other neoplasias in genetic 
CCM patients does not appear to be increased (E. Tournier-Lasserve, personal 
communication), the specificity of vascular and organ localization for the CCM pathology 
suggests that endothelial differentiation and/or local factors in the organ cooperate with β-
catenin signaling for the expression of the mutated phenotype. In particular, as far as is known 
for CCM3, mutation of this gene in neuronal cells activates astrocytes and produces vascular 
lesions that resemble this pathology162. This thus reinforces the importance of cellular 
crosstalk within the neurovascular unit.  
In CCM human patients the organ-specific development of vascular lesions can be 
explained by the two–hits model149. Indeed, a good amount of data support the hypothesis that 
familial CCM patients are heterozygous for LOF mutations in any of the three CCM genes and 
a second hit, likely a LOF mutation in the other allele, would be the driving force for the 
development of the pathology149. For instance, in our mouse model only homozygous deletion 
of CCM3 induce CCM phenotype. This model resembles tumor progression. Indeed, many 
other characteristics in CCMs are in common with tumors such as hyper-proliferation, 
acquisition of invasive and migratory properties, formation of abnormal structures, loss of 
contact inhibition, cadherin-switch, junction disorganization and acquisition of mesenchymal 
markers128. Therefore, we can dare to assume that cavernomas express features of endothelial 
tumors. One of the characteristics of tumors, even if still controversial, is the presence of 
cancer stem cell. A hazardous, but suggestive hypothesis could be that CCM arise from 
endothelial cell progenitors, which lose their control mechanisms and give raise to clonal 
lesions. Some preliminary data from our lab using reporter mice known as rosa confetti202 
support the clonal origin of CCM lesions. In this mice different reporter genes (GFP, RFP, 
YFP, CFP) are flanked by flox sequences. Expression of Cre-recombinase allows the 
recombination (by chance) and subsequent expression of only one of these reporter genes per 
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cell. In this way all the cells generating from a single clone should share the expression of the 
same reporter protein.  Anyway, additional studies are necessary to definitively address this 
point. CCM3 would act as a tumor suppressor and its loss would trigger β-catenin pathway 
and tumor/lesion progression. β-catenin pathway is well known to play a crucial signaling role 
in stem cell maintenance and tumor progression and it is likely that its hyper-activation could 
lead to ECs de-differentiation and to major defects of vascular structure. The fact that CCM 
genes deletion in murine models result in CCM phenotype only if genes recombination is 
performed during the first post natal days and that this ability decreases at increasing ages143 
might fit with the hypothesis of a pool of progenitor ECs which is more numerous in pups and 
decreases in adults also considering that ECs of BBB acquire their differentiated phenotype 
early after birth77.  
Another interesting aspect of our observations is that CCM lesions develop exclusively 
in the venous compartment128. Although the reason for this specific location is still unknown, 
it is interesting to notice that Wnt/β-catenin pathway is important also for arterial-venous 
differentiation via Sox17/Notch pathway28, 29. Failure in arterial-venous differentiation due to 
the de-regulation of such signaling pathways could be crucial for CCM development in 
particular in the venous compartment. Moreover, Bmp2, which we demonstrated to be a target 
of β-catenin-mediated transcription in CCM3 null ECs, is reported to be crucial for veins 
development30. Taking together this findings suggest that de-regulation of these signaling 
pathways could be more relevant in venous tract than in arterial one and justify in part the 
preferential development of CCM lesions within the venous bed. How these pathways can be 
inter-connected one to the other still need to be investigated. 
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Future directions 
In the present work we have been able to elucidate a new molecular pathway implicated 
in CCM pathogenesis and in the process of EndMT. Anyway, many important issues remain 
still obscures, laying the foundations for further studies. In particular for the future it would be 
interesting to better analyze the molecular mechanisms linking the absence of CCM3 with the 
activation of β-catenin signaling. Preliminary data produced in the lab suggest that the 
activation of this pathway is in common at least with CCM1 KO ECs suggesting that such 
signaling could play a pivotal role in familial CCM pathology. Further experiments in CCM2 
KO ECs could definitively address this point. Another common feature between CCM1, 
CCM2 and CCM3 KO is the dismantling of the junctions that we propose as potential 
molecular mechanism between CCM proteins and enhanced β-catenin mediated transcription 
as previously discussed. However, how CCM complex could regulate junction clusters needs 
still to be addressed. An important player for this process could be Rap1 that is been 
demonstrated to be a partner at least of CCM1. Whether also other CCM proteins could 
influence Rap1 activity is not clear even if we observed that in the absence of CCM3 CCM1 
protein results down regulated. In this hypothesis CCM protein complex would acquire a great 
relevance in junction stability by regulating Rap1 thus explaining why deletion of these 3 
independent genes could lead to the very same phenotype. Further investigation of the 
relationship between CCM proteins, Rap1 and junctions stability would help to better 
understand these issues. 
Another open question is linked with the activation of Tgfβ/Bmp pathway in CCM3 KO 
ECs. Even if it’s clear that enhanced Tgfβ/Bmp pathway plays an important role in CCM 
pathogenesis, nowadays the reasons behind the up regulation of this pathway are still 
unraveled. Our data suggest that Tgfβ/Bmp pathway is activated in later stages of CCM 
development, following β-catenin activation. Whether these two pathways can crosstalk is 
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now matter of study in our lab. In particular we showed that Bmp2 is a direct target of β-
catenin. Now we are trying to understand which is the role of Bmp2 in EndMT and CCM, 
whether Bmp2 could be responsible of the activation of Tgfβ/Bmp pathway and which is the 
relationship with Bmp6 that has been demonstrated to be involved in EndMT in CCM. In 
literature many examples of crosstalk between these pathways have been described even if the 
subsequent activation of Tgfβ/Bmp pathway by β-catenin signaling seems likely to occur 
because of time-dependent activation of the two signaling cascades. However, we cannot 
exclude a synergist effect at transcriptional level between downstream effectors of the two 
pathways (p-Smad, TCF4 and β-catenin) that has been often observed in literature, in 
particular for EMT/EndMT genes66-68. 
The molecular mechanisms leading to β-catenin translocation are currently unknown 
and have not been investigated in the present study. Anyway, an active transport of β-catenin 
in the nucleus seems to be the most reasonable hypothesis and address this point in CCM3 KO 
cells could represent a big step toward the understanding of β-catenin pathway both in 
pathology an physiological processes. 
Since astrocytes-specific CCM3 deletion leads to CCM in a mouse model, it is clear that 
the crosstalk between different units in the BBB is a crucial aspect of CCM. In particular we 
could speculate that CCM3 deletion in astrocytes could activate angiogenic stimuli, which 
influence EC physiology, junctions state and intracellular pathways thus activating indirectly 
the same pathways responsible for pathogenesis in endothelial-specific CCM3 KO. Further 
study in this direction using different stimuli and co-culture in vitro could help to address this 
point. 
We hypothesized that CCM could resemble benign endothelial tumors since they share 
lot of classical tumor characteristics as we have observed in our work. However, additional 
experiments could help to better understand this point. For example it would be interesting to 
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inject WT and CCM3 KO ECs in nude mice in order to check for their ability to form tumor 
and their characteristics. 
Previously we used Tgfβ/Bmp pathway inhibitors in order to reduce CCM lesion 
extension. Now we found that also β-catenin inhibitor can strongly counteract CCM 
development. These finding highlighted the need in the future to try to combine treatments 
with β-catenin inhibitors (such as sulindac) and Tgfβ/Bmp pathway inhibitors (such as 
DMH1) in order to define new therapeutic opportunity for CCM patients. Some preliminary 
studies in vitro are already on going in our lab even if the most interesting aspect will be to 
test these drugs in vivo. A synergistic effect between these drugs could lead to an increase of 
survival of CCM3-ECKO mice. 
 
Concluding remarks 
In conclusion, this study highlights the importance of β-catenin signaling for the onset 
and development of CCM3 pathology and shows that targeting β-catenin signaling in ECs 
with specific pharmacological tools can effectively reduces vascular malformations in a 
CCM3-ECKO mouse model. These observations suggest a promising strategy for inhibiting 
the development of vascular lesions and preventing the appearance of new ones in genetic 
CCM3 patients.  
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List%of%gene%generated%comparing%WT%vs.%WT%+%Wnt3a%(threshold=1.3)
Affymetrix%raw%data%(log2) Fold%change%(linear)
Gene_Symbol WT-WNT3a CCM3-KO-WNT3a s.d.-WT-WNT3a s.d.-CCM3-KO-WNT3a Gene_Symbol KO-VS-KO-WNT WT-vs-WT-WNT
ABCB1A 11.9061 12.0066 0.137320137 0.110450079 ABCB1A 1.322942 1.436741
ABCC6 8.17133 8.432845 0.1738917 0.041118259 ABCC6 1.452628 1.869335
ABCC9 7.753295 7.37274 0.081437488 0.10118698 ABCC9 0.729179 0.808366
ABHD2 12.6579 12.78735 0.151745115 0.063427478 ABHD2 1.564932 1.662610
ACE 10.1855 10.29715 0.518450692 0.518521403 ACE 0.506997 0.483035
ACP6 10.69235 10.5645 0.206545891 0.188514668 ACP6 1.305181 1.400377
ADAM12 9.997695 9.74413 0.183854834 0.091740034 ADAM12 0.606359 0.604549
ADRB2 9.249495 9.3629 0.017486751 0.212867425 ADRB2 1.517393 1.341266
AHRR 8.89206 8.411625 0.222413367 0.113398714 AHRR 2.002178 1.923455
AI607873 7.254435 7.369155 0.217074711 0.033608785 AI607873 0.396947 0.464835
AIM1 8.086095 8.283965 0.381533606 0.359599154 AIM1 0.646741 0.790512
AK4 8.672885 8.909055 0.001477853 0.020286894 AK4 0.743624 0.913170
AKAP12 10.77675 9.780155 0.380777002 1.252208328 AKAP12 0.709488 0.790343
ALDH1A3 7.84026 9.55733 0.056766532 2.169219757 ALDH1A3 0.487380 0.497566
AMD1 8.10734 7.87716 0.008315576 0.211085516 AMD1 0.804986 0.895075
ANKRD37 9.065435 8.866555 0.144157859 1.144728097 ANKRD37 0.752845 0.895072
ANO1 11.1064 10.50695 0.066468037 1.460387635 ANO1 0.697251 0.822251
ANPEP 7.84837 10.212595 0.43043004 1.940732343 ANPEP 0.592528 0.641998
APLNR 10.028265 10.20728 1.750280202 1.663709119 APLNR 0.440227 0.765397
APOD 9.12002 10.752705 0.88423703 1.466532393 APOD 0.573464 1.529224
APOE 12.67315 11.9973 0.181938575 0.788141218 APOE 1.592287 1.380796
APOL9A 7.362175 9.94893 0.06960052 3.101327916 APOL9A 0.529306 0.707788
APOL9B 7.394595 7.58744 0.033820917 0.302585134 APOL9B 0.507263 0.644854
AQP11 10.108875 8.9095 0.169740983 2.066590279 AQP11 1.761977 1.813561
ARHGAP20 9.839715 9.8481 0.528046131 0.087638814 ARHGAP20 1.443469 1.730405
ARHGAP28 9.408305 9.45181 0.229491506 0.389530984 ARHGAP28 1.381437 1.376715
ARID3A 8.49664 8.783425 0.193535126 0.541509444 ARID3A 1.390487 1.381131
ARL4A 9.06263 9.02347 0.121212244 0.522707475 ARL4A 1.636122 1.828132
ARRDC4 9.394075 9.18986 0.09224208 0.111737014 ARRDC4 0.541291 0.445831
ARXES2 7.63477 7.874225 0.511068497 0.610820051 ARXES2 3.300673 3.475210
ATP10A 10.7127 9.48105 0.335027193 2.24711464 ATP10A 1.491444 1.378023
ATP13A3 11.96655 11.3257 0.000212132 0.973403195 ATP13A3 0.892330 0.908967
ATP1B1 7.653015 10.36816 0.170745074 2.517639552 ATP1B1 1.563691 3.575686
ATP2B4 7.69238 9.05598 0.951214184 0.402654885 ATP2B4 0.560824 0.568724
AW112010 10.18145 9.163015 0.128198459 1.671296375 AW112010 0.698315 0.649657
AXIN2 8.448225 9.263225 0.221331494 1.24447258 AXIN2 2.805135 2.997937
AZIN1 9.93719 9.39811 0.060005081 0.960378288 AZIN1 0.733892 0.832430
BEX1 4.89191 7.340645 0.623201491 3.155739783 BEX1 1.696469 2.833451
BHLHE41 6.603545 6.864395 0.19137845 0.219422305 BHLHE41 0.686387 0.848005
BMP6 11.7271 7.883555 0.229526861 4.789156447 BMP6 1.362352 1.025552
BNIP3 9.86381 11.00995 0.039258568 1.206253458 BNIP3 0.774359 0.898132
BOK 10.000385 8.00058 0.024487108 3.23108201 BOK 1.357366 1.368855
BST2 10.17855 8.4456 0.193110862 2.126468081 BST2 0.701614 0.714928
C130074G19RIK 10.9595 10.96095 0.026870058 0.193676547 C130074G19RIK 1.328824 1.168696
C1QL3 7.762095 8.724295 0.524482313 1.6881538 C1QL3 0.471262 0.482205
C1QTNF1 9.376765 10.0032 0.272186613 0.365715627 C1QTNF1 2.075746 2.131856
CACHD1 11.1163 10.54445 0.063073925 0.811970717 CACHD1 1.380939 1.322392
CACNA1B 8.55119 9.697085 0.289814785 1.185839285 CACNA1B 1.501365 1.671826
CACNA1E 7.780715 7.82589 0.107657007 0.200394062 CACNA1E 1.666897 1.361937
CACNG4 9.143755 8.69819 0.182949737 0.155662487 CACNG4 0.737835 0.859256
CADM1 9.00596 9.886765 0.340231499 1.627950729 CADM1 2.029255 1.748491
CAR2 9.91782 8.781265 0.11721002 0.618937637 CAR2 1.480731 1.363283
CASC4 8.48311 7.933045 0.196858528 0.905711863 CASC4 1.402072 1.259346
CCDC134 9.52735 9.18672 0.000608112 0.576065752 CCDC134 0.768198 0.885010
CCDC141 8.05143 8.87979 0.192573461 0.57353431 CCDC141 1.575276 2.892486
CCDC85A 9.667435 9.10172 0.240098108 0.518549687 CCDC85A 2.094332 1.926778
CD53 8.195135 7.99313 0.304091271 0.020350533 CD53 1.428291 1.533693
CDH2 11.6633 10.486645 0.295004949 1.389259764 CDH2 1.366324 1.422077
CDON 9.826565 9.832905 0.139816224 0.035376552 CDON 1.690201 1.721773
CEACAM2 7.462545 8.70333 0.20905612 0.583688364 CEACAM2 0.677522 1.043869
CEBPD 8.94837 8.56122 0.117789848 0.783431887 CEBPD 1.363571 1.233378
CFH 8.068655 10.25811 1.276334811 1.89701193 CFH 1.411462 1.412749
CFTR 7.215065 8.27538 1.481565483 2.234839266 CFTR 1.445071 1.278365
CHRM3 9.340905 8.36257 0.793720291 0.78411071 CHRM3 1.551448 1.759725
CHST2 9.56272 9.299015 0.479658814 0.600156881 CHST2 1.305765 1.387574
CLCA5 8.17294 7.78949 0.398383961 0.682386328 CLCA5 0.695065 0.914002
CLEC14A 11.16215 8.910565 0.121268813 2.932987004 CLEC14A 1.381657 1.189619
CLIC6 10.417 9.98882 0.18356492 0.38619344 CLIC6 0.715860 0.774091
CLVS1 9.25649 9.11216 0.604420734 0.341730565 CLVS1 1.639914 1.650331
CMPK2 8.806685 8.80688 0.141159727 0.935290139 CMPK2 0.475507 0.585800
COL10A1 8.89344 10.126245 1.166712047 0.661505465 COL10A1 1.525947 1.315481
COL15A1 10.74245 10.064325 0.069508597 0.448836029 COL15A1 0.584287 0.560641
COL8A1 10.57915 9.64992 0.481186165 1.714988503 COL8A1 0.662366 0.703318
COLEC12 10.6326 9.579445 0.103379011 1.401846265 COLEC12 1.424198 1.209684
CORO2B 9.91774 8.821815 0.158052508 1.653378289 CORO2B 1.872798 1.610440
CPNE7 7.45015 8.658695 0.060797041 2.014554291 CPNE7 0.618942 0.659295
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CRIP1 10.9661 10.9082 0.251022907 1.10846059 CRIP1 0.745304 0.857673
CSF1 11.446 10.83655 0.035921024 0.873630428 CSF1 1.328364 1.254272
CSF2RB 8.25085 9.143445 0.535067701 0.799575135 CSF2RB 1.646212 1.517083
CSF2RB2 10.26915 8.79048 0.421647774 2.241981045 CSF2RB2 1.801664 1.673218
CSN3 7.67541 9.24738 0.511280629 3.279730957 CSN3 0.428056 0.406450
CST6 8.136885 10.02976 0.206750952 1.720305946 CST6 0.679363 0.688849
CTDSPL 8.80215 8.392865 0.320941626 0.773921301 CTDSPL 1.365965 1.063400
CTLA2A 10.782 9.968965 0.639507373 0.366047967 CTLA2A 1.314396 1.289977
CTSC 10.274225 8.163655 0.628016888 3.363770598 CTSC 2.077617 2.225362
CTTNBP2 9.224445 9.047855 0.011476343 0.101066772 CTTNBP2 1.420565 1.260180
CTXN1 9.99733 9.071865 0.100083894 1.025707884 CTXN1 1.361904 1.556801
CX3CL1 11.0029 11.12765 0.218778838 0.249679404 CX3CL1 0.667898 1.026796
CXCL12 11.2814 10.240595 0.181867864 1.057555973 CXCL12 0.705931 0.682287
CXCL16 8.78597 8.638365 0.058746431 0.079627295 CXCL16 0.651705 0.694798
CYP1B1 8.084105 9.36616 0.086373093 0.110379369 CYP1B1 1.619294 1.977250
CYP39A1 9.584155 10.819855 0.44638944 1.579457346 CYP39A1 1.333234 1.327047
D14ERTD668E 8.495365 10.19145 0.101109199 2.018577728 D14ERTD668E 0.649846 0.716240
D8ERTD82E 10.8034 9.738445 0.18356492 1.525872794 D8ERTD82E 0.756494 0.774668
DAPK2 9.405485 9.39651 0.047312515 0.682612602 DAPK2 0.693842 0.595051
DARC 7.916475 9.069045 0.6216105 0.034655303 DARC 1.426520 1.239304
DDX60 6.70956 7.89802 0.037236243 0.7061734 DDX60 0.546910 0.563327
DHX58 8.090155 9.47435 0.181252681 1.187020154 DHX58 0.611969 0.726616
DISP2 10.86035 9.613525 0.604505587 1.539194686 DISP2 1.325512 1.347747
DNAHC6 5.395045 6.36802 0.128361094 1.560683661 DNAHC6 0.941120 0.929077
DNAJB5 10.1397 8.46858 0.0417193 2.422010431 DNAJB5 1.314715 1.280352
DNM3 8.62547 8.579765 0.304649886 1.089602052 DNM3 1.457236 1.559653
DOCK8 9.28388 10.162495 0.209671303 1.358076355 DOCK8 0.641282 0.630475
DPP4 9.106425 7.232465 0.524496455 2.710248368 DPP4 2.361281 2.532847
DUB2A 7.2474 8.286675 0.401834642 2.46345396 DUB2A 1.407110 0.683987
DUSP2 8.48393 8.745425 0.230559237 0.620974104 DUSP2 1.630727 1.379834
DUSP4 8.85804 8.82139 0.030575297 0.33951025 DUSP4 1.503745 1.387382
EDN1 12.3917 10.377165 0.226557013 1.648315404 EDN1 1.424346 1.381466
EFEMP1 9.683345 8.167145 0.181167828 2.354799932 EFEMP1 1.316584 1.421782
EFNA3 7.43474 8.21441 0.129556104 0.11469272 EFNA3 0.600699 1.141669
EFNB2 11.73645 10.025755 0.01039447 2.271714885 EFNB2 0.742802 0.773059
EGFL8 10.42385 11.3379 0.417687976 0.652518138 EGFL8 0.698460 0.775205
EIF2AK2 9.38805 9.41432 0.12224462 0.383916556 EIF2AK2 0.727198 0.827270
ELOVL7 10.183 10.117035 0.136330187 0.52731074 ELOVL7 1.971167 1.709750
EMP2 10.92785 11.5203 0.518945667 0.027860007 EMP2 0.606740 0.612571
ENPP2 10.38085 10.06362 0.076862507 0.344332718 ENPP2 1.639584 1.492266
ENTPD1 11.5965 10.74188 0.033516861 1.708539689 ENTPD1 1.557303 1.643874
EPDR1 10.14702 10.20078 0.460156809 0.584098486 EPDR1 1.432927 1.369520
EPHA7 8.197895 9.394715 1.143879569 2.432143271 EPHA7 0.585441 0.704197
EPHB1 6.406475 7.72902 0.295238294 2.284958995 EPHB1 0.894765 0.754637
ERN1 11.5621 12.0012 0.035921024 0.658457835 ERN1 1.380939 1.231614
ESR1 7.70649 9.17043 0.206135769 1.933611777 ESR1 1.523532 1.335269
ETL4 9.032965 9.03584 0.017557461 0.49525759 ETL4 0.711534 0.769525
F2RL1 7.943135 7.57795 0.075059385 1.311697221 F2RL1 0.689826 0.795332
FABP7 7.4502 9.27713 0.066100342 2.861618717 FABP7 0.723753 1.025345
FADS3 11.23765 9.35568 0.116884751 2.805403728 FADS3 0.708652 0.803266
FAH 9.225175 9.50837 0.252104781 0.691281731 FAH 0.726679 1.085361
FAM102A 10.8023 9.644185 0.068730779 1.612224674 FAM102A 1.514456 1.605497
FAM102B 10.9563 9.04799 0.267852049 2.909758547 FAM102B 1.425680 1.573323
FAM13A 8.502375 9.779205 0.011702617 1.887260928 FAM13A 3.001035 1.934070
FAM13C 9.23345 9.65643 0.201454722 0.746662335 FAM13C 1.439298 1.324093
FAM181B 6.501635 8.599395 0.08621753 2.892073806 FAM181B 1.045150 0.938361
FAM38B 9.225065 9.70883 0.257167665 1.17262346 FAM38B 1.335259 1.394594
FAM69B 8.66802 8.41363 0.082759778 1.149614205 FAM69B 1.372532 2.288068
FAR2 10.3801 9.790825 0.246638845 1.685424368 FAR2 0.750982 0.699138
FGFBP1 6.947585 6.55314 0.139179828 0.453326157 FGFBP1 1.838463 1.818936
FKBP14 9.543825 9.37765 0.23203709 0.392783675 FKBP14 0.767783 0.928549
FLNC 10.1487 9.79568 0.215950411 0.625817786 FLNC 0.658863 0.744606
FLRT2 8.893245 9.73997 0.060846539 0.869783767 FLRT2 1.675515 1.809047
FMO2 6.899185 6.944285 0.354182716 0.141442569 FMO2 0.543499 0.561001
FOXC1 8.791355 9.40168 0.250223877 0.729027091 FOXC1 1.530916 1.726625
FOXF2 11.9925 11.18345 0.010323759 0.958341821 FOXF2 2.039337 2.166626
FOXQ1 8.15054 8.49029 0.150543034 0.1153574 FOXQ1 1.370127 1.929758
FRRS1 9.719645 7.886205 0.105662966 2.655688009 FRRS1 1.356435 1.399736
FRZB 11.25595 9.8524 0.159594001 1.552523649 FRZB 1.373446 1.305498
FUT11 7.198315 9.4754 0.916601307 3.591961027 FUT11 1.412519 0.906469
FUT4 7.61991 8.318515 0.09442704 1.035211399 FUT4 1.501204 1.439213
FXYD6 11.31815 10.598245 0.419102189 1.405664641 FXYD6 1.335981 1.201553
FZD6 12.21545 11.5472 0.12508719 0.841881334 FZD6 1.344528 1.488026
GADD45G 8.301105 7.771365 0.214755401 1.226285793 GADD45G 0.640995 0.715245
GALNTL2 10.2134 8.63739 0.249467272 1.759479661 GALNTL2 1.449706 1.043764
GJA1 10.79565 10.6874 0.168503546 0.042284986 GJA1 0.618523 0.698291
GJA4 8.675705 10.772875 1.078019643 2.161802207 GJA4 0.445779 0.672215
GJA5 10.6098 9.695385 0.464144891 1.725786023 GJA5 0.423769 0.455430
GKN3 7.16793 8.05886 0.576787001 1.404299925 GKN3 1.838660 1.482827
GLI3 8.931615 9.99881 0.096060456 1.158368187 GLI3 1.603818 1.583915
GM12824 9.54618 8.228365 0.376237376 1.496739995 GM12824 3.200528 2.770603
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GM129 8.72687 9.578825 0.354727188 0.726163309 GM129 1.369453 1.653921
GM14005 10.38395 8.43463 0.095105862 2.942087469 GM14005 0.793609 0.850982
GM3893 8.683415 8.963965 0.287559115 0.39778292 GM3893 1.575751 1.807624
GM4884 5.57531 7.25408 0.057996898 3.054729579 GM4884 1.458383 0.978040
GM5972 12.219 10.9956 0.146512525 2.236578749 GM5972 0.698848 0.772657
GM6548 9.997345 9.51682 0.047736779 0.776092119 GM6548 0.767104 0.883070
GM8995 9.8192 10.49785 0.09906566 0.013647161 GM8995 0.652093 0.790014
GNA14 8.121555 8.575875 0.328231897 0.178240406 GNA14 0.601347 0.778066
GNG4 8.014795 6.69 0.178183838 2.06216379 GNG4 0.716081 0.998684
GPC4 10.37855 11.59965 0.074599765 1.883944597 GPC4 0.641557 0.735680
GPIHBP1 8.62062 9.332335 0.07694736 1.227063611 GPIHBP1 0.551677 0.564831
GPM6A 9.510535 9.974675 0.155754411 0.818723587 GPM6A 1.852739 1.737081
GPR126 10.48325 9.285315 0.400717413 2.265407492 GPR126 5.818914 4.486219
GPR143 8.13882 8.238745 0.558373941 0.618414378 GPR143 1.450319 1.413831
GPR182 10.08687 10.142 0.305653977 0.071276364 GPR182 1.609770 1.133398
GPX3 7.950005 8.17243 0.557758758 0.27587064 GPX3 0.670805 0.842746
GRAP 11.7586 10.36068 0.062932504 1.735126904 GRAP 1.394550 1.394212
GRIN2A 8.1589 8.853685 0.13098446 1.372190206 GRIN2A 0.580420 0.710556
GRRP1 9.319025 8.977825 0.541368023 1.169816246 GRRP1 1.323350 1.292666
GSTA4 9.73934 9.87056 0.272731086 0.60081449 GSTA4 1.758877 2.351009
GSTM7 9.05795 8.35576 0.096845345 1.266909078 GSTM7 1.390829 1.783152
GSTO1 10.40685 11.164 0.158604051 0.755048621 GSTO1 0.751998 0.772336
GUK1 10.04486 8.93017 0.332255334 1.535029827 GUK1 0.756132 0.891990
H19 6.91953 7.81973 0.029613632 1.554800533 H19 0.957846 0.884602
H1FX 10.107205 10.5475 0.648268426 0.050487424 H1FX 1.373779 1.373655
H2=Q4 10.75895 10.016185 0.337643488 1.266025194 H2=Q4 0.702149 0.681294
H2=Q6 10.31105 10.66225 0.217293914 0.326754044 H2=Q6 0.501997 0.479699
H2=Q8 9.587475 9.97739 0.210145064 0.253441213 H2=Q8 0.710435 0.670531
H2=T22 10.5004 8.81538 0.102530483 2.499367913 H2=T22 0.740386 0.819832
H2=T23 9.423645 9.826335 0.209819795 0.170391521 H2=T23 0.763913 0.922301
HMCN1 7.099975 8.702945 0.002906209 2.099760658 HMCN1 1.027704 0.968897
HMGA2 10.9496 10.093055 0.131804704 1.04700594 HMGA2 0.722515 0.663009
HS3ST1 8.90974 8.901355 0.202204255 0.021163706 HS3ST1 1.411638 1.087511
HTR2A 9.91791 10.70395 0.167287322 0.051972348 HTR2A 1.447441 1.611356
HTRA1 9.812205 10.21215 0.62153979 0.258871793 HTRA1 0.564073 0.698025
I830012O16RIK 5.542365 6.791585 0.161184991 0.521653886 I830012O16RIK 0.338637 0.522856
ID2 10.046155 10.199375 0.608316893 0.707283558 ID2 1.531839 1.407671
IFI203 8.68193 8.518035 0.046527626 0.990819235 IFI203 0.481434 0.560362
IFI204 9.01195 9.80958 0.341702281 0.66796135 IFI204 0.445522 0.567367
IFI205 6.449275 8.83413 0.055727085 2.670841307 IFI205 0.408331 0.686737
IFI35 9.7472 8.03643 0.038424182 2.93176371 IFI35 0.765699 0.871311
IFI44 9.761535 9.637525 0.151483486 1.532689304 IFI44 0.351718 0.522820
IFIH1 10.03185 9.35723 0.044901281 1.456597543 IFIH1 0.718595 0.805078
IFIT1 8.694595 9.382695 0.038091842 0.412405888 IFIT1 0.393259 0.579381
IFIT2 7.36993 7.395925 0.181500169 0.974060804 IFIT2 0.562933 0.688933
IFIT3 8.77348 9.87436 0.129881374 0.207804541 IFIT3 0.291947 0.478968
IGSF5 9.0834 9.28133 0.136457467 0.396319209 IGSF5 1.352923 1.183915
IIGP1 6.95097 8.64238 0.276903016 1.968047878 IIGP1 0.692344 0.649448
IL17RD 8.19173 8.651735 0.082632498 0.309479425 IL17RD 1.470233 1.365056
IL17RD 8.19173 7.887305 0.082632498 0.771587849 IL17RD 1.470233 1.365056
IL1RAP 8.715505 9.06994 0.083389103 0.293958431 IL1RAP 0.665292 0.823192
INSR 11.97695 10.542835 0.244729657 2.081814288 INSR 2.162575 2.248792
INSR 11.97695 9.139395 0.244729657 4.06657817 INSR 2.162575 2.248792
IRF7 8.405075 8.80988 0.269895587 1.084475528 IRF7 0.347150 0.533188
IRGM1 10.50215 9.42082 0.13767369 1.948475162 IRGM1 0.642692 0.785863
IRGM2 8.84916 9.14389 0.027775154 0.402103342 IRGM2 0.653421 0.884694
ISG15 6.56584 9.587115 0.065463946 3.757968486 ISG15 0.583458 0.692756
ISG20 9.209335 11.002105 0.159162665 1.756870437 ISG20 0.754810 0.964732
ISM1 9.908585 8.95911 0.729755411 0.513034254 ISM1 1.676456 1.738545
ISYNA1 9.11876 10.038385 0.399147636 0.849680721 ISYNA1 1.385830 1.631416
ITGA4 10.28885 9.605605 0.374130198 0.436801072 ITGA4 1.722758 1.991720
JUB 10.3321 8.465175 0.086267027 2.527376413 JUB 1.444565 1.405438
KANK4 7.560505 8.394545 0.195536238 1.189162687 KANK4 1.576893 1.321696
KBTBD11 8.823765 9.444125 0.229816775 0.449005735 KBTBD11 1.684272 2.513696
KBTBD11 8.823765 9.060765 0.229816775 0.093147176 KBTBD11 1.684272 2.513696
KCNE3 8.918345 9.513445 0.056844314 1.149409144 KCNE3 0.640984 0.790929
KCNIP3 10.3748 10.34595 0.226132749 0.113773481 KCNIP3 2.329177 2.257475
KCNJ2 10.8684 9.223975 0.220900158 1.78986404 KCNJ2 1.595380 1.751177
KCNJ8 8.189815 8.063945 0.087207479 0.56359946 KCNJ8 0.623132 0.728378
KCNK5 8.32735 8.12717 0.298837468 0.474185807 KCNK5 2.447129 1.994317
KLHL6 9.095225 8.691955 0.009383307 0.064778052 KLHL6 1.584601 1.217258
LAMA1 8.55841 9.31936 0.364428693 0.537146595 LAMA1 2.130084 2.056541
LBH 10.046655 9.86049 0.169910688 0.108385327 LBH 0.740928 0.810102
LCN2 7.48825 8.48571 0.791252488 0.692031265 LCN2 1.516158 1.708594
LEF1 9.51405 8.96762 0.303263956 1.500452305 LEF1 2.220708 2.733122
LGALS3 8.421985 8.415655 0.020767726 0.275029183 LGALS3 0.705587 0.822718
LGALS3BP 12.0424 10.394795 0.404889343 3.003230992 LGALS3BP 0.600152 0.648173
LIFR 8.500875 9.38695 0.584444968 0.867266467 LIFR 0.737853 0.719589
LIMCH1 10.06985 8.457315 0.09694434 1.961224297 LIMCH1 1.444996 1.431294
LONRF2 7.333885 8.20889 0.729896833 1.871867213 LONRF2 1.605992 1.261968
LPHN2 13.2206 10.854745 0.015132085 3.268749588 LPHN2 0.911554 0.895490
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LPHN3 10.138135 10.81765 0.514582818 1.20017234 LPHN3 2.074998 2.106357
LRG1 8.668535 9.701495 1.829391309 2.340389095 LRG1 1.418115 1.653932
LRP8 10.061195 9.911685 0.227836876 0.283853875 LRP8 1.496503 1.441209
LRRC7 6.830385 6.6443 0.439063814 0.253200796 LRRC7 1.608159 1.398921
LSR 9.726295 12.1576 0.091761247 1.419587574 LSR 2.290988 2.453158
LTBP4 10.96635 11.0626 0.583716648 1.311541658 LTBP4 0.612826 0.778841
LYST 9.83102 9.66847 0.060698046 0.506472303 LYST 1.372304 1.340281
MAFB 8.37377 9.06257 0.30077494 1.331524495 MAFB 1.409028 1.177906
MAL 9.58058 8.505595 0.517870864 2.405160077 MAL 2.366754 3.463883
MAOA 11.19675 11.25685 0.184484159 0.426738942 MAOA 1.484729 1.587493
MARVELD2 9.09815 10.31005 0.275785787 2.007122598 MARVELD2 1.624145 1.601191
MDGA2 6.726505 8.52015 0.330070374 2.162403248 MDGA2 0.676525 0.728580
MDGA2 6.726505 7.336165 0.330070374 0.487995603 MDGA2 0.676525 0.728580
MEIS2 8.85288 9.82549 1.639950331 3.084131079 MEIS2 3.154738 2.268612
MEST 10.6621 10.98135 0.189080353 0.449224938 MEST 0.653383 0.748098
MFSD7C 9.799615 9.764545 0.057777695 0.872930392 MFSD7C 4.381394 7.341017
MGLL 7.692625 8.0128 0.145741779 1.04104503 MGLL 0.590183 0.566575
MIR126 8.80776 8.01096 0.438462773 1.038442877 MIR126 1.405701 1.167846
MIR181B?1 9.168395 9.1125 0.273473548 0.226910566 MIR181B?1 1.677846 1.334126
MMP28 9.09793 9.83567 0.161149635 0.435337361 MMP28 1.373384 1.553918
MMRN1 8.75858 9.649695 0.521024561 1.657748209 MMRN1 3.417355 3.457454
MOGAT2 8.6081 8.37165 0.427177349 0.033417866 MOGAT2 2.859336 1.923655
MRPS36 6.344855 7.411745 0.005239661 1.426722281 MRPS36 0.708670 0.869959
MX2 5.578865 7.623005 0.25687068 1.835189585 MX2 0.583533 0.689781
MYH10 12.4171 10.895235 0.233203816 2.004456806 MYH10 1.444179 1.401285
MYL4 11.211 9.684195 0.026162951 1.956571535 MYL4 2.416669 2.670648
NCAM1 8.71035 8.356005 0.250754207 0.883013735 NCAM1 0.654275 0.826399
NEFL 9.90045 7.950335 0.851992961 1.954662346 NEFL 1.402728 1.481347
NEFM 9.147045 6.807655 0.640872089 2.171942118 NEFM 1.823159 1.632514
NEURL1B 10.465 11.385 0.090933932 1.511511455 NEURL1B 1.557401 1.087481
NEURL1B 10.465 10.67595 0.090933932 0.508763329 NEURL1B 1.557401 1.087481
NLRC5 7.206605 7.876995 0.041485955 0.884201675 NLRC5 0.779510 0.707705
NMNAT2 9.451495 10.0416 0.098874741 0.030405592 NMNAT2 0.707239 0.856990
NNMT 10.6838 9.79765 0.605990511 1.051962758 NNMT 0.710152 0.728070
NOMO1 12.19665 11.03122 0.133289628 1.58332522 NOMO1 1.303237 1.327305
NOS2 8.881515 9.3867 0.009142891 0.742377267 NOS2 0.537129 0.556042
NOSTRIN 10.038305 8.752255 0.056702893 2.263088182 NOSTRIN 2.395372 2.376157
NPNT 11.6016 11.4856 0.220758737 1.556907711 NPNT 2.135391 1.475649
NPR3 10.01245 10.054005 1.112066835 1.337697538 NPR3 2.550818 1.557978
NPTX1 8.79984 10.91863 0.347514699 1.891468213 NPTX1 0.646542 0.861958
NQO1 9.7227 9.416355 0.023730504 1.151516322 NQO1 1.316525 1.371134
NR2F1 7.275785 8.727765 0.474899985 2.633456572 NR2F1 1.453121 1.209998
NRBP2 9.30417 11.01287 0.002404163 2.163930598 NRBP2 1.425176 1.376634
NRGN 9.23842 9.70183 0.208059099 0.194539218 NRGN 1.527005 1.754026
NRP2 11.53535 10.226675 0.024960869 1.803581911 NRP2 0.767213 0.681601
NT5E 8.997505 10.078815 0.616660753 0.981867263 NT5E 0.466565 0.459183
OAS1A 7.772885 7.51508 0.443193317 0.660720576 OAS1A 0.629651 0.729207
OAS1G 7.972505 8.984465 0.153887649 0.710734239 OAS1G 0.555938 0.731262
OASL1 8.50484 9.60514 0.151547125 1.337223776 OASL1 0.642547 0.708940
OASL2 10.68945 11.4093 0.06569022 0.093338095 OASL2 0.468412 0.581903
OGDHL 8.625835 8.386865 0.133438121 0.138062599 OGDHL 1.378295 1.302118
OLFML2A 11.26765 9.763635 0.387989491 2.965556343 OLFML2A 2.404472 2.786106
OLFR517 5.60896 6.855315 0.19640598 1.605832429 OLFR517 0.683148 0.889135
P2RY1 9.451755 9.20676 0.190416785 0.953689058 P2RY1 1.314792 1.758445
P2RY2 10.5257 10.8312 0.10323759 0.414505995 P2RY2 0.684062 0.683257
P4HA2 8.753295 8.77494 0.151073364 0.590278599 P4HA2 0.634090 0.745541
PAPSS2 9.7713 10.84499 0.372503852 1.237168166 PAPSS2 0.757491 0.781387
PARP12 11.04655 8.57181 0.066397327 3.880163609 PARP12 0.767958 0.847009
PARP14 9.39497 9.804715 0.152155237 0.024006275 PARP14 0.659281 0.659532
PCDH7 9.771125 10.521585 0.110131881 1.484096926 PCDH7 1.543168 1.301161
PDE7B 11.0368 10.07637 0.041860721 1.48114829 PDE7B 2.949908 3.038965
PGLYRP1 10.8223 10.85702 0.17833233 1.801821216 PGLYRP1 2.802142 3.830811
PHLDA1 8.76589 10.014965 0.154036141 1.405353514 PHLDA1 1.736798 2.658661
PKNOX2 7.95434 8.7622 0.263128575 0.738629601 PKNOX2 1.784018 1.862790
PLAU 12.2266 10.63708 0.051335952 2.15811818 PLAU 0.721915 0.718470
PLEKHF1 7.50424 9.49158 0.162266864 2.634849572 PLEKHF1 0.703831 0.892504
PLSCR2 9.522745 11.26335 0.393851406 2.480884142 PLSCR2 1.340968 1.105340
PLVAP 8.540385 9.36729 0.503650947 0.82543403 PLVAP 0.603362 0.447556
PLXNB1 8.092165 7.80088 0.093684577 0.079026254 PLXNB1 0.976973 0.937600
PPARG 7.70367 9.79695 0.093281527 3.195486255 PPARG 0.708778 0.652123
PPP1R2 12.1662 10.20006 0.124026529 3.326428289 PPP1R2 0.695465 0.788974
PPP1R3C 6.14989 7.189625 0.215116025 1.448373891 PPP1R3C 0.649310 0.913432
PRKG1 8.47991 8.32193 0.135439233 0.078743411 PRKG1 2.051359 1.473391
PROKR2 7.43433 7.814705 0.507504679 0.30461453 PROKR2 0.671449 0.924468
PRRG3 9.40786 8.45342 0.048861079 1.180005654 PRRG3 0.742699 0.883177
PRSS12 8.866695 10.823435 0.100981919 2.90686648 PRSS12 1.511640 1.648467
PTCHD1 10.81355 8.55915 0.171756237 3.119967251 PTCHD1 0.663561 0.674131
PTCHD1 10.81355 9.22592 0.171756237 2.177012074 PTCHD1 0.663561 0.674131
PTER 9.229195 8.246695 0.244680159 1.413966075 PTER 0.740112 0.735061
PTHLH 7.812845 9.125825 0.029012591 0.200952676 PTHLH 0.608228 0.791812
RAMP3 9.404755 9.572155 1.192104251 0.797680089 RAMP3 1.360786 1.733707
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RASA4 8.244395 9.58091 0.258355605 1.877495783 RASA4 0.644093 0.543369
RASGRP2 7.45499 9.57312 0.180609214 1.888512507 RASGRP2 0.694427 0.819074
RASSF9 9.732165 9.641925 0.079867711 0.503198399 RASSF9 1.486413 1.657139
RCAN2 10.051265 9.54512 0.464194389 0.046768043 RCAN2 1.336157 1.180465
RDH10 9.662325 10.80577 0.051837998 1.52597886 RDH10 1.318872 1.285941
REEP1 9.18898 8.874005 0.116078649 0.818638734 REEP1 2.490007 2.953345
RERG 7.712935 8.24282 0.517736514 0.156694863 RERG 1.415626 1.739256
RGS2 8.30777 8.81742 0.33951025 1.4537974 RGS2 2.414074 2.822669
RHOBTB1 10.6158 10.1854 0.074387633 0.767210858 RHOBTB1 1.685913 1.808082
RND1 10.52115 9.97616 0.27739799 0.295768624 RND1 0.711063 0.794379
RNF125 10.226785 10.016465 0.390909842 0.857911444 RNF125 0.696833 0.813351
RNF183 9.32662 8.158915 0.029811622 1.403288763 RNF183 1.657409 2.065284
RNF213 10.7687 9.756955 0.219061681 1.95521389 RNF213 0.731510 0.749864
RNF213 10.7687 10.82915 0.219061681 0.438901179 RNF213 0.731510 0.749864
RNU2 10.93595 10.8895 0.091428907 0.478994134 RNU2 0.731662 0.842472
ROBO1 9.916015 9.753345 0.434425193 0.504669181 ROBO1 1.447532 1.819466
RPS6KA2 10.7339 9.825145 0.069437886 0.783976359 RPS6KA2 0.739668 0.737646
RSAD2 9.691005 10.62185 0.300612306 0.467892557 RSAD2 0.414545 0.470472
RTP3 8.93204 10.37187 0.123319423 0.821417663 RTP3 0.751279 0.816271
RTP4 9.50638 10.4491 0.023702219 0.306318658 RTP4 0.428430 0.550447
RUNX1 9.068665 9.458605 0.106115515 0.523449937 RUNX1 0.761125 0.715816
S100A6 11.66845 10.9566 0.259578899 0.818122546 S100A6 0.704099 0.764559
SAMD4 9.25507 9.17947 0.199064701 0.064360859 SAMD4 0.764374 0.766432
SAMD9L 10.2843 10.3354 0.080610173 0.384524668 SAMD9L 0.743188 0.834799
SCD1 8.91039 9.679575 1.01833276 0.565862202 SCD1 0.503576 0.645308
SCGB3A1 8.326195 9.18109 0.662580267 0.473492843 SCGB3A1 1.408662 1.535906
SCN3B 10.73285 11.3486 0.237375746 0.979484313 SCN3B 1.386550 1.437548
SDCBP2 9.50562 9.48696 0.128453018 0.415920209 SDCBP2 0.684198 0.799217
SEMA3G 10.94305 10.716 0.176281721 0.413657467 SEMA3G 0.713062 0.766682
SEMA4B 9.798015 9.38992 0.03449974 0.430670456 SEMA4B 0.755244 0.811805
SERPINA1C 5.108275 6.32095 0.284787256 2.183206329 SERPINA1C 1.530465 1.018806
SESN1 10.3361 10.2789 0.271387583 0.269690526 SESN1 1.365936 1.315891
SESN3 11.458 10.64583 0.138310086 1.004332046 SESN3 1.887204 2.315606
SHISA6 7.196505 8.91183 0.692618163 2.510045225 SHISA6 0.666580 0.802565
SIX1 9.332405 9.25913 0.289850141 0.375784828 SIX1 0.759715 0.894234
SLC16A3 10.65755 7.773 0.085064946 4.605669309 SLC16A3 0.733312 0.972183
SLC16A4 9.91809 9.99845 0.369689567 0.035143207 SLC16A4 2.280595 2.873104
SLC16A6 9.94305 10.358015 0.019813132 1.307560647 SLC16A6 1.703563 1.656336
SLC16A9 4.01685 5.876945 0.05238247 2.363143792 SLC16A9 0.871338 1.018528
SLC19A3 8.70529 9.414285 0.145833703 0.340026438 SLC19A3 1.946328 3.491580
SLC1A1 10.1465 10.6016 0.052325902 0.825617878 SLC1A1 1.323731 1.340206
SLC22A14 7.440135 8.541855 0.495208092 2.569548261 SLC22A14 2.265312 1.550910
SLC22A4 7.996635 8.90467 0.076699873 0.962612746 SLC22A4 0.701371 0.685413
SLC24A2 6.17948 5.095405 0.051505658 1.476813726 SLC24A2 0.381591 0.513576
SLC25A23 8.21742 9.078865 0.225354931 1.265459509 SLC25A23 1.426743 1.342358
SLC25A42 9.50031 9.67834 0.156539299 0.018568624 SLC25A42 1.311402 1.301644
SLC35F2 9.672325 8.195785 0.002227386 2.033872448 SLC35F2 3.640761 3.494849
SLC39A8 10.130845 9.23891 0.298335422 1.218755106 SLC39A8 2.449114 2.331147
SLC40A1 11.7349 8.762835 0.078913117 3.673794495 SLC40A1 1.700313 1.715346
SLC44A1 12.2969 10.14749 0.009475231 2.856159853 SLC44A1 1.350927 1.267688
SLC44A5 7.311155 8.55573 0.071071303 1.410791166 SLC44A5 0.669908 0.667045
SLC9A7 7.939515 8.77883 0.34374582 1.548012308 SLC9A7 1.541602 1.421762
SLCO1A4 9.89261 9.92195 0.100677864 0.747624 SLCO1A4 8.075099 9.987614
SLCO1A5 6.37141 8.91171 0.377962717 3.686557772 SLCO1A5 1.463629 1.822154
SLCO1C1 8.904465 10.875525 0.711738331 1.823451612 SLCO1C1 3.712832 4.901421
SLCO2B1 10.59085 8.995835 0.098641396 2.745787555 SLCO2B1 2.392535 2.352639
SNCG 8.80367 8.816585 0.000410122 1.395383309 SNCG 0.603525 0.706587
SNED1 10.14743 10.35475 0.361996246 0.195515025 SNED1 2.082996 1.758938
SNORA20 6.22496 6.2812 0.180566788 0.536453631 SNORA20 1.451586 1.258583
SOD3 9.015755 8.77494 0.200542554 0.300096118 SOD3 2.234543 1.484097
SP100 10.39765 10.79225 0.017465537 0.004313351 SP100 0.759331 0.844313
SPINT2 9.387575 9.383995 0.203540687 0.020541452 SPINT2 1.324332 1.131860
SPNS2 11.017 10.773 0.040729351 0.218495995 SPNS2 1.338530 1.137329
SPP1 11.84065 9.053465 0.658669967 4.534301021 SPP1 0.760200 0.773032
SPRR1A 8.0627 8.235045 0.439580002 0.171989582 SPRR1A 0.574729 0.610469
SPRY1 9.12422 9.540665 0.085814479 1.164230102 SPRY1 1.893263 1.595579
SPRY4 10.3198 9.74072 0.003676955 0.912139463 SPRY4 0.713557 0.778301
SRPX2 9.41938 9.73956 0.579799276 1.535751076 SRPX2 1.458292 1.388421
SSBP2 9.737765 10.45823 0.285763063 0.875921454 SSBP2 1.445406 1.420585
ST3GAL5 9.425945 8.924555 0.202706301 0.654731382 ST3GAL5 1.736094 1.750491
ST3GAL6 11.4316 9.971945 0.174796796 1.989734843 ST3GAL6 1.624280 1.323905
ST6GALNAC2 10.7901 10.7651 0.178190909 0.518167849 ST6GALNAC2 1.444480 1.418632
ST8SIA6 10.61965 10.060965 0.050416713 1.215566054 ST8SIA6 0.650085 0.781165
STAT1 10.9562 10.32523 0.014849242 1.301599736 STAT1 0.681342 0.743549
STAT2 9.83069 9.68194 0.112599684 0.974053733 STAT2 0.700492 0.826800
STAT4 7.495805 9.571185 0.553021142 2.19360787 STAT4 0.678297 0.943455
STC2 9.596265 10.217295 0.515784899 1.009331291 STC2 1.985490 2.047325
STMN2 9.862255 11.0268 0.238075782 0.033092597 STMN2 0.648467 0.732220
STOM 10.064625 10.64695 0.164720525 0.159028315 STOM 0.673115 0.828573
STXBP5 10.5484 10.27981 0.057134228 0.417461701 STXBP5 1.308261 1.266283
STXBP6 10.13335 8.66914 0.083792154 1.937557433 STXBP6 1.616222 1.612836
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SUSD4 8.341465 8.870095 0.315093853 1.158445969 SUSD4 1.866111 1.547645
SWAP70 10.8849 11.143 0.016404877 0.115541248 SWAP70 1.321338 1.347234
SYNM 10.2998 10.4479 0.060669762 0.021496046 SYNM 1.611814 1.586426
SYT5 7.93642 9.953985 1.567585023 1.158686385 SYT5 1.427618 1.477656
TAF1D 7.886175 8.905975 0.26812782 1.105200828 TAF1D 1.097092 1.054066
TBC1D30 8.61631 8.18532 0.171416826 0.604321739 TBC1D30 1.398175 1.687947
TBC1D8 10.001005 10.676835 0.023610295 1.020022745 TBC1D8 1.476207 1.537951
TBX1 12.20035 11.39275 0.207252998 1.122673436 TBX1 1.920524 1.979931
TBX4 9.11201 8.02775 0.010238906 1.651843867 TBX4 1.344976 1.205770
TCF7 8.68668 8.25808 0.07800802 0.665359197 TCF7 2.864692 2.689056
TGFBR3 10.80845 9.87115 0.180807204 1.562776697 TGFBR3 1.537323 1.331355
TGTP1 9.568725 9.944235 0.078043375 0.250690567 TGTP1 0.564844 0.631034
TGTP1 9.568725 11.05395 0.078043375 1.318683436 TGTP1 0.564844 0.631034
THSD1 10.9332 10.03105 0.130531912 1.443275651 THSD1 1.318365 1.393729
TIMP3 12.0599 10.39557 0.162351717 2.962254154 TIMP3 0.743987 1.099616
TINAGL1 10.8676 10.92385 0.347755115 0.952119281 TINAGL1 0.655537 0.778760
TMEM178 9.713295 9.471005 0.078453497 0.245259987 TMEM178 0.647362 0.723144
TNFRSF19 8.71635 9.314725 0.435379787 0.024246692 TNFRSF19 2.047523 2.309771
TPD52L1 9.035165 9.80416 0.1730361 1.604764698 TPD52L1 1.374393 1.433096
TRF 10.69565 11.8491 0.140643539 2.060367739 TRF 1.613010 1.410606
TRIM14 8.575335 10.687715 0.63008164 2.067417594 TRIM14 0.671880 0.749674
TRIM30A 11.1322 10.62889 0.06462956 1.091362748 TRIM30A 0.720840 0.744090
TRIM30D 8.020205 8.585055 0.446926841 0.378874884 TRIM30D 0.691219 0.686340
TRPV4 9.149275 9.79209 0.219549584 1.27818036 TRPV4 0.698262 0.915543
TSHZ2 10.49035 10.28535 0.047164022 0.240345595 TSHZ2 1.437553 1.336477
TSPAN33 8.43354 8.23542 0.307025764 0.201115311 TSPAN33 0.652265 0.687504
TTBK2 10.64115 10.85195 0.213334116 0.376110097 TTBK2 1.454371 1.433011
TTYH2 12.2887 10.004435 0.088388348 2.704351098 TTYH2 1.478670 1.355382
TUBB3 7.541275 9.462725 0.494882823 2.577934548 TUBB3 0.727329 0.670793
UBE2L6 9.950045 10.2671 0.14065061 0.112005714 UBE2L6 0.588880 0.719866
UPP1 12.10385 10.375965 0.017041273 2.8157487 UPP1 0.746182 0.817194
USP18 10.2716 10.77255 0.193322994 0.055366461 USP18 0.447140 0.579207
USP53 10.70555 11.23905 0.32632978 0.938259988 USP53 1.376300 1.285434
VIL1 8.593785 8.327235 0.17256941 0.826105781 VIL1 2.091575 2.218555
VSIG2 11.2033 10.65455 0.075801847 0.692469671 VSIG2 1.365851 1.308805
VWF 12.48365 12.27955 0.083933575 0.065124535 VWF 2.269068 2.436567
WBSCR27 10.02046 10.2089 0.105132636 0.268700577 WBSCR27 1.356195 1.291663
WNK2 8.46679 9.166985 0.108187338 1.11435079 WNK2 1.455298 1.445932
XAF1 9.129845 9.232275 0.052799663 0.473697904 XAF1 0.647726 0.714841
XYLT1 9.23178 10.061225 0.134124014 1.328194022 XYLT1 0.692356 0.767945
ZBP1 7.26186 9.910955 0.076028121 2.854229451 ZBP1 0.676853 0.789702
ZIC2 11.4337 10.668255 0.180029386 1.321080528 ZIC2 1.303734 1.340852
ZIC3 10.41635 9.41748 0.151391562 1.354420613 ZIC3 1.766379 1.794634
ZNRF3 9.44037 9.53958 0.220475894 0.415029254 ZNRF3 1.416671 1.491847
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List%of%gene%generated%comparing%WT%vs.%CCM3%KO%(threshold=1.3)
Affymetrix%raw%data%(log2) Fold%change%(linear)
Gene_Symbol WT+WNT CCM32KO s.d.2WT2WNT3a s.d.2CCM32KO2WNT3a Gene_Symbol WT2VS2KO WT2vs2WT2WNT
A4GALT 9.469495 10.16574 0.329080425 0.284624622 A4GALT 1.383080 0.853605
ACER3 8.71395 9.223155 0.076721086 0.320948697 ACER3 1.362338 0.957192
ADAMTS5 10.61755 11.31375 0.23878996 0.165109433 ADAMTS5 1.414655 0.873119
ADAMTSL1 7.166005 8.44057 0.222703281 0.869331219 ADAMTSL1 2.404488 0.993895
AFAP1L2 7.516615 8.85352 0.572452437 0.337883904 AFAP1L2 2.113714 0.836754
AHNAK 10.5463 11.0541 0.397394011 0.476165706 AHNAK 1.321567 0.929451
AHNAK2 10.9506 11.56765 0.649124025 0.56207918 AHNAK2 1.385590 0.903408
ALOX5AP 7.19162 8.05255 0.07773932 0.307138901 ALOX5AP 1.810314 0.996754
ANKRD33B 7.40566 7.798225 0.21998092 0.102226427 ANKRD33B 1.361687 1.037298
ANLN 9.94231 10.5551 0.848655417 0.243386154 ANLN 1.495746 0.978114
ANPEP 7.84837 9.574935 0.43043004 0.395944442 ANPEP 1.960905 0.592528
APOD 9.12002 11.00205 0.88423703 0.431123004 APOD 2.113758 0.573464
APOLD1 12.531 12.95265 0.064063874 0.043204224 APOLD1 1.397405 1.043261
ARF2 10.45285 10.95755 0.023688077 0.232991684 ARF2 1.528429 1.077248
ARHGAP18 11.2228 10.6572 0.199262691 0.274498852 ARHGAP18 0.752910 1.114310
ARL4D 7.92974 8.65511 0.017140268 0.244871078 ARL4D 1.668353 1.009090
ARRDC4 9.394075 9.87393 0.09224208 0.036769553 ARRDC4 0.754886 0.541291
ASS1 8.823505 9.91264 0.518514332 0.031635957 ASS1 1.745621 0.820517
ASS1 8.823505 9.91264 0.518514332 0.031635957 ASS1 1.745621 0.820517
ATP10D 8.52695 8.86611 0.209727871 0.236216091 ATP10D 1.448044 1.144681
ATP2A3 7.30733 8.12221 0.341009316 0.394311025 ATP2A3 1.620321 0.921081
ATP2B4 7.69238 9.190445 0.951214184 0.275877711 ATP2B4 1.584124 0.560824
BAIAP2L1 9.117405 9.59039 0.239447569 0.00516188 BAIAP2L1 1.357366 0.977945
BCL2L11 10.59175 9.9579 0.287156064 0.545462171 BCL2L11 0.744942 1.155927
BST1 9.709005 10.5671 0.056179634 0.304763023 BST1 1.915273 1.056619
C2CD2L 10.5445 10.9087 0.229244018 0.110308658 C2CD2L 1.444530 1.122255
CACNG4 9.143755 9.01266 0.182949737 0.109898536 CACNG4 0.673745 0.737835
CADM3 7.59468 8.47445 0.218439427 0.482020551 CADM3 1.602112 0.870674
CALCRL 11.0602 11.6096 0.245507474 0.074953319 CALCRL 1.364952 0.932677
CAPN5 9.74897 10.37175 0.000509117 0.086337738 CAPN5 1.487418 0.965956
CAR2 9.91782 8.5299 0.11721002 0.446141953 CAR2 0.565810 1.480731
CAR4 6.731835 7.661025 0.18177594 0.331215887 CAR4 1.625806 0.853797
CAR5B 9.438805 9.89995 0.191746146 0.288570277 CAR5B 1.363411 0.990394
CBFA2T3 10.11635 10.6343 0.083085047 0.061094026 CBFA2T3 1.336584 0.933421
CCDC141 8.05143 8.03932 0.192573461 0.28381852 CCDC141 1.562109 1.575276
CD24A 8.73289 8.20946 0.493122127 0.518775961 CD24A 0.611581 0.879067
CD276 10.5123 10.35675 0.019657569 0.098782817 CD276 0.720590 0.802626
CD38 12.9138 12.38555 0.067316566 0.507207694 CD38 0.753067 1.086057
CD55 7.51668 8.89261 0.251998715 0.823595552 CD55 2.361903 0.910051
CDC42EP3 10.228 9.759735 0.121339524 0.001237437 CDC42EP3 0.763571 1.056359
CDCA7L 9.87573 9.622215 0.463678201 0.392918025 CDCA7L 0.765195 0.912196
CEACAM1 11.1053 12.00635 0.062083975 0.058053467 CEACAM1 1.478311 0.791631
CHST15 10.038335 9.561305 0.148160084 0.883027877 CHST15 0.731277 1.017846
CHST7 9.871655 9.343715 0.137397919 0.091294557 CHST7 0.762863 1.099948
CKB 10.72065 11.6428 0.166382226 0.048931789 CKB 1.497961 0.790507
CLEC2D 9.825235 9.06648 0.137779756 0.751583798 CLEC2D 0.661572 1.119399
CLIC5 9.64125 10.88675 0.034407816 0.392514974 CLIC5 1.883068 0.794206
CLIC6 10.417 10.37385 0.18356492 0.154785674 CLIC6 0.694766 0.715860
CMKLR1 7.242115 8.25133 0.455115138 0.784153136 CMKLR1 1.915658 0.951730
COL15A1 10.74245 11.0673 0.069508597 0.106773124 COL15A1 0.731840 0.584287
CRCT1 8.918805 9.730185 0.026566002 0.328359176 CRCT1 1.679248 0.956897
CRIP1 10.9661 11.85075 0.251022907 0.043062803 CRIP1 1.376066 0.745304
CRYAB 8.910145 9.07221 1.006191736 0.350838101 CRYAB 1.470019 1.313822
CSN3 7.67541 7.655535 0.511280629 0.075794776 CSN3 0.422200 0.428056
CST6 8.136885 9.432595 0.206750952 0.468932004 CST6 1.667822 0.679363
CTXN1 9.99733 8.982095 0.100083894 0.193754329 CTXN1 0.673799 1.361904
CXX1A 12.09905 12.76535 0.235820112 0.02298097 CXX1A 1.409760 0.888319
CYP1B1 8.084105 8.600155 0.086373093 0.18634385 CYP1B1 2.315654 1.619294
CYSLTR1 6.444915 7.376565 0.422050824 0.338598082 CYSLTR1 1.670234 0.875634
DAPK2 9.405485 9.468405 0.047312515 0.095325065 DAPK2 0.724772 0.693842
DCN 6.98133 10.67328 0.152126953 1.401513925 DCN 11.239298 0.869664
DDIT4 10.45 9.87607 0.02602153 0.249368277 DDIT4 0.717410 1.067917
DHCR24 10.2094 10.66705 0.099419213 0.044901281 DHCR24 1.382855 1.006956
DHH 9.30462 10.010015 0.352591725 0.099963686 DHH 1.339022 0.821188
DLL1 8.806365 10.4176 0.011575338 0.062225397 DLL1 2.614980 0.855930
DNM3 8.62547 8.62615 0.304649886 0.350229989 DNM3 1.457923 1.457236
DOC2B 8.786095 8.63852 0.399140565 0.310476445 DOC2B 0.684558 0.758289
DOK4 9.660245 10.31945 0.005154808 0.03542605 DOK4 1.408100 0.891647
DPY19L3 9.099685 8.30704 0.01489874 0.525408623 DPY19L3 0.681696 1.180866
DYNC1I1 8.193185 8.93093 0.829895874 0.742122709 DYNC1I1 1.762282 1.056798
E2F8 8.611715 8.82475 0.76444607 0.572289802 E2F8 1.398369 1.206401
EDA2R 10.17765 10.058585 0.099348503 0.13734135 EDA2R 0.758586 0.823848
EDN1 12.3917 11.2048 0.226557013 0.115258405 EDN1 0.625638 1.424346
EDNRB 10.444 11.39225 0.136895873 0.019728279 EDNRB 1.499831 0.777304
EFHD1 7.628505 8.504835 0.211700699 0.398772869 EFHD1 1.820904 0.991940
EFNA3 7.43474 8.828695 0.129556104 0.600171023 EFNA3 1.578627 0.600699
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EFR3B 9.113465 9.518005 0.352287669 0.170943064 EFR3B 1.323626 0.999969
ELOVL7 10.183 9.778065 0.136330187 0.185735738 ELOVL7 1.488764 1.971167
EMP3 11.52695 12.0586 0.043487067 0.093055252 EMP3 1.393826 0.964197
ENPP2 10.38085 9.00493 0.076862507 1.071012215 ENPP2 0.631743 1.639584
ENTPD1 11.5965 11.4913 0.033516861 0.091216775 ENTPD1 1.447788 1.557303
ESM1 8.56836 7.31198 0.535110128 0.322214418 ESM1 0.427110 1.020347
F2R 10.76165 10.458 0.070215703 0.084004286 F2R 0.749448 0.925016
F5 6.44601 7.158895 0.316882833 0.037059466 F5 1.761983 1.074984
FABP7 7.4502 7.08596 0.066100342 0.129697526 FABP7 0.562268 0.723753
FAM107A 7.877815 9.470065 0.138628284 0.008647916 FAM107A 2.899070 0.961487
FAM110C 9.2513 8.97724 0.003167838 0.046499342 FAM110C 0.744299 0.900011
FAM189A2 7.76387 9.58435 0.307831866 0.499203245 FAM189A2 3.246308 0.919120
FAM20A 8.785285 9.78255 0.205336738 0.126515545 FAM20A 2.280547 1.142437
FAR2 10.3801 11.18515 0.246638845 0.181938575 FAR2 1.312120 0.750982
FBLN2 8.29856 9.44827 0.246582277 0.063738605 FBLN2 1.692933 0.763032
FNDC1 8.085185 9.717705 0.654476823 0.503311536 FNDC1 2.459525 0.793257
FUCA2 10.4527 11.1911 0.081458701 0.557624408 FUCA2 1.595103 0.956111
GADD45A 9.984515 9.194495 0.150733953 0.21097945 GADD45A 0.737227 1.274737
GALNTL4 9.55237 9.28295 0.185657956 0.39811526 GALNTL4 0.737045 0.888378
GDPD5 11.56315 11.06315 0.087186266 0.353058416 GDPD5 0.728272 1.029933
GEM 6.790545 8.213615 0.198972777 0.84013478 GEM 2.400741 0.895283
GJA4 8.675705 8.780135 1.078019643 1.399625949 GJA4 0.479243 0.445779
GM11428 7.972085 6.769635 0.612121127 0.789590787 GM11428 0.589592 1.356830
GM5972 12.219 13.12655 0.146512525 0.287721749 GM5972 1.310938 0.698848
GM8995 9.8192 10.86095 0.09906566 0.21998092 GM8995 1.342479 0.652093
GPIHBP1 8.62062 9.045125 0.07694736 0.413508975 GPIHBP1 0.740412 0.551677
GPRC5A 10.68475 11.37485 0.073751237 0.116601908 GPRC5A 1.420797 0.880625
GRIN2A 8.1589 8.35705 0.13098446 0.189971308 GRIN2A 0.665873 0.580420
GYS1 10.3389 10.20885 0.025738687 0.097368604 GYS1 0.767533 0.839935
HEY1 11.0533 10.8566 0.00834386 0.264740779 HEY1 0.733592 0.840751
HTR2A 9.91791 9.786275 0.167287322 0.201207235 HTR2A 1.321219 1.447441
HTRA1 9.812205 11.0776 0.62153979 0.28255987 HTRA1 1.355993 0.564073
HYAL1 9.17945 10.034485 0.00456791 0.123906321 HYAL1 1.524816 0.842997
ICOSL 7.07223 8.01002 0.082717351 0.01834235 ICOSL 1.574534 0.821957
ID2 10.046155 8.63319 0.608316893 1.306309068 ID2 0.575266 1.531839
ID3 10.66275 9.53934 0.258447529 0.566109689 ID3 0.514356 1.120583
IGFBP4 10.21144 9.46571 0.626157197 0.941286405 IGFBP4 0.612918 1.027754
IGFBP5 7.93703 9.55137 0.870448448 1.507594084 IGFBP5 3.240486 1.058385
INHBB 9.664415 9.574495 0.418727423 0.270475415 INHBB 0.752107 0.800476
IRX3 8.769385 9.076125 0.326902536 0.25852531 IRX3 1.607318 1.299462
ITGA2 10.05435 9.96941 0.044901281 0.177752503 ITGA2 0.738137 0.782900
ITGA8 10.25755 9.82765 0.165533697 0.081684975 ITGA8 0.761412 1.025729
JAG2 10.9935 11.16365 0.082872915 0.006010408 JAG2 1.303328 1.158333
JAM2 10.88915 11.33395 0.241194123 0.171614816 JAM2 1.351958 0.993265
KCNB1 7.81401 9.04547 0.140728392 0.1640912 KCNB1 2.086797 0.888735
KCNE3 8.918345 9.0118 0.056844314 0.11846867 KCNE3 0.683880 0.640984
KCNJ2 10.8684 9.40504 0.220900158 0.70385409 KCNJ2 0.578561 1.595380
KCNJ8 8.189815 8.288135 0.087207479 0.171381471 KCNJ8 0.667079 0.623132
KCTD12 9.915335 10.0948 0.093359308 0.169281363 KCTD12 1.325062 1.170070
KLF2 9.86349 10.8013 0.092277435 0.154432121 KLF2 1.731545 0.903909
KLF4 9.809585 11.3648 0.178707097 0.337714199 KLF4 2.800239 0.952859
KLK8 7.27614 7.960335 0.074543197 0.337410143 KLK8 1.569342 0.976685
KRAS 10.72345 11.23775 0.064417428 0.052255191 KRAS 1.362258 0.953761
L1CAM 8.59392 9.48771 0.781098435 0.58558341 L1CAM 1.826998 0.983287
LAMB2 10.9262 11.3416 0.058689863 0.017253405 LAMB2 1.312484 0.984116
LBP 9.6743 10.87805 0.472488751 0.290550176 LBP 1.942305 0.843243
LCP2 11.59075 11.16735 0.179675833 0.107268099 LCP2 0.748461 1.003750
LDLR 9.134135 10.086665 0.235516056 0.125631662 LDLR 1.686819 0.871622
LMCD1 9.09464 9.715335 0.040078812 0.132858293 LMCD1 1.529383 0.994646
LPAR4 10.54655 9.952225 0.099631345 0.060577838 LPAR4 0.642147 0.969491
LRG1 8.668535 9.60747 1.829391309 1.64067158 LRG1 2.718687 1.418115
LSR 9.726295 10.061565 0.091761247 0.307358105 LSR 2.890342 2.290988
LTBP4 10.96635 12.22025 0.583716648 0.157048416 LTBP4 1.461500 0.612826
LYNX1 9.548975 10.09322 0.301333555 0.214083649 LYNX1 1.365486 0.936383
MACF1 11.29515 11.64935 0.501267997 0.523895414 MACF1 1.456494 1.139420
MAF1 10.40675 10.01013 0.148421713 0.149298526 MAF1 0.744674 0.980303
MAL 9.58058 9.313905 0.517870864 0.669128076 MAL 1.967325 2.366754
MALAT1 11.0127 11.7876 0.448447121 1.121895619 MALAT1 1.629241 0.952176
MCOLN2 8.58369 8.95246 0.528647172 0.494055508 MCOLN2 1.744266 1.350834
MEST 10.6621 10.8223 0.189080353 0.366988419 MEST 0.730117 0.653383
MGLL 7.692625 9.368135 0.145741779 0.228869252 MGLL 1.885236 0.590183
MIR505 7.98089 8.61456 0.056907954 0.766800736 MIR505 1.823405 1.175248
MKI67 10.278945 10.63525 0.756399195 0.366352023 MKI67 1.392208 1.087541
MN1 9.276835 9.863665 0.103584072 0.179046508 MN1 1.472242 0.980225
MT1 10.1432 10.78135 0.0417193 0.021001071 MT1 1.337603 0.859459
MT2 11.48545 11.1989 0.356169686 0.091499617 MT2 0.690470 0.842180
MTAP6 8.66651 9.263865 0.241278976 0.033835059 MTAP6 1.403438 0.927623
MUSTN1 10.50995 11.25215 0.117591858 0.125228611 MUSTN1 1.785218 1.067251
NBEAL1 10.3731 10.9052 0.280014285 0.350866385 NBEAL1 1.367888 0.945959
NEK7 11.2367 11.94225 0.037759502 0.208667211 NEK7 1.384821 0.849185
NEURL2 8.21281 9.56288 0.237446457 0.415962635 NEURL2 2.942699 1.154341
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NKD1 8.76605 8.894885 0.248859161 0.063858813 NKD1 1.388378 1.269768
NKD2 8.443755 8.80376 0.195338248 0.011709688 NKD2 1.563176 1.217967
NMNAT2 9.451495 10.44655 0.098874741 0.113914902 NMNAT2 1.409638 0.707239
NOSTRIN 10.038305 9.222575 0.056702893 0.055345248 NOSTRIN 1.360866 2.395372
NOV 10.6325 10.8576 0.248053059 0.106066017 NOV 1.330944 1.138670
NPNT 11.6016 12.0034 0.220758737 0.307167186 NPNT 2.821183 2.135391
NPPB 6.969335 7.716025 0.060747544 0.153194684 NPPB 1.626640 0.969428
NQO1 9.7227 10.04648 0.023730504 0.10284161 NQO1 1.647770 1.316525
NR4A1 9.951185 10.92605 0.081479914 0.357442478 NR4A1 2.353732 1.197553
NR4A2 8.977235 9.93358 0.004787113 0.076056405 NR4A2 2.025068 1.043641
NRGN 9.23842 9.384375 0.208059099 0.101095057 NRGN 1.689575 1.527005
NUSAP1 9.72959 10.087525 0.925616919 0.576256671 NUSAP1 1.306059 1.019092
OLFR1372>PS1 10.4813 10.71245 0.348179379 0.577494108 OLFR1372>PS1 1.411785 1.202778
OSGIN1 9.888845 9.27374 0.041627376 0.347726831 OSGIN1 0.717883 1.099559
P2RY2 10.5257 11.89715 0.10323759 0.180100097 P2RY2 1.769878 0.684062
PALMD 11.9784 12.24225 0.00311127 0.032597623 PALMD 1.416568 1.179806
PBP2 6.53319 7.65462 0.266013571 0.755218327 PBP2 1.615572 0.742578
PDCD10 8.947135 8.3248 0.130241998 0.507702669 PDCD10 0.590261 0.908627
PDGFA 10.44605 11.4774 0.121410234 0.025455844 PDGFA 1.611663 0.788509
PDZD2 9.148545 9.74156 0.275722147 0.021227346 PDZD2 1.321934 0.876384
PGLYRP1 10.8223 10.6367 0.17833233 0.052608745 PGLYRP1 2.463877 2.802142
PHGDH 9.799555 10.338005 0.547081446 0.620266997 PHGDH 1.325448 0.912584
PHXR4 7.277205 8.135175 0.324625652 0.877710434 PHXR4 1.884818 1.039907
PIK3CG 9.07639 8.32068 0.261403235 0.183536636 PIK3CG 0.691416 1.167429
PIR 10.6491 10.96565 0.002262742 0.052538034 PIR 1.376448 1.105271
PLAGL1 9.746195 10.81015 0.394714076 0.346270191 PLAGL1 1.951631 0.933502
PLOD2 9.51767 9.396485 0.219839498 0.247593439 PLOD2 0.751602 0.817463
PLTP 13.10245 13.68345 0.008555992 0.004454773 PLTP 1.633878 1.092248
PLVAP 8.540385 9.740475 0.503650947 0.112479476 PLVAP 1.386248 0.603362
PMP22 11.58265 12.1775 0.253073517 0.03337544 PMP22 1.346067 0.891249
POLE 8.92238 9.28467 0.612213051 0.35844657 POLE 1.340350 1.042697
PPAP2B 11.4131 11.7467 0.11158145 0.188797511 PPAP2B 1.418238 1.125448
PPP1R2 12.1662 13.0575 0.124026529 0.327673282 PPP1R2 1.289981 0.695465
PRDM1 8.516965 7.78816 0.077505974 0.273537187 PRDM1 0.619594 1.026832
PRKCC 9.14697 9.824475 0.106023591 0.110810704 PRKCC 1.345614 0.841340
PRKCH 7.639705 8.06988 0.067663048 0.343851886 PRKCH 1.600353 1.187737
PRR11 9.729165 10.09482 1.008949453 0.554343432 PRR11 1.308537 1.015577
PTHLH 7.812845 9.58466 0.029012591 0.21667166 PTHLH 2.076998 0.608228
PTPRJ 10.123265 11.0265 0.728086639 0.185261977 PTPRJ 1.604329 0.857813
PTPRJ 10.123265 11.0265 0.728086639 0.185261977 PTPRJ 1.604329 0.857813
RAMP3 9.404755 10.21664 1.192104251 0.98409465 RAMP3 2.388873 1.360786
RASGRP2 7.45499 8.583615 0.180609214 0.017430182 RASGRP2 1.518366 0.694427
RET 8.117725 10.21953 0.540307363 0.611463518 RET 4.636352 1.080111
RGL1 10.2799 9.66841 0.193605837 0.627472415 RGL1 0.729533 1.114607
RGS16 11.03835 10.611 0.043204224 0.031819805 RGS16 0.746700 1.004133
RIPPLY3 8.11768 8.821095 0.082222377 0.069713658 RIPPLY3 1.498802 0.920440
RND3 9.712735 8.96355 0.175807959 0.296009041 RND3 0.581544 0.977484
RNF144A 10.9344 10.6034 0.164614459 0.232213867 RNF144A 0.733643 0.922838
ROBO1 9.916015 8.7491 0.434425193 0.163935636 ROBO1 0.644691 1.447532
RPS6KA1 10.7206 10.3477 0.219485945 0.442648845 RPS6KA1 0.762284 0.987122
RRM2 9.58031 9.988365 0.805804746 0.239475854 RRM2 1.346309 1.014631
RTP3 8.93204 10.22015 0.123319423 0.297904087 RTP3 1.834682 0.751279
S1PR4 8.968775 9.28006 0.107699434 0.349169329 S1PR4 1.340559 1.080388
SAMD5 8.356815 8.68346 0.029960114 0.281527494 SAMD5 1.717714 1.369686
SCARNA13 10.30445 10.67685 0.009687363 0.08237794 SCARNA13 1.337510 1.033222
SCARNA17 10.85005 10.150605 0.231011785 0.890523209 SCARNA17 0.654337 1.062564
SCARNA17 10.85005 10.150605 0.231011785 0.890523209 SCARNA17 0.654337 1.062564
SCN3B 10.73285 9.84849 0.237375746 0.520727576 SCN3B 0.751133 1.386550
SELP 7.99802 9.05292 0.463225652 0.034803796 SELP 1.831690 0.881648
SERPINB1A 6.7888 7.72185 0.062791082 0.014608826 SERPINB1A 1.871487 0.980191
SERPINB8 7.971955 8.431095 0.22826114 0.293739228 SERPINB8 1.678689 1.221112
SERPINB9B 7.36764 9.613135 0.381130555 0.943796634 SERPINB9B 4.820591 1.016574
SESN3 11.458 10.10791 0.138310086 0.164458895 SESN3 0.740289 1.887204
SIX1 9.332405 9.244905 0.289850141 0.380642651 SIX1 0.715007 0.759715
SIX4 9.790655 9.19881 0.17197544 0.146710515 SIX4 0.681483 1.027113
SLC45A4 11.62965 11.4636 0.281216367 0.335310036 SLC45A4 0.720590 0.808489
SLC46A3 10.23715 11.12805 0.000777817 0.091853171 SLC46A3 1.764183 0.951384
SLC6A17 8.737595 8.403395 0.459725474 0.425671211 SLC6A17 0.677470 0.854072
SLC7A6 9.83354 9.19088 0.115173553 0.175404908 SLC7A6 0.708979 1.106862
SLCO2A1 7.79354 8.65313 0.448701679 0.765909781 SLCO2A1 1.810057 0.997539
SLFN2 7.914915 8.990325 0.142984062 0.493313046 SLFN2 1.572168 0.746050
SLFN3 9.99119 10.7422 0.076240253 0.253992756 SLFN3 1.366466 0.811937
SLFN9 9.18195 9.628635 0.677719423 0.422503373 SLFN9 1.328198 0.974534
SNCG 8.80367 10.08743 0.000410122 0.252253273 SNCG 1.469418 0.603525
SNED1 10.14743 9.741045 0.361996246 0.251963359 SNED1 1.571639 2.082996
SNORD57 12.47015 11.98895 0.16680649 0.494479772 SNORD57 0.757674 1.057641
SOX4 10.7837 10.109 0.054588644 0.099277792 SOX4 0.735298 1.173730
STMN2 9.862255 11.5871 0.238075782 0.269690526 STMN2 2.143473 0.648467
SUOX 9.049565 9.287335 0.123496199 0.02225265 SUOX 1.347920 1.143111
SYNE2 8.59955 9.152595 0.209869293 0.413834244 SYNE2 1.434020 0.977399
SYNE2 8.59955 9.152595 0.209869293 0.413834244 SYNE2 1.434020 0.977399
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Table 1.  Affymetrix data. Data coming from Affymetrix analysis have been analyzed and listed in this table. 
The table present raw data about the condition WT+Wnt3a, KO+Wnt3a and KO and the fold changes about the 
comparison between the following conditions: WT vs. WT+Wnt3a, KO vs. KO+Wnt3a and WT vs. KO. Genes 
listed here were pre-selected comparing respectively WT vs. WT+Wnt3a and WT vs. KO in order to analyze only 
genes experimentally regulated by Wnt3a and CCM3 ablation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TDG 9.866995 9.43311 0.0235113 0.280990093 TDG 0.716563 0.967981
THBD 11.109 12.1939 0.001838478 0.315793888 THBD 1.889953 0.890971
TINAGL1 10.8676 12.2341 0.347755115 0.164897301 TINAGL1 1.690266 0.655537
TMEM140 9.63001 10.1588 0.095261426 0.044264885 TMEM140 1.359160 0.942082
TMEM173 11.57795 10.9688 0.36394786 0.671327178 TMEM173 0.755917 1.153046
TMEM223 11.919 11.42385 0.008909545 0.357018214 TMEM223 0.763500 1.076128
TMTC1 8.378085 9.731805 0.402661957 0.028715606 TMTC1 2.035510 0.796458
TNFAIP2 10.4653 10.96885 0.246638845 0.231577471 TNFAIP2 1.323630 0.933648
TOMM7 10.186 9.828585 0.088246926 0.112012785 TOMM7 0.755674 0.968115
TOX3 8.935025 7.868995 0.278112168 0.891088895 TOX3 0.513014 1.074079
TRPV4 9.149275 11.11805 0.219549584 0.15747268 TRPV4 2.733255 0.698262
TSC22D3 8.519525 9.31771 0.31686162 0.339991083 TSC22D3 1.723684 0.991243
TUBA4A 8.55442 8.99229 0.206545891 0.079365665 TUBA4A 1.365704 1.008195
UNC5B 12.11965 11.8487 0.073751237 0.188373247 UNC5B 0.757123 0.913546
VWF 12.48365 10.84255 0.083933575 1.089015154 VWF 0.727490 2.269068
XDH 7.914035 9.088095 0.289864283 0.3642802 XDH 1.811456 0.802787
XYLT1 9.23178 9.24315 0.134124014 0.336710107 XYLT1 0.697834 0.692356
ZBTB7C 7.425105 8.173195 0.013159257 0.119706107 ZBTB7C 1.567228 0.933114
ZFP697 9.875725 10.51025 0.586863273 0.5787669 ZFP697 1.601063 1.031329
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